<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Psychological and pharmacological interventions for depression in patients with coronary artery disease - Tully, PJ - 2021 | Cochrane Library</title> <meta content="Psychological and pharmacological interventions for depression in patients with coronary artery disease - Tully, PJ - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008012.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Psychological and pharmacological interventions for depression in patients with coronary artery disease - Tully, PJ - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008012.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008012.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Psychological and pharmacological interventions for depression in patients with coronary artery disease" name="citation_title"/> <meta content="Phillip J Tully" name="citation_author"/> <meta content="University of Adelaide" name="citation_author_institution"/> <meta content="phillip.tully@adelaide.edu.au" name="citation_author_email"/> <meta content="Ser Yee Ang" name="citation_author"/> <meta content="University of Adelaide" name="citation_author_institution"/> <meta content="Emily JL Lee" name="citation_author"/> <meta content="University of Adelaide" name="citation_author_institution"/> <meta content="Eileen Bendig" name="citation_author"/> <meta content="Ulm University" name="citation_author_institution"/> <meta content="Natalie Bauereiß" name="citation_author"/> <meta content="Ulm University" name="citation_author_institution"/> <meta content="Jürgen Bengel" name="citation_author"/> <meta content="University of Freiburg" name="citation_author_institution"/> <meta content="Harald Baumeister" name="citation_author"/> <meta content="Ulm University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD008012.pub4" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/12/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008012.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008012.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008012.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Coronary Artery Disease [complications]; *Depression [therapy]; Escitalopram; Psychotherapy; Quality of Life" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008012.pub4&amp;doi=10.1002/14651858.CD008012.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="jxlIh5Me";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008012\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008012\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ko","ms","ja","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008012.pub4",title:"Psychological and pharmacological interventions for depression in patients with coronary artery disease",firstPublishedDate:"Dec 15, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008012.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008012.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008012.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008012.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008012.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008012.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008012.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008012.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008012.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008012.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4227 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008012.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-sec-0095"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-sec-0089"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/appendices#CD008012-sec-0100"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/table_n/CD008012StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/table_n/CD008012StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Psychological and pharmacological interventions for depression in patients with coronary artery disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/information#CD008012-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Phillip J Tully</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/information#CD008012-cr-0005">Ser Yee Ang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/information#CD008012-cr-0006">Emily JL Lee</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/information#CD008012-cr-0007">Eileen Bendig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/information#CD008012-cr-0008">Natalie Bauereiß</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/information#CD008012-cr-0009">Jürgen Bengel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008012.pub4/information#CD008012-cr-0010">Harald Baumeister</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/information/en#CD008012-sec-0111">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 December 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008012.pub4">https://doi.org/10.1002/14651858.CD008012.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008012-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008012-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008012-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008012-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008012-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008012-abs-0004">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008012-abs-0001" lang="en"> <section id="CD008012-sec-0001"> <h3 class="title" id="CD008012-sec-0001">Background</h3> <p>Depression occurs frequently in individuals with coronary artery disease (CAD) and is associated with a poor prognosis. </p> </section> <section id="CD008012-sec-0002"> <h3 class="title" id="CD008012-sec-0002">Objectives</h3> <p>To determine the effects of psychological and pharmacological interventions for depression in CAD patients with comorbid depression. </p> </section> <section id="CD008012-sec-0003"> <h3 class="title" id="CD008012-sec-0003">Search methods</h3> <p>We searched the CENTRAL, MEDLINE, Embase, PsycINFO, and CINAHL databases up to August 2020. We also searched three clinical trials registers in September 2021. We examined reference lists of included randomised controlled trials (RCTs) and contacted primary authors. We applied no language restrictions. </p> </section> <section id="CD008012-sec-0004"> <h3 class="title" id="CD008012-sec-0004">Selection criteria</h3> <p>We included RCTs investigating psychological and pharmacological interventions for depression in adults with CAD and comorbid depression. Our primary outcomes included depression, mortality, and cardiac events. Secondary outcomes were healthcare costs and utilisation, health‐related quality of life, cardiovascular vital signs, biomarkers of platelet activation, electrocardiogram wave parameters, non‐cardiac adverse events, and pharmacological side effects. </p> </section> <section id="CD008012-sec-0005"> <h3 class="title" id="CD008012-sec-0005">Data collection and analysis</h3> <p>Two review authors independently examined the identified papers for inclusion and extracted data from the included studies. We performed random‐effects model meta‐analyses to compute overall estimates of treatment outcomes. </p> </section> <section id="CD008012-sec-0006"> <h3 class="title" id="CD008012-sec-0006">Main results</h3> <p>Thirty‐seven trials fulfilled our inclusion criteria. Psychological interventions may result in a reduction in end‐of‐treatment depression symptoms compared to controls (standardised mean difference (SMD) −0.55, 95% confidence interval (CI) −0.92 to −0.19, I<sup>2</sup> = 88%; low certainty evidence; 10 trials; n = 1226). No effect was evident on medium‐term depression symptoms one to six months after the end of treatment (SMD −0.20, 95% CI −0.42 to 0.01, I<sup>2</sup> = 69%; 7 trials; n = 2654). The evidence for long‐term depression symptoms and depression response was sparse for this comparison. There is low certainty evidence that psychological interventions may result in little to no difference in end‐of‐treatment depression remission (odds ratio (OR) 2.02, 95% CI 0.78 to 5.19, I<sup>2</sup> = 87%; low certainty evidence; 3 trials; n = 862). Based on one to two trials per outcome, no beneficial effects on mortality and cardiac events of psychological interventions versus control were consistently found. The evidence was very uncertain for end‐of‐treatment effects on all‐cause mortality, and data were not reported for end‐of‐treatment cardiovascular mortality and occurrence of myocardial infarction for this comparison. </p> <p>In the trials examining a head‐to‐head comparison of varying psychological interventions or clinical management, the evidence regarding the effect on end‐of‐treatment depression symptoms is very uncertain for: cognitive behavioural therapy compared to supportive stress management; behaviour therapy compared to person‐centred therapy; cognitive behavioural therapy and well‐being therapy compared to clinical management. There is low certainty evidence from one trial that cognitive behavioural therapy may result in little to no difference in end‐of‐treatment depression remission compared to supportive stress management (OR 1.81, 95% CI 0.73 to 4.50; low certainty evidence; n = 83). Based on one to two trials per outcome, no beneficial effects on depression remission, depression response, mortality rates, and cardiac events were consistently found in head‐to‐head comparisons between psychological interventions or clinical management. </p> <p>The review suggests that pharmacological intervention may have a large effect on end‐of‐treatment depression symptoms (SMD −0.83, 95% CI −1.33 to −0.32, I<sup>2</sup> = 90%; low certainty evidence; 8 trials; n = 750). Pharmacological interventions probably result in a moderate to large increase in depression remission (OR 2.06, 95% CI 1.47 to 2.89, I<sup>2</sup> = 0%; moderate certainty evidence; 4 trials; n = 646). We found an effect favouring pharmacological intervention versus placebo on depression response at the end of treatment, though strength of evidence was not rated (OR 2.73, 95% CI 1.65 to 4.54, I<sup>2</sup> = 62%; 5 trials; n = 891). Based on one to four trials per outcome, no beneficial effects regarding mortality and cardiac events were consistently found for pharmacological versus placebo trials, and the evidence was very uncertain for end‐of‐treatment effects on all‐cause mortality and myocardial infarction. </p> <p>In the trials examining a head‐to‐head comparison of varying pharmacological agents, the evidence was very uncertain for end‐of‐treatment effects on depression symptoms. The evidence regarding the effects of different pharmacological agents on depression symptoms at end of treatment is very uncertain for: simvastatin versus atorvastatin; paroxetine versus fluoxetine; and escitalopram versus Bu Xin Qi. </p> <p>No trials were eligible for the comparison of a psychological intervention with a pharmacological intervention. </p> </section> <section id="CD008012-sec-0007"> <h3 class="title" id="CD008012-sec-0007">Authors' conclusions</h3> <p>In individuals with CAD and depression, there is low certainty evidence that psychological intervention may result in a reduction in depression symptoms at the end of treatment. There was also low certainty evidence that pharmacological interventions may result in a large reduction of depression symptoms at the end of treatment. Moderate certainty evidence suggests that pharmacological intervention probably results in a moderate to large increase in depression remission at the end of treatment. Evidence on maintenance effects and the durability of these short‐term findings is still missing. The evidence for our primary and secondary outcomes, apart from depression symptoms at end of treatment, is still sparse due to the low number of trials per outcome and the heterogeneity of examined populations and interventions. As psychological and pharmacological interventions can seemingly have a large to only a small or no effect on depression, there is a need for research focusing on extracting those approaches able to substantially improve depression in individuals with CAD and depression. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008012-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008012-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008012-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008012-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008012-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008012-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008012-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008012-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008012-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008012-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008012-abs-0002" lang="en"> <h3>Treatments for depression in individuals with coronary artery disease</h3> <p>This review examined clinical trials on psychological treatments and antidepressant drugs in individuals with coronary artery disease and depression. The objective was to determine the effects of these treatments on depression, mortality, cardiac events such as another heart attack, or heart surgery. </p> <p>We identified 37 trials as relevant for the review. Fifteen trials investigated psychological treatments, and 21 trials investigated pharmacological interventions including antidepressant drugs. </p> <p>Generally, psychological treatments compared to controls, and antidepressant drugs compared to placebo (inactive drug), may result in a reduction in depression symptoms at the end of treatment; however, the evidence is generally of low certainty. The evidence is very uncertain as to whether psychological treatments compared to control and antidepressant drugs compared to placebo reduce mortality and cardiovascular events. </p> <p>The evidence is current to August 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008012-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008012-sec-0095"></div> <h3 class="title" id="CD008012-sec-0096">Implications for practice</h3> <section id="CD008012-sec-0096"> <p>Psychological interventions may result in a reduction in depression symptoms at end of treatment. Pharmacological interventions may result in a reduction in depression symptoms and probably result in a moderate to large increase in depression remission at end of treatment. The National Institute for Health and Care Excellence (NICE) guideline on depression in adults with a chronic physical health problem favours the use of psychological interventions as first‐line interventions in patients with minor and mild‐to‐moderate depression due to the adverse effects of antidepressants and the resulting poor risk‐benefit ratio (<a href="./references#CD008012-bbs2-0207" title="National Institute for Health and Clinical Excellence. Depression in adults with a chronic physical health problem: recognition and management Clinical guideline [CG91]. www.nice.org.uk/guidance/CG91 (accessed 26 July 2011).">NICE 2009</a>). In the primary studies of the current review, antidepressant medications compared to placebo were associated with increased rates of dizziness, diarrhoea, somnolence, sweating, palpitations, libido reduction or sexual difficulties in <a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; fatigue, appetite changes and weight gain in <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; fatigue and increased sexual problems in <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>; and nausea and diarrhoea in <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>. Nortriptyline had a higher rate of adverse events compared to paroxetine in <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>. These side effects must be weighted against the positive effects on depression outcomes when considering initiating pharmacological treatment in depressed coronary artery disease (CAD) patients. The trials conducted by <a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>, <a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>, <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>, <a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a>, and <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a> reported no meaningful adverse events for omega‐3 add‐on therapy, simvastatin versus atorvastatin (with a few side effects reported for simvastatin but not for atorvastatin), saffron versus fluoxetine, sertraline augmented with red yeast rice, and Xinkeshu tablets. Conversely, more side effects were observed with escitalopram versus Bu Xin Qi (<a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>). There was insufficient evidence to make recommendations on the relative safety of serotonergic drugs with regard to electrocardiogram (ECG) wave parameters. Prolongation of the QTc interval is a possible side effect of selective serotonin reuptake inhibitor (SSRI) drugs (<a href="./references#CD008012-bbs2-0215" title="RochesterMP , KaneAM , LinneburSA , FixenDR . Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence. Therapeutic Advances in Drug Safety2018;9(6):297-308.">Rochester 2018</a>), and have received a warning from the US Food and Drug Administration (<a href="./references#CD008012-bbs2-0181" title="GerlachLB , KalesHC , MaustDT , ChiangC , StanoC , ChoeHM , et al. Unintended consequences of adjusting citalopram prescriptions following the 2011 FDA warning. American Journal of Geriatric Psychiatry2017;25(4):407-14.">Gerlach 2017</a>). Data from three serotonergic drug versus placebo trials indicated that further investigation is warranted, as two trials did not report sufficient data (<a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>). The evidence for more specific recommendations is scarce. </p> <p>There is no evidence to recommend a particular type of psychological intervention (e.g. cognitive‐behavioural therapy (CBT)) on the basis of this review. Specifically, comparable effect sizes were found for psychological interventions and those for CBT‐only interventions on end‐of‐treatment depression symptoms. There was modest attenuation in effect size but still considerable heterogeneity, thereby precluding differential conclusions between CBT and non‐CBT approaches. Similarly, with regard to pharmacological interventions, there is comparable evidence from sensitivity analyses for pharmacological interventions and specifically for serotonergic antidepressants. However, an insufficient number of studies investigating TCAs and the small evidence base regarding cardiac endpoints in the included studies precluded recommendations on the benefits and risks of SSRIs versus other antidepressant drug classes, such as tricyclic antidepressants (TCAs), for the treatment of depression in CAD patients. The TCAs are viewed as highly cardiotoxic in overdose and may therefore worsen outcomes in CAD patients (<a href="./references#CD008012-bbs2-0200" title="LichtmanJH , BiggerJT , BlumenthalJA , Frasure-SmithN , KaufmannPG , LesperanceF , et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation2008;118:1768-75.">Lichtman 2008</a>; <a href="./references#CD008012-bbs2-0228" title="TaylorD . Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatrica Scandinavica2008;118:434-42.">Taylor 2008</a>). </p> <p>With regard to initiating treatment for CAD patients with depression, this review focused on psychological and pharmacological interventions as stand‐alone approaches, which neither permit any conclusions on collaborative care (<a href="./references#CD008012-bbs2-0231" title="TullyPJ , BaumeisterH . Collaborative care for comorbid depression and coronary heart disease: a systematic review and meta-analysis of randomised controlled trials. BMJ Open2015;5:e009128.">Tully 2015</a>), nor on other treatment options such as exercise (<a href="./references#CD008012-bbs2-0135" title="AndersonL , OldridgeN , ThompsonDR , Zwisler A-D, ReesK , MartinN , et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database of Systematic Reviews2016, Issue 1. Art. No: CD001800. [DOI: 10.1002/14651858.CD001800.pub3]">Anderson 2016</a>). For example, <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a> conducted a three‐arm trial comparing sertraline and aerobic exercise with placebo, finding no differences between the active trial arms except for heart rate variability in favour of exercise. It may thus be worth considering evidence‐based alternatives beyond the frequently suggested two psychological and pharmacological approaches, taking patient preferences into account. </p> </section> <h3 class="title" id="CD008012-sec-0097">Implications for research</h3> <section id="CD008012-sec-0097"> <p>The presence of depression in CAD patients is associated with a high additional burden and a negative medical prognosis (<a href="./references#CD008012-bbs2-0143" title="BaumeisterH , BalkeK , HärterM . Psychiatric and somatic comorbidities are negatively associated with quality of life in physically ill patients. Journal of Clinical Epidemiology2005;58:1090-100.">Baumeister 2005</a>; <a href="./references#CD008012-bbs2-0149" title="BaumeisterH , HutterN , BengelJ , HärterM . Quality of life in somatically ill persons with comorbid mental disorders: a systematic review and meta-analysis. Psychotherapy and Psychosomatics2011;80:275-86.">Baumeister 2011a</a>; <a href="./references#CD008012-bbs2-0153" title="BaumeisterH , HaschkeA , MunzingerM , HutterN , TullyPJ . Inpatient and outpatient costs in patients with coronary artery disease and mental disorders: a systematic review. BioPsychoSocial Medicine2015;9:11.">Baumeister 2015</a>; <a href="./references#CD008012-bbs2-0172" title="DempeC , JüngerJ , HoppeS , KatzenbergerML , MöltnerA , LadwigKH , et al. Association of anxious and depressive symptoms with medication nonadherence in patients with stable coronary artery disease. Journal of Psychosomatic Research2013;74:122–7.">Dempe 2013</a>; <a href="./references#CD008012-bbs2-0178" title="Frasure-SmithN , LesperanceF . Depression and other psychological risks following myocardial infarction. Archives of General Psychiatry2003;60:627-36.">Frasure‐Smith 2003</a>; <a href="./references#CD008012-bbs2-0186" title="HaschkeA , HutterN , BaumeisterH . Indirect costs in patients with coronary artery disease and mental disorders: a systematic review and meta-analysis. International Journal of Occupational Medicine and Environmental Health2012;25:319-29.">Haschke 2012</a>; <a href="./references#CD008012-bbs2-0187" title="Herrmann-LingenC , BussU . Anxiety and depression in patients with coronary heart disease. In: JordanJ , BardéB , ZeiherAM , editors(s). Contributions Toward Evidence-Based Psychocardiology: a Systematic Review of the Literature. Washington, DC: American Psychological Association, 2006:125-57.">Herrmann‐Lingen 2006</a>; <a href="./references#CD008012-bbs2-0201" title="LichtmanJH , FroelicherES , BlumenthalJA , CarneyRM , DoeringLV , Frasure-SmithN , et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation2014;129:1350-69.">Lichtman 2014</a>). Furthermore, the rather sparse evidence regarding the durability of depression interventions on depression and other outcomes in CAD populations leads to uncertainty in the evidence base. Accordingly, there is a need for further trials focusing on outcomes not yet sufficiently examined. Alternatively, past trials could improve the standard of evidence by reporting long‐term outcomes based on intention‐to‐treat (ITT). Several post hoc analyses of trials included in this review were no longer in ITT or per‐protocol groups, and were ineligible for inclusion in long‐term analyses of depression, mortality, and cardiac events. Rather, post hoc analyses were based on responders to depression treatment and participants with major depression versus those without major depression. This applies at least to medium‐ and long‐term depression, quality of life, mortality, specific cardiac events, and healthcare costs. Moreover, to examine differential effects of depression treatments, more comparative trials of psychological and pharmacological interventions are needed. Finally, there is a need for trials of psychological interventions examining the minimum dose required for a clinical meaningful treatment response. </p> <p>With regard to the divergent effects of both psychological and pharmacological interventions for depression in CAD patients contingent on depression disorder and mixed samples, a change in the current research agenda away from generic depression patient samples regardless of their specific depression subtype and severity may also be needed (<a href="./references#CD008012-bbs2-0145" title="BaumeisterH , MaerckerA , CaseyP . Adjustment disorders with depressed mood: a critique of its DSM-IV and ICD-10 conceptualization and recommendations for the future. Psychopathology2009;42:139-47.">Baumeister 2009a</a>; <a href="./references#CD008012-bbs2-0146" title="BaumeisterH , KufnerK . It is time to adjust the adjustment disorder category. Current Opinion in Psychiatry2009;22:409-12.">Baumeister 2009b</a>; <a href="./references#CD008012-bbs2-0151" title="BaumeisterH , ParkerG . Meta-review of depressive subtyping models. Journal of Affective Disorders2012;139:126-40.">Baumeister 2012a</a>; <a href="./references#CD008012-bbs2-0154" title="BauneB , StuartM , GilmourA , WerschingH , HeindelW , AroltV , et al. The relationship between subtypes of depression and cardiovascular disease: a systematic review of biological models.. Translational Psychiatry2012;2:e92.">Baune 2012</a>; <a href="./references#CD008012-bbs2-0155" title="BechP . Is the antidepressive effect of second-generation antidepressants a myth?Psychological Medicine2010;40:181-6.">Bech 2010</a>; <a href="./references#CD008012-bbs2-0212" title="PigottHE , LeventhalAM , AlterGS , BorenJJ . Efficacy and effectiveness of antidepressants: current status of research. Psychotherapy and Psychosomatics2010;79:267-79.">Pigott 2010</a>). As summarised earlier (<a href="./references#CD008012-bbs2-0148" title="BaumeisterH , ParkerG . A second thought on subtyping major depression. Psychotherapy and Psychosomatics2010;79:388-9.">Baumeister 2010b</a>; <a href="./references#CD008012-bbs2-0199" title="LichtenbergP , BelmakerRH . Subtyping major depressive disorder. Psychotherapy and Psychosomatics2010;79:131-5.">Lichtenberg 2010</a>), the effectiveness of depression treatments may vary depending on depression subtypes. The evidence of depression treatment in general emphasises that treatment effectiveness should at least be examined for different levels of depression severity (<a href="./references#CD008012-bbs2-0150" title="BaumeisterH . Inappropriate prescriptions of antidepressant drugs in patients with subthreshold to mild depression: time for the evidence to become practice. Journal of Affective Disorders2012;139(3):240-3. [DOI: doi:10.1016/j.jad.2011.05.025]">Baumeister 2011b</a>; <a href="./references#CD008012-bbs2-0176" title="FournierJC , DeRubeisRJ , HollonSD , DimidjianS , AmsterdamJD , SheltonRC , et al. Antidepressant drug effects and depression severity. A patient-level meta-analysis. JAMA2010;303:47-53.">Fournier 2010</a>; <a href="./references#CD008012-bbs2-0207" title="National Institute for Health and Clinical Excellence. Depression in adults with a chronic physical health problem: recognition and management Clinical guideline [CG91]. www.nice.org.uk/guidance/CG91 (accessed 26 July 2011).">NICE 2009</a>), taking clinical significance of depression into account (<a href="./references#CD008012-bbs2-0144" title="BaumeisterH , MorarV . The impact of clinical significance criteria on subthreshold depression prevalence rates. Acta Psychiatrica Scandinavica2008;118:443-50.">Baumeister 2008</a>; <a href="./references#CD008012-bbs2-0147" title="BaumeisterH . A clinical significance criterion is essential for diagnosing subthreshold depression. American Journal of Psychiatry2010;167:866.">Baumeister 2010a</a>; <a href="./references#CD008012-bbs2-0234" title="WakefieldJC , SchmitzMF , BaerJC . Does the DSM-IV clinical significance criterion for major depression reduce false positives? Evidence from the National Comorbidity Survey Replication. American Journal of Psychiatry2010;167:298-304.">Wakefield 2010</a>). In CAD patients the need for subtyping depression might particularly apply to the differentiation of new‐onset depression, recurrent depression, atypical depression, and treatment‐resistant depression (<a href="./references#CD008012-bbs2-0173" title="DickensC , McGowanL , PercivalC , TomensonB , CotterL , HeagertyA , et al. New onset depression following myocardial infarction predicts cardiac mortality. Psychosomatic Medicine2008;70:450-5.">Dickens 2008</a>; <a href="./references#CD008012-bbs2-0220" title="ScherrerJF , ChruscielT , GarfieldLD , FreedlandKE , CarneyRM , HauptmanPJ , et al. Treatment-resistant and insufficiently treated depression and all-cause mortality following myocardial infarction. British Journal of Psychiatry2012;200(2):137-42.">Scherrer 2012</a>). </p> <p>The current evidence also argues for research efforts beyond the standard treatments that better align with patient needs (<a href="./references#CD008012-bbs2-0163" title="CollopyCM , CoshSM , TullyPJ . Screening and referral is not enough: a qualitative exploration of barriers to access and uptake of mental health services in patients with cardiovascular diseases. BMC Health Services Research2021;21(1):49.">Collopy 2021</a>), with a focus on alternatives that improve accessibility, availability, efficacy, and attrition of depression interventions for individuals with CAD and depression. Uncertainty remains regarding the optimal delivery of psychotherapy for depression in CAD via individual or group therapy, or new ways of providing psychological care such as by means of internet‐ and mobile‐based interventions (<a href="./references#CD008012-bbs2-0156" title="BendigE , BauereissN , EbertDD , SnoekF , AnderssonG , BaumeisterH . Internet-based interventions in chronic somatic disease. Deutsches Arzteblatt International2018;115:659-65.">Bendig 2018</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>). Alternatives to improve accessibility and availability might apply to new biological interventions (<a href="./references#CD008012-bbs2-0194" title="KasterMP , MorettiM , CunhaMP , RodriguesAL . Novel approaches for the management of depressive disorders. European Journal of Pharmacology2016;771:236–40.">Kaster 2016</a>), such as examining the drug‐repurposing potential of standard cardiovascular medications like lipid‐ or blood pressure‐lowering agents (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>; <a href="./references#CD008012-bbs2-0161" title="CiprianiA , SaundersK , AttenburrowMJ , StefaniakJ , PanchalP , StocktonS , et al. A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development. Molecular Psychiatry2016;21:1324-32.">Cipriani 2016</a>), or add‐on therapies using cardiovascular health‐promoting agents such as omega‐3 (<a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008012-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008012-sec-0008"></div> <div class="table" id="CD008012-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Psychological treatment compared to control for depression in patients with coronary artery disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Psychological treatment compared to control for depression in patients with coronary artery disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> health problem or population<br/><b>Setting:</b> cardiology in‐ and outpatient<br/><b>Intervention:</b> Psychological treatment<br/><b>Comparison:</b> Control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Psychological treatment</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression symptoms ‐ short‐term<br/>assessed with: objective and self‐reported measures of depression symptoms, higher scores indicate more severe symptoms </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.55 SD lower</b><br/>(0.92 lower to 0.19 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1226<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is low certainty evidence that psychological treatment may result in a moderate reduction in depression symptoms at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression remission ‐ short term<br/>assessed with: below cut‐points on objective and self‐report measures of depression </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>319 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>486 per 1000</b><br/>(267 to 708) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.02</b><br/>(0.78 to 5.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>862<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is low certainty evidence that psychological treatment may result in no difference in depression remission at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ short‐term<br/>assessed with: mortality records </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/>(1 to 50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.31</b><br/>(0.05 to 2.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>324<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of psychological treatment on all‐cause mortality at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality ‐ long‐term<br/>assessed with: cause of death according to standardised criteria on mortality records </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b><br/>(54 to 93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.83</b><br/>(0.62 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2720<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data for cardiovascular mortality at end of treatment in trials comparing psychological interventions versus usual care </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myocardial infarction ‐ short term (end of treatment) ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data for occurrence of myocardial infarction at end of treatment in trials comparing psychological interventions versus usual care </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_427596582080189491" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_427596582080189491</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Risk of bias rated down one level ‐ trials that contributed to this outcome were rated as unclear risk of bias<br/><sup>b</sup> Inconsistency rated down one level ‐ though confidence intervals generally overlapped, there was considerable unexplained statistical heterogeneity<br/><sup>c</sup> Imprecision rated down one level ‐ confidence intervals encompass an adverse effect to beneficial effect<br/><sup>d</sup> Risk of bias rated down two levels ‐ most trials that contributed to this outcome were rated as high or unclear risk of bias<br/><sup>e</sup> Imprecision rated down two levels ‐ sparse events and wide confidence intervals encompass an adverse effect to beneficial effect </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008012-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Psychological treatment 1 compared to psychological treatment 2 for depression in patients with coronary artery disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Psychological treatment 1 compared to psychological treatment 2 for depression in patients with coronary artery disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> health problem or population<br/><b>Setting:</b> cardiology outpatient settings<br/><b>Intervention:</b> Psychological Treatment 1<br/><b>Comparison:</b> Psychological Treatment 2 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Psychological Treatment 2</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Psychological Treatment 1</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression symptoms ‐ short term (end of treatment)<br/>assessed with: objective and self‐reported measures of depression symptoms; higher scores indicate more severe symptoms </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No meta‐analysis performed due to clinical heterogeneity. The evidence is very uncertain as to whether different psychological interventions may result in a reduction in depression symptoms at the end of treatment for: cognitive‐behavioural therapy compared to supportive stress management (Freedland 2009); behaviour therapy compared to person‐centred therapy (Brown 1993); cognitive‐behavioural therapy and well‐being therapy compared to clinical management (TREATED‐ACS 2020). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression remission ‐ short term (end of treatment)<br/>assessed with: below cut‐off on Hamilton Rating Scale for Depression </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>571 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>707 per 1000</b><br/>(493 to 857) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.81</b><br/>(0.73 to 4.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is low certainty evidence from one trial that cognitive‐behavioural therapy may result in no difference in depression remission at the end of treatment compared to supportive stress management (Freedland 2009). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ short term (end of treatment) ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data for all‐cause mortality at end of treatment in trials comparing psychological intervention versus another psychological intervention/clinical management </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality ‐ short term (end of treatment) ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data for cardiovascular mortality at end of treatment in trials comparing psychological intervention versus another psychological intervention/clinical management </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myocardial infarction ‐ short term (end of treatment) ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data for the occurrence of myocardial infarction at end of treatment in trials comparing psychological intervention versus another psychological intervention/clinical management </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_427665509108780589" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_427665509108780589</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Imprecision rated down two levels ‐ wide confidence intervals from one trial encompass an adverse effect to beneficial effect </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008012-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ Pharmacological treatment compared to placebo for depression in patients with coronary artery disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pharmacological treatment compared to placebo for depression in patients with coronary artery disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> health problem or population<br/><b>Setting:</b> cardiology in‐ and outpatient settings<br/><b>Intervention:</b> Pharmacological<br/><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Pharmacological</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression symptoms ‐ short term<br/>assessed with: objective and self‐reported measures of depression; higher scores indicate more severe symptoms </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.83 lower</b><br/>(1.33 lower to 0.32 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>750<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is low certainty evidence that pharmacological intervention may result in a large reduction in depression symptoms at the end of treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression remission ‐ short term<br/>assessed with: below cut‐point on objective measure of depression (Hamilton Rating Scale for Depression) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>323 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>496 per 1000</b><br/>(412 to 580) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.06</b><br/>(1.47 to 2.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>646<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is moderate certainty evidence that pharmacological intervention probably results in a moderate to large increase in depression remission at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ short term<br/>assessed with: mortality records </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b><br/>(4 to 53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.38</b><br/>(0.10 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>437<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of pharmacological intervention on all‐cause mortality at the end of treatment. In addition to the pooled results, data could not be extracted from 2 studies where no deaths occurred and from 1 trial which remained unclear. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality ‐ short term (end of treatment) ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data for cardiovascular mortality at end of treatment in trials comparing pharmacological intervention versus placebo </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myocardial infarction ‐ short term<br/>assessed with: standardised criteria for fatal or non‐fatal myocardial infarction </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b><br/>(6 to 45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.74</b><br/>(0.26 to 2.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>728<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of pharmacological intervention on myocardial infarction at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_427666962988765745" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_427666962988765745</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Risk of bias rated down one level ‐ trials that contributed to this outcome were rated as unclear or high risk of bias<br/><sup>b</sup> Inconsistency rated down one level ‐ though confidence intervals generally overlapped, there was considerable unexplained statistical heterogeneity<br/><sup>c</sup> Imprecision rated down two levels ‐ sparse events and wide confidence intervals encompass an adverse effect to beneficial effect </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008012-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings table ‐ Pharmacological treatment 1 compared to pharmacological treatment 2 for depression in patients with coronary artery disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pharmacological treatment 1 compared to pharmacological treatment 2 for depression in patients with coronary artery disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> health problem or population<br/><b>Setting:</b> cardiology in‐ and outpatient settings<br/><b>Intervention:</b> Pharmacological intervention 1<br/><b>Comparison:</b> Pharmacological intervention 2 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Pharmacological intervention 2</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Pharmacological intervention 1</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression symptoms ‐ short term (end of treatment)<br/>assessed with: objective measure of depression (Hamilton Rating Scale for Depression); higher scores indicate more severe symptoms </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>442<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No meta‐analysis performed due to clinical heterogeneity. The evidence is very uncertain as to whether different pharmacological interventions may result in a reduction in depression symptoms at the end of treatment for: simvastatin compared to atorvastatin (Abbasi 2015); sertraline plus omega‐3 compared to sertraline plus placebo (Carney 2009); paroxetine compared to fluoxetine (Tian 2016); escitalopram compared to Bu Xin Qi (Wang 2020). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression remission ‐ short term (end of treatment)<br/>assessed with: below cut‐points on objective and self‐report measures of depression </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No meta‐analysis performed due to clinical heterogeneity. The evidence is very uncertain about the effect of pharmacological treatment compared to another pharmacological treatment on depression remission at the end of treatment . </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ short term (end of treatment)<br/>assessed with: mortality records </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b><br/>(14 to 281) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.72</b><br/>(0.51 to 14.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence from 1 trial is very uncertain about the effect of sertraline vs Shugan Jieyu on all‐cause mortality at the end of treatment (Liu 2016). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality ‐ short term (end of treatment) ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data for cardiovascular mortality at end of treatment in trials comparing a pharmacological intervention versus another pharmacological intervention </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myocardial infarction ‐ short term (end of treatment)<br/>assessed with: standardised criteria for fatal and non‐fatal myocardial infarction </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>396<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No meta‐analysis performed due to clinical heterogeneity. The evidence is very uncertain about the effect of pharmacological treatment compared to another pharmacological treatment on the occurrence of myocardial infarction at end of treatment for: sertraline plus omega‐3 compared to sertraline plus placebo (Carney 2009); paroxetine compared to fluoxetine (Tian 2016); escitalopram compared to Bu Xin Qi (Wang 2020). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_428037497253281678" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_428037497253281678</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Risk of bias rated down one level ‐ the trial(s) that contributed to this outcome were rated as unclear or high risk of bias<br/><sup>b</sup> Imprecision rated down two levels ‐ sparse events and wide confidence intervals encompass an adverse effect to beneficial effect </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008012-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008012-sec-0009"></div> <p>Coronary artery disease (CAD) is amongst the leading causes of death for both men and women in middle‐ and high‐ income countries (<a href="./references#CD008012-bbs2-0217" title="RothGA , JohnsonC , AbajobirA , Abd-AllahF , AberaSF , AbyuG , et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. Journal of the American College of Cardiology2017;70(1):1-25.">Roth 2017</a>). A strong association between CAD and comorbid depression has been consistently reported (<a href="./references#CD008012-bbs2-0154" title="BauneB , StuartM , GilmourA , WerschingH , HeindelW , AroltV , et al. The relationship between subtypes of depression and cardiovascular disease: a systematic review of biological models.. Translational Psychiatry2012;2:e92.">Baune 2012</a>; <a href="./references#CD008012-bbs2-0195" title="KendlerKS , GardnerCO , FiskeA , GatzM . Major depression and coronary artery disease in the Swedish twin registry: phenotypic, genetic, and environmental sources of comorbidity. Archives of General Psychiatry2009;66(8):857-63.">Kendler 2009</a>; <a href="./references#CD008012-bbs2-0219" title="ScherrerJF , XianH , BucholzKK , EisenSA , LyonsMJ , GoldbergJ , et al. A twin study of depression symptoms, hypertension, and heart disease in middle-aged men. Psychosomatic Medicine2003;65(4):548-57.">Scherrer 2003</a>; <a href="./references#CD008012-bbs2-0221" title="Schulman-MarcusJ , ShahT , SwaminathanRV , FeldmanDN , WongSC , SinghHS , et al. Comparison of recent trends in patients with and without major depression and acute ST-elevation myocardial infarction. American Journal of Cardiology2016;118(6):779-84.">Schulman‐Marcus 2016</a>; <a href="./references#CD008012-bbs2-0225" title="StenmanM , HolzmannMJ , SartipyU . Relation of major depression to survival after coronary artery bypass grafting. American Journal of Cardiology2014;114(5):698-703.">Stenman 2014</a>), which is similar to the association observed in other chronic disease populations (<a href="./references#CD008012-bbs2-0160" title="ChenSF , ChienYH , ChenPC , WangIJ . Association of age with risk of major depression among patients with chronic kidney disease over midlife: a nationwide cohort study in Taiwan. International Psychogeriatrics2019;31(8):1171-9.">Chen 2019</a>; <a href="./references#CD008012-bbs2-0184" title="HärterM , BaumeisterH , ReuterK , JacobiF , HöflerM , BengelJ , et al. Increased 12-month prevalence rates of mental disorders in patients with chronic somatic diseases. Psychotherapy and Psychosomatics2007;76:354-60.">Härter 2007</a>; <a href="./references#CD008012-bbs2-0202" title="MatteDL , PizzichiniMM , HoepersAT , DiazAP , KarlohM , DiasM , et al. Prevalence of depression in COPD: a systematic review and meta-analysis of controlled studies. Respiratory Medicine2016;117:154-61.">Matte 2016</a>; <a href="./references#CD008012-bbs2-0203" title="MezukB , HehV , Prom-WormleyE , KendlerKS , PedersenNL . Association between major depression and type 2 diabetes in midlife: findings from the Screening Across the Lifespan Twin Study. Psychosomatic Medicine2015;77(5):559-66.">Mezuk 2015</a>; <a href="./references#CD008012-bbs2-0211" title="PetrakF , BaumeisterH , SkinnerTC , BrownA , HoltRI . Depression and diabetes: treatment and health-care delivery. Lancet Diabetes &amp; Endocrinology2015;3(6):472-85.">Petrak 2015</a>). Results from the World Mental Health Surveys, <a href="./references#CD008012-bbs2-0210" title="OrmelJ , Von KorffM , BurgerH , ScottK , DemyttenaereK , HuangYQ , et al. Mental disorders among persons with heart disease - results from World Mental Health surveys. General Hospital Psychiatry2007;29:325-34.">Ormel 2007</a>, indicate a twofold increased risk of depression for individuals with heart disease compared to those without heart disease and conversely, an increased risk of developing incident heart disease in individuals with depression compared to those without depression (<a href="./references#CD008012-bbs2-0223" title="ScottKM , deJongeP , AlonsoJ , VianaMC , LiuZ , O'NeillS , et al. Associations between DSM-IV mental disorders and subsequent heart disease onset: beyond depression. International Journal of Cardiology2013;168(6):5293-9.">Scott 2013</a>). Prevalence rates of major depression in CAD populations, including those undergoing coronary revascularisation procedures, range from 15% to 20% (<a href="./references#CD008012-bbs2-0209" title="NieuwsmaJA , Williams JW Jr, NamdariN , WashamJB , RaitzG , BlumenthalJA , et al. Diagnostic accuracy of screening tests and treatment for post-acute coronary syndrome depression: a systematic review. Annals of Internal Medicine2017;167(10):725-35.">Nieuwsma 2017</a>; <a href="./references#CD008012-bbs2-0229" title="ThombsBD , deJongeP , CoyneJC , WhooleyMA , Frasure-SmithN , MitchellAJ , et al. Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA2008;300(18):2161-71.">Thombs 2008</a>; <a href="./references#CD008012-bbs2-0230" title="TullyPJ , BakerRA . Depression, anxiety, and cardiac morbidity outcomes after coronary artery bypass surgery: a contemporary and practical review. Journal of Geriatric Cardiology2012;9(2):197-208.">Tully 2012</a>), and are thus disproportionate to that observed in the general community (<a href="./references#CD008012-bbs2-0196" title="KesslerRC , BirnbaumH , BrometE , HwangI , SampsonN , ShahlyV . Age differences in major depression: results from the National Comorbidity Survey Replication (NCS-R). Psychological Medicine2010;40(2):225-37.">Kessler 2010</a>). </p> <p>The increased prevalence rates raise the issue of the impact of comorbid depression on the lives of these individuals and the healthcare system. Several original studies and systematic reviews document a significant prognostic association between comorbid depression and increased mortality, morbidity, and healthcare costs, as well as diminished quality of life and adherence to treatment regimen (<a href="./references#CD008012-bbs2-0133" title="AbbergerB , HaschkeA , TullyPJ , ForkmannT , BergerJ , WirtzM , et al. Development and validation of parallel short forms PaSA-cardio for the assessment of general anxiety in cardiovascular rehabilitation patients using Rasch analysis. Clinical Rehabilitation2017;31(1):104-14.">Abberger 2017</a>; <a href="./references#CD008012-bbs2-0141" title="BarthJ , SchumacherM , Herrmann-LingenC . Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosomatic Medicine2004;66:802-13.">Barth 2004</a>; <a href="./references#CD008012-bbs2-0238" title="BaumeisterH , HutterN , BengelJ . Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD008012. [DOI: 10.1002/14651858.CD008012.pub3]">Baumeister 2011c</a>; <a href="./references#CD008012-bbs2-0179" title="Frasure-SmithN , LesperanceF . Depression and other psychological risks following myocardial infarction. Archives of General Psychiatry2003;60(6):627-36.">Frasure‐Smith 2003a</a>; <a href="./references#CD008012-bbs2-0180" title="Frasure-SmithN , LespéranceF . Depression and anxiety as predictors of cardiac events in patients with stable coronary artery disease. Archives Of General Psychiatry2008;65(1):62-71.">Frasure‐Smith 2008</a>; <a href="./references#CD008012-bbs2-0201" title="LichtmanJH , FroelicherES , BlumenthalJA , CarneyRM , DoeringLV , Frasure-SmithN , et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation2014;129:1350-69.">Lichtman 2014</a>; <a href="./references#CD008012-bbs2-0208" title="NicholsonA , KuperH , HemingwayH . Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 146 538 participants. European Heart Journal2006;27(23):2763-74.">Nicholson 2006</a>). </p> <section id="CD008012-sec-0010"> <h3 class="title" id="CD008012-sec-0010">Description of the condition</h3> <p>Coronary artery disease is one of the most common forms of heart disease. One of the main underlying problems in cardiovascular disease is atherosclerosis, a process that obstructs blood vessels with deposits of fat, cholesterol, and other substances (<a href="./references#CD008012-bbs2-0235" title="World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Clinical description and diagnostic guidelines. 10th edition. Geneva: World Health Organization, 1992.">WHO 1992</a>). It is most serious when it restricts the blood supply to the heart itself (myocardial ischaemia). Clinical manifestations of CAD are acute coronary syndrome comprising myocardial infarction (MI) and unstable angina (<a href="./references#CD008012-bbs2-0136" title="AntmanEM , AnbeDT , ArmstrongPW , BatesER , GreenLA , HandM , et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation2004;44:e82-292.">Antman 2004</a>), as well as stable angina pectoris (<a href="./references#CD008012-bbs2-0177" title="FoxK , GarciaMA , ArdissinoD , BuszmanP , CamiciPG , CreaF , et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. European Heart Journal2006;27:1341-81.">Fox 2006</a>). MI refers to what is commonly known as a 'heart attack'. It occurs when prolonged myocardial ischaemia leads to myocardial cell death (necrosis) (<a href="./references#CD008012-bbs2-0134" title="AlpertJS , ThygesenK , AntmanE , BassandJP . Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Journal of the American College of Cardiology2000;36:959-69.">Alpert 2000</a>). </p> <p>Depression is an emotional state characterised by strong feelings of sadness, worthlessness and guilt, withdrawal from others, sleeplessness, and loss of appetite, sexual desire, and interest in usual activities (<a href="./references#CD008012-bbs2-0170" title="DavisonGC , NealeJM . Abnormal Psychology. New York, NY: John Wiley &amp; Sons, 2003.">Davison 2003</a>), occurring in several subtypes (<a href="./references#CD008012-bbs2-0154" title="BauneB , StuartM , GilmourA , WerschingH , HeindelW , AroltV , et al. The relationship between subtypes of depression and cardiovascular disease: a systematic review of biological models.. Translational Psychiatry2012;2:e92.">Baune 2012</a>). Two key diagnostic criteria for major depression are depressed mood and loss of pleasure or interest in activities (anhedonia; <a href="./references#CD008012-bbs2-0138" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. Washington, DC: American Psychiatric Association, 2013.">APA 2013</a>). Depressive disorders can be reliably diagnosed through structured clinical interviews. The severity of depressive symptoms is usually assessed by patient‐ or clinician‐administered rating scales that have undergone psychometric validation. Cut‐off scores have been validated for these scales that correspond to the likelihood of an indication of depression (<a href="./references#CD008012-bbs2-0218" title="SadockBJ , SadockVA , RuizP , editor(s). Kaplan &amp; Sadock’s Comprehensive Textbook of Psychiatry. 9th edition. Philadelphia; London: Lippincott Williams &amp; Wilkins, 2009.">Sadock 2009</a>). Recommendations for the assessment of depression in individuals with cardiovascular disease are available (<a href="./references#CD008012-bbs2-0169" title="DavidsonKW , KupferDJ , BiggerJT , CaliffRM , CarneyRM , CoyneJC , et al. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute working group report. Annals of Behavioral Medicine2006;32:121-6.">Davidson 2006</a>; <a href="./references#CD008012-bbs2-0201" title="LichtmanJH , FroelicherES , BlumenthalJA , CarneyRM , DoeringLV , Frasure-SmithN , et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation2014;129:1350-69.">Lichtman 2014</a>; <a href="./references#CD008012-bbs2-0209" title="NieuwsmaJA , Williams JW Jr, NamdariN , WashamJB , RaitzG , BlumenthalJA , et al. Diagnostic accuracy of screening tests and treatment for post-acute coronary syndrome depression: a systematic review. Annals of Internal Medicine2017;167(10):725-35.">Nieuwsma 2017</a>; <a href="./references#CD008012-bbs2-0229" title="ThombsBD , deJongeP , CoyneJC , WhooleyMA , Frasure-SmithN , MitchellAJ , et al. Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA2008;300(18):2161-71.">Thombs 2008</a>). </p> </section> <section id="CD008012-sec-0011"> <h3 class="title" id="CD008012-sec-0011">Description of the intervention</h3> <p>Psychological interventions comprise cognitive behavioural therapy (CBT), psychodynamic psychotherapy, interpersonal therapy (IPT), other approaches such as problem‐solving therapy, non‐directive or supportive therapy and counselling as well as single techniques of these interventions (<a href="./references#CD008012-bbs2-0170" title="DavisonGC , NealeJM . Abnormal Psychology. New York, NY: John Wiley &amp; Sons, 2003.">Davison 2003</a>). Other interventions comprise acceptance and commitment therapy, mindfulness‐based cognitive therapy and mindfulness‐based stress reduction, emotion‐focused therapy, and metacognitive therapy (<a href="./references#CD008012-bbs2-0140" title="The Australian Psychological Society. Evidence-Based Psychological Interventions in the Treatment of Mental Disorders: a Literature Review. 4th edition. The Australian Psychological Society Ltd, 2018.">Australian Psychological Society 2018</a>). The mode of delivery comprises individual, group, or family (including couple) therapy carried out by a healthcare professional. </p> <p>A network meta‐analysis comparing seven psychotherapeutic approaches concluded that most approaches were equally effective, with IPT being more effective than supportive therapy (Cohen's d = −0.30, 95% confidence interval (CI) −0.54 to −0.05) (<a href="./references#CD008012-bbs2-0142" title="BarthJ , MunderT , GergerH , NüeschE , TrelleS , ZnojH , et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. PLoS Medicine2013;10:e1001454.">Barth 2013</a>). However, this conclusion needs to be considered preliminary, as single trials lack statistical power, and meta‐analyses are limited by the heterogeneous methodological standards of primary studies (<a href="./references#CD008012-bbs2-0168" title="CuijpersP . Are all psychotherapies equally effective in the treatment of adult depression? The lack of statistical power of comparative outcome studies. Evidence-Based Mental Health2016;19:39-42.">Cuijpers 2016</a>). This might be even more true regarding psychological depression interventions for individuals with CAD, given the diversity of psychological interventions offered, from nurse‐led and low‐intensive, two‐session interventions to regular psychotherapies with at least 12 to 16 therapy sessions, offered at varying time points post‐cardiac event (<a href="./references#CD008012-bbs2-0238" title="BaumeisterH , HutterN , BengelJ . Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD008012. [DOI: 10.1002/14651858.CD008012.pub3]">Baumeister 2011c</a>; <a href="./references#CD008012-bbs2-0152" title="BaumeisterH , HutterN , BengelJ . Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD008381. [DOI: 10.1002/14651858.CD008381.pub2]">Baumeister 2012b</a>; <a href="./references#CD008012-bbs2-0174" title="DoyleF , FreedlandKE , CarneyRM , deJongeP , DickensC , PedersenSS , et al. Hybrid systematic review and network meta-analysis of randomized controlled trials of interventions for depressive symptoms in patients with coronary artery disease. Psychosomatic Medicine2021;83:423-31.">Doyle 2021</a>). </p> <p>Antidepressant drugs are commonly used treatments in people with depression. In general, the available medications do not differ in their overall efficacy and effectiveness, but differ substantially with regard to short‐ and long‐term side effects (<a href="./references#CD008012-bbs2-0207" title="National Institute for Health and Clinical Excellence. Depression in adults with a chronic physical health problem: recognition and management Clinical guideline [CG91]. www.nice.org.uk/guidance/CG91 (accessed 26 July 2011).">NICE 2009</a>; <a href="./references#CD008012-bbs2-0218" title="SadockBJ , SadockVA , RuizP , editor(s). Kaplan &amp; Sadock’s Comprehensive Textbook of Psychiatry. 9th edition. Philadelphia; London: Lippincott Williams &amp; Wilkins, 2009.">Sadock 2009</a>). Antidepressant treatment selection depends on the type of depressive disorder and the presence of comorbid somatic or mental disorders. The main pharmacological classes of antidepressant medications are selective serotonin reuptake inhibitors (SSRIs), serotonin‐norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). For CAD patients with moderate, severe, or recurrent depression, SSRIs are viewed as safe and effective pharmacological agents (<a href="./references#CD008012-bbs2-0200" title="LichtmanJH , BiggerJT , BlumenthalJA , Frasure-SmithN , KaufmannPG , LesperanceF , et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation2008;118:1768-75.">Lichtman 2008</a>). In contrast, TCAs and MAOIs are contraindicated in CAD patients because of their cardiac side effects such as prolongation of the QT interval on electrocardiogram (<a href="./references#CD008012-bbs2-0200" title="LichtmanJH , BiggerJT , BlumenthalJA , Frasure-SmithN , KaufmannPG , LesperanceF , et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation2008;118:1768-75.">Lichtman 2008</a>). Other potential pharmacological interventions include repurposing vascular drugs intended to lower cholesterol or blood pressure for the treatment of depression (<a href="./references#CD008012-bbs2-0161" title="CiprianiA , SaundersK , AttenburrowMJ , StefaniakJ , PanchalP , StocktonS , et al. A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development. Molecular Psychiatry2016;21:1324-32.">Cipriani 2016</a>; <a href="./references#CD008012-bbs2-0227" title='TaraganoFE , BagnattiP , AllegriRF . A double-blind, randomized clinical trial to assess the augmentation with nimodipine of antidepressant therapy in the treatment of "vascular depression". International Psychogeriatrics2005;17:487-98.'>Taragano 2005</a>). In addition, interventions may explore diet and supplements such as n‐3 polyunsaturated fatty acids, also known as omega‐3 oils (<a href="./references#CD008012-bbs2-0139" title="AppletonKM , SallisHM , PerryR , NessAR , ChurchillR . Omega‐3 fatty acids for depression in adults. Cochrane Database of Systematic Reviews2015, Issue 11. Art. No: CD004692. [DOI: 10.1002/14651858.CD004692.pub4]">Appleton 2015</a>). </p> <p>A systematic review experimentally comparing psychological or psychotherapy and pharmacological approaches indicated that overall, psychological and pharmacological interventions are equally effective for treating depression, with pharmacotherapy seemingly being superior in dysthymia (Hedges' g = 0.3) as well as compared to non‐directive counselling (Hedges' g = 0.33), and psychotherapy being superior to tricyclic antidepressants (Hedges' g = 0.21) (<a href="./references#CD008012-bbs2-0167" title="CuijpersP , SijbrandijM , KooleSL , AnderssonG , BeekmanAT , ReynoldsCF . The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry2013;12:137-48.">Cuijpers 2013</a>). Combining both pharmacotherapy and psychotherapy is superior to pharmacotherapy alone at six months or longer postrandomisation (odds ratio (OR) 2.93). However, and conversely, psychotherapy alone compared to combined therapy resulted in equal depression effects at six months follow‐up and longer (<a href="./references#CD008012-bbs2-0193" title="KaryotakiE , SmitY , Holdt HenningsenK , HuibersMJ , RobaysJ , deBeursD , et al. Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects. Journal of Affective Disorders2016;194:144-52.">Karyotaki 2016</a>). </p> </section> <section id="CD008012-sec-0012"> <h3 class="title" id="CD008012-sec-0012">How the intervention might work</h3> <p>Many biological and behavioural mechanisms linking CAD and depression have been proposed (<a href="./references#CD008012-bbs2-0158" title="CarneyRM , FreedlandKE . Depression and coronary heart disease. Nature Reviews Cardiology2017;14:145-55.">Carney 2017</a>; <a href="./references#CD008012-bbs2-0185" title="HärterM , BaumeisterH . Etiology of mental disorders in chronic somatic diseases [Ätiologie psychischer Störungen bei chronischen körperlichen Erkrankungen]. In: HärterM , BaumeisterH , BengelJ , editors(s). Psychische Störungen bei körperlichen Erkrankungen. Heidelberg: Springer, 2007:1-13.">Härter 2007a</a>; <a href="./references#CD008012-bbs2-0192" title="JoyntKE , WhellanDJ , O'ConnorCM . Depression and cardiovascular disease: mechanisms of interaction. Biological Psychiatry2003;54:248-61.">Joynt 2003</a>; <a href="./references#CD008012-bbs2-0205" title="MusselmanDL , EvansDL , NemeroffCB . The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Archives of General Psychiatry1998;55:580-92.">Musselman 1998</a>; <a href="./references#CD008012-bbs2-0224" title="SkalaJA , FreedlandKE , CarneyRM . Coronary heart disease and depression: a review of recent mechanistic research. Canadian Journal of Psychiatry2006;51:738-45.">Skala 2006</a>), comprising pathophysiological pathways such as decreased heart rate variability, platelet activation, and endothelial dysfunction in depressed CAD patients (<a href="./references#CD008012-bbs2-0136" title="AntmanEM , AnbeDT , ArmstrongPW , BatesER , GreenLA , HandM , et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation2004;44:e82-292.">Antman 2004</a>). Furthermore, an accumulation of behavioural (smoking, physical inactivity, and imbalanced diet) and medical risk factors (hypertension, diabetes, and obesity) in depressed patients might affect the development and course of CAD (<a href="./references#CD008012-bbs2-0192" title="JoyntKE , WhellanDJ , O'ConnorCM . Depression and cardiovascular disease: mechanisms of interaction. Biological Psychiatry2003;54:248-61.">Joynt 2003</a>; <a href="./references#CD008012-bbs2-0236" title="WhooleyMA , deJongeP , VittinghoffE , OtteC , MoosR , CarneyRM , et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA2008;300:2379-88.">Whooley 2008</a>). Psychosocial stress constitutes a risk factor for both CAD and depression (<a href="./references#CD008012-bbs2-0192" title="JoyntKE , WhellanDJ , O'ConnorCM . Depression and cardiovascular disease: mechanisms of interaction. Biological Psychiatry2003;54:248-61.">Joynt 2003</a>). </p> <p>A review concluded that pharmacological interventions for depression might influence physiological pathways linking depression and CAD (<a href="./references#CD008012-bbs2-0158" title="CarneyRM , FreedlandKE . Depression and coronary heart disease. Nature Reviews Cardiology2017;14:145-55.">Carney 2017</a>). Psychological treatments may also affect physiological processes, but the interrelations between behavioural and physiological mechanisms remain less clear (<a href="./references#CD008012-bbs2-0158" title="CarneyRM , FreedlandKE . Depression and coronary heart disease. Nature Reviews Cardiology2017;14:145-55.">Carney 2017</a>). Psychological interventions might improve not only depression outcomes in CAD patients with comorbid depressive disorder, but also medical outcome parameters, by encouraging behaviour changes towards a healthier lifestyle in these patients (<a href="./references#CD008012-bbs2-0175" title="FirthJ , SiddiqiN , KoyanagiA , SiskindD , RosenbaumS , GalletlyC , et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry2019;6:675-712.">Firth 2019</a>; <a href="./references#CD008012-bbs2-0214" title="RichardsSH , AndersonL , JenkinsonCE , WhalleyB , ReesK , DaviesP , et al. Psychological interventions for coronary heart disease. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD002902. [DOI: 10.1002/14651858.CD002902.pub4]">Richards 2017</a>). </p> </section> <section id="CD008012-sec-0013"> <h3 class="title" id="CD008012-sec-0013">Why it is important to do this review</h3> <p>Due to high prevalence rates and the impact of comorbid depression on both medical and psychosocial outcomes, there is a need for effective depression treatments in CAD. In various systematic reviews, psychological and psychopharmacological interventions have proven to be effective interventions for the treatment of major depression (<a href="./references#CD008012-bbs2-0164" title="CuijpersP , vanStratenA , AnderssonG , vanOppenP . Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. Journal of Consulting and Clinical Psychology2008;76:909-22.">Cuijpers 2008a</a>; <a href="./references#CD008012-bbs2-0165" title="CuijpersP , vanStratenA , AnderssonG , vanOppenP . Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. Journal of Clinical Psychiatry2008;69:1675-85.">Cuijpers 2008b</a>; <a href="./references#CD008012-bbs2-0167" title="CuijpersP , SijbrandijM , KooleSL , AnderssonG , BeekmanAT , ReynoldsCF . The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry2013;12:137-48.">Cuijpers 2013</a>; <a href="./references#CD008012-bbs2-0193" title="KaryotakiE , SmitY , Holdt HenningsenK , HuibersMJ , RobaysJ , deBeursD , et al. Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects. Journal of Affective Disorders2016;194:144-52.">Karyotaki 2016</a>; <a href="./references#CD008012-bbs2-0207" title="National Institute for Health and Clinical Excellence. Depression in adults with a chronic physical health problem: recognition and management Clinical guideline [CG91]. www.nice.org.uk/guidance/CG91 (accessed 26 July 2011).">NICE 2009</a>; <a href="./references#CD008012-bbs2-0218" title="SadockBJ , SadockVA , RuizP , editor(s). Kaplan &amp; Sadock’s Comprehensive Textbook of Psychiatry. 9th edition. Philadelphia; London: Lippincott Williams &amp; Wilkins, 2009.">Sadock 2009</a>). However, the evidence on the effectiveness of psychological and pharmacological depression interventions for people with CAD and depression is far less conclusive (Baumeister 2011c), and prone to bias in the literature (<a href="./references#CD008012-bbs2-0174" title="DoyleF , FreedlandKE , CarneyRM , deJongeP , DickensC , PedersenSS , et al. Hybrid systematic review and network meta-analysis of randomized controlled trials of interventions for depressive symptoms in patients with coronary artery disease. Psychosomatic Medicine2021;83:423-31.">Doyle 2021</a>), which argues for an update of our Cochrane Review. Several clinical guidelines recommend depression intervention in CAD populations whilst noting the limited efficacy in preventing major adverse cardiac events, based on few trials to date (<a href="./references#CD008012-bbs2-0190" title="HillisLD , SmithPK , AndersonJL , BittlJA , BridgesCR , ByrneJG , et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation2011;124(23):e652-735.">Hillis 2011</a>; <a href="./references#CD008012-bbs2-0201" title="LichtmanJH , FroelicherES , BlumenthalJA , CarneyRM , DoeringLV , Frasure-SmithN , et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation2014;129:1350-69.">Lichtman 2014</a>). </p> <p>Another Cochrane Review examined the effects of non‐specific psychological interventions in CAD patients and found small to moderate reductions in depression, anxiety, and stress symptoms as well as a 22% reduction in MI compared to usual care (Richards 2017). However, the review did not study the effects of depression‐specific treatment in the population of CAD patients with a comorbid depressive disorder or depression symptoms. Furthermore, the review included non‐specific psychological interventions and interventions delivered in combination with cardiac rehabilitation, whereas the focus of our review is on depression‐specific psychological or pharmacological interventions explicitly used for treating depression in populations with depression. Some randomised controlled trials may be included in both reviews, but the research questions remain different owing to the focus of our review on the effects of depression treatments in depressed CAD patients. </p> <p>The current review will permit the drawing of conclusions on the effects of depression treatment in CAD patients with comorbid depressive disorders. Depending on the number of primary studies, conclusions may be drawn concerning differential effects of type of intervention on depression and mortality or cardiovascular events, as well as on participant quality of life (QoL), thus providing a basis for treatment recommendations. Furthermore, follow‐up data may be examined concerning the healthcare costs of the interventions. Sources of heterogeneity in the results of the primary studies can be explored and could help provide suggestions for the design of future studies. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008012-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008012-sec-0014"></div> <p>To determine the effects of psychological and pharmacological interventions for depression in CAD patients with comorbid depression. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008012-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008012-sec-0015"></div> <section id="CD008012-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008012-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled clinical trials (RCTs) of any length of treatment and any length of follow‐up. Both individually and cluster‐randomised clinical trials were eligible. We included studies reported as full text, those published as abstract only, and unpublished data. </p> </section> <section id="CD008012-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adults (18 years or older) with CAD (International Statistical Classification of Diseases and Related Health Problems (ICD‐10): I20‐I25, <a href="./references#CD008012-bbs2-0235" title="World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Clinical description and diagnostic guidelines. 10th edition. Geneva: World Health Organization, 1992.">WHO 1992</a>, or later versions of the ICD) and comorbid depressive disorder (ICD‐10: F32/33/34.1 (<a href="./references#CD008012-bbs2-0235" title="World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Clinical description and diagnostic guidelines. 10th edition. Geneva: World Health Organization, 1992.">WHO 1992</a>); <i>Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised</i> (<i>DSM‐III‐R</i>): 296.xx; 300.4, <a href="./references#CD008012-bbs2-0137" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-III-R. 3rd edition. Washington, DC: American Psychiatric Association, 1987.">APA 1987</a>, or later versions of diagnostic classification systems; including subthreshold conditions) assessed by standardised interviews, self‐reports, medical records, or physicians' diagnosis. Studies comprised of individuals with non‐CAD conditions were ineligible. Inclusion of primary studies was not further limited to specific clinical subgroups in order to increase the generalisability of the results of the review. </p> <p>With regard to comorbid depression, studies comprising mixed study samples (e.g. both depressed CAD patients and CAD patients with low social support (<a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>)) were included in the review. </p> </section> <section id="CD008012-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Psychological interventions comprise CBT, psychodynamic psychotherapy, IPT, non‐directive or supportive therapy and counselling (<a href="./references#CD008012-bbs2-0170" title="DavisonGC , NealeJM . Abnormal Psychology. New York, NY: John Wiley &amp; Sons, 2003.">Davison 2003</a>), acceptance and commitment therapy, mindfulness‐based cognitive therapy, mindfulness‐based stress reduction, emotion‐focused therapy, and metacognitive therapy (<a href="./references#CD008012-bbs2-0140" title="The Australian Psychological Society. Evidence-Based Psychological Interventions in the Treatment of Mental Disorders: a Literature Review. 4th edition. The Australian Psychological Society Ltd, 2018.">Australian Psychological Society 2018</a>). In the first instance, we pooled all psychological interventions together, conducted analyses of heterogeneity, and took this into consideration when adjudicating the strength of evidence. The mode of delivery was defined as individual, group, or family (including couple) therapy carried out in whole or in part by a healthcare professional. The comparison group was defined consistent with a similar review of type 1 diabetes interventions (<a href="./references#CD008012-bbs2-0237" title="WinkleyK , UpsherR , StahlD , PollardD , BrennanA , HellerS , et al. Systematic review and meta-analysis of randomized controlled trials of psychological interventions to improve glycaemic control in children and adults with type 1 diabetes. Diabetic Medicine2020;37(5):735-46.">Winkley 2020</a>): 'no intervention', 'usual care', 'wait‐list control', 'attention‐control' or 'clinical management' (CM). </p> <p>With regard to differential or incremental effects of different treatment approaches, we also considered trials with a control group receiving pharmacological treatment or another psychological treatment (Comparison 2 and Comparison 4). In accordance with the previous review (<a href="./references#CD008012-bbs2-0238" title="BaumeisterH , HutterN , BengelJ . Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD008012. [DOI: 10.1002/14651858.CD008012.pub3]">Baumeister 2011c</a>), we grouped separately studies using CM as a comparator intervention or other psychological intervention. The rationale for this was that CM, which consists of information about depression and depression treatment, provides a more concerted approach to depression management than does usual care (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>), with CM delivered by health professionals and often for equal intensity as an intervention. By contrast, usual care commonly involves no depression treatment at all, even when incentives are provided (<a href="./references#CD008012-bbs2-0191" title="JaniBD , PurvesD , BarryS , CavanaghJ , McLeanG , MairFS . Challenges and implications of routine depression screening for depression in chronic disease and multimorbidity. PLoS ONE2013;8:e74610.">Jani 2013</a>; <a href="./references#CD008012-bbs2-0216" title="RollmanBL , BelnapBH , LeMenagerMS , MazumdarS , HouckPR , CounihanPJ , et al. Telephone-delivered collaborative care for treating post-CABG depression: a randomized controlled trial. JAMA2009;302:2095-103. [PMID: 19918088]">Rollman 2009</a>). In head‐to‐head comparison trials of psychological interventions or CM, we abstained from pooling across different treatments, consistent with the original review (<a href="./references#CD008012-bbs2-0238" title="BaumeisterH , HutterN , BengelJ . Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD008012. [DOI: 10.1002/14651858.CD008012.pub3]">Baumeister 2011c</a>), owing to the heterogeneity in clinical interventions and their heterogenous comparators. </p> <p>Pharmacological interventions included all antidepressant medications and other drug therapies used explicitly for treating depressive disorders (<a href="./references#CD008012-bbs2-0218" title="SadockBJ , SadockVA , RuizP , editor(s). Kaplan &amp; Sadock’s Comprehensive Textbook of Psychiatry. 9th edition. Philadelphia; London: Lippincott Williams &amp; Wilkins, 2009.">Sadock 2009</a>). The control group was placebo. In the first instance, we pooled all pharmacological interventions and conducted analyses of heterogeneity. We included pharmacological treatments compared to other pharmacological medications, as well as add‐on therapies or augmentation strategies, or by comparison to psychological interventions, to determine differential or incremental effects. In accordance with the previous review (<a href="./references#CD008012-bbs2-0238" title="BaumeisterH , HutterN , BengelJ . Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD008012. [DOI: 10.1002/14651858.CD008012.pub3]">Baumeister 2011c</a>), we grouped separately head‐to‐head comparison trials of pharmacological interventions. We abstained from pooling across different studies owing to the heterogeneity in clinical interventions and their heterogenous comparators. </p> </section> <section id="CD008012-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Reporting one or more of the outcomes listed here in the trial was not an inclusion criterion for the review. Where a published report did not appear to report one of these outcomes, we accessed the trial protocol and contacted the trial authors to ascertain whether the outcomes were measured but not reported. Relevant trials that measured these outcomes but did not report the data at all, or not in a useable format, were included in the review as part of the narrative. </p> <p>We assessed outcomes at three follow‐up periods, consistent with the previous review by <a href="./references#CD008012-bbs2-0238" title="BaumeisterH , HutterN , BengelJ . Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD008012. [DOI: 10.1002/14651858.CD008012.pub3]">Baumeister 2011c</a>: </p> <p> <ul id="CD008012-list-0001"> <li> <p>short term (at the end of treatment), which was the primary time point of clinical interest for the review; </p> </li> <li> <p>medium term (one to six months after the end of treatment);</p> </li> <li> <p>long term (more than six months after the end of treatment).</p> </li> </ul> </p> <p>Multiple observations in primary studies were allocated to separate analyses by different time frames, which reflect short‐, medium‐, and long‐term follow‐up. The rationale for subdividing outcomes by time was to assess the durability of interventions, given that evidence was sparse for longer‐term outcomes in the previous review (<a href="./references#CD008012-bbs2-0238" title="BaumeisterH , HutterN , BengelJ . Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD008012. [DOI: 10.1002/14651858.CD008012.pub3]">Baumeister 2011c</a>). </p> <section id="CD008012-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008012-list-0002"> <li> <p>Depression (measured either dimensionally or categorically) following the intervention, as assessed by validated self‐report questionnaires or standardised interviews. Depression may be quantified categorically as 'remitted' or 'response', the latter defined as a 50% or more reduction in severity from baseline. </p> </li> <li> <p>All‐cause mortality.</p> </li> <li> <p>Cardiovascular mortality.</p> </li> <li> <p>Non‐fatal cardiac events according to standardised criteria (e.g. <a href="./references#CD008012-bbs2-0235" title="World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Clinical description and diagnostic guidelines. 10th edition. Geneva: World Health Organization, 1992.">WHO 1992</a> or subsequent iterations): </p> <ul id="CD008012-list-0003"> <li> <p>myocardial infarction (MI);</p> </li> <li> <p>angina;</p> </li> <li> <p>heart failure;</p> </li> <li> <p>arrhythmia;</p> </li> <li> <p>stroke;</p> </li> <li> <p>Coronary revascularisation for CAD: coronary artery bypass graft (CABG) and/or percutaneous coronary intervention (PCI) or angioplasty. </p> </li> </ul> </li> </ul> </p> <p>We analysed the primary outcomes separately and abstained from pooling a composite outcome, with two exceptions: 1) acute coronary syndromes (inclusive of ST and non‐ST elevated MI, and/or unstable angina) were collapsed into MI (for one study, <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>); and 2) coronary revascularisation for CAD was inclusive of CABG and/or PCI or angioplasty. Here we grouped coronary revascularisation for CAD under cardiac events, as opposed to healthcare utilisation, in line with common definitions of major adverse cardiac events (<a href="./references#CD008012-bbs2-0157" title="BoscoE , HsuehL , McConeghyKW , GravensteinS , SaadeE . Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Medical Research Methodology2021;21(1):241.">Bosco 2021</a>). </p> </section> <section id="CD008012-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008012-list-0004"> <li> <p>Healthcare costs or resource utilisation, including:</p> <ul id="CD008012-list-0005"> <li> <p>hospitalisations;</p> </li> <li> <p>emergency department visits;</p> </li> <li> <p>length of stay.</p> </li> </ul> </li> <li> <p>Health‐related quality of life.</p> </li> <li> <p>Cardiovascular vital signs:</p> <ul id="CD008012-list-0006"> <li> <p>systolic blood pressure (BP) measured in mmHg;</p> </li> <li> <p>diastolic BP measured in mmHg;</p> </li> <li> <p>heart rate measured in beats per minute (bpm).</p> </li> </ul> </li> <li> <p>Biomarkers of platelet activation:</p> <ul id="CD008012-list-0007"> <li> <p>β‐thromboglobulin (βTG);</p> </li> <li> <p>platelet factor 4 (PF4);</p> </li> <li> <p>P‐selectin;</p> </li> <li> <p>platelet/endothelial cell adhesion molecule‐1 (PECAM‐1);</p> </li> <li> <p>thromboxane B<sub>2</sub> (TxB<sub>2</sub>). </p> </li> </ul> </li> <li> <p>Electrocardiogram (ECG) wave recording in milliseconds:</p> <ul id="CD008012-list-0008"> <li> <p>PR interval;</p> </li> <li> <p>QRS interval;</p> </li> <li> <p>QT interval;</p> </li> <li> <p>QTc interval.</p> </li> </ul> </li> <li> <p>Non‐cardiac adverse events (psychiatric admission, suicide, worsening depression). In pharmacological interventions side effects were also assessed. </p> </li> </ul> </p> <p>Analysis of the secondary outcomes cardiovascular vital signs and biomarkers of platelet activation was considered in the previous review but not reported (<a href="./references#CD008012-bbs2-0238" title="BaumeisterH , HutterN , BengelJ . Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD008012. [DOI: 10.1002/14651858.CD008012.pub3]">Baumeister 2011c</a>). We also added important adverse effects (ECG wave recording, non‐cardiac adverse events, and pharmacological side effects) to this updated review, which we define as post hoc outcomes. We analysed the secondary outcomes separately and abstained from pooling any composite outcomes apart from pharmacological side effects, which we considered as a composite of any quantified side effect by self‐report scale, checklist, or adverse outcome. </p> </section> </section> </section> <section id="CD008012-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008012-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases for RCTs of treatment of depressive disorders in CAD patients on 3 August 2020: </p> <p> <ul id="CD008012-list-0009"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library, Issue 8 of 12, 2020); </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 31 July 2020); </p> </li> <li> <p>Embase (Ovid, 1980 to 2020 Week 31);</p> </li> <li> <p>PsycINFO (Ovid, 1806 to July Week 4 2020);</p> </li> <li> <p>CINAHL (Cumulative Index to Nursing and Allied Health Literature) (EBSCO, 1937 to 3 August 2020); </p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE) and NHS Economic Evaluation Database (EED) (Cochrane Library, Issue 2 of 4, 2015); </p> </li> <li> <p>Health Technology Assessment Database (HTA) (Cochrane Library Issue 4 of 4, 2016).</p> </li> </ul> </p> <p>The Cochrane sensitivity‐maximising RCT filter was used for MEDLINE, and for Embase, terms as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> were applied (<a href="./references#CD008012-bbs2-0197" title="LefebvreC , ManheimerE , Glanville J In: Higgins JPT &amp; Green S (editors). Chapter 6: Searching for studies. In: Higgins JP &amp; Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from training.cochrane.org/handbook.">Lefebvre 2011</a>). Adaptations of these RCT filters were applied to the other databases, except CENTRAL. See <a href="./appendices#CD008012-sec-0101">Appendix 1</a> for details of the 2009 search strategies and <a href="./appendices#CD008012-sec-0107">Appendix 2</a> for the updated 2020 search strategies. No language restrictions were applied. </p> </section> <section id="CD008012-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the World Heath Organization International Clinical Trials Registry Platform (<a href="https://trialsearch.who.int/" target="_blank">https://trialsearch.who.int/</a>), ISRCTN registry (<a href="http://isrctn.org/" target="_blank">http://isrctn.org/</a>), and ClinicalTrials.gov (<a href="https://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>) on 2 September 2021 (<a href="./appendices#CD008012-sec-0107">Appendix 2</a>). We also examined the reference lists of all included trials to identify other potentially relevant studies. We contacted corresponding authors of the included trials to ask about other RCTs, published or unpublished, which might be relevant to the review. We handsearched the list of included and excluded studies in the Cochrane Review by <a href="./references#CD008012-bbs2-0214" title="RichardsSH , AndersonL , JenkinsonCE , WhalleyB , ReesK , DaviesP , et al. Psychological interventions for coronary heart disease. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD002902. [DOI: 10.1002/14651858.CD002902.pub4]">Richards 2017</a> and the network meta‐analysis by <a href="./references#CD008012-bbs2-0174" title="DoyleF , FreedlandKE , CarneyRM , deJongeP , DickensC , PedersenSS , et al. Hybrid systematic review and network meta-analysis of randomized controlled trials of interventions for depressive symptoms in patients with coronary artery disease. Psychosomatic Medicine2021;83:423-31.">Doyle 2021</a>. </p> </section> </section> <section id="CD008012-sec-0026"> <h3 class="title" id="CD008012-sec-0026">Data collection and analysis</h3> <section id="CD008012-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently in pairs selected studies for inclusion (original review: NH, HB; update: SYA, EJLL, EB, NB). We examined a list of titles and abstracts; if title and abstract contained sufficient information to determine exclusion, the article was rejected. We retrieved the full papers of all remaining articles, which two review authors independently reviewed. In addition, any other potentially relevant articles identified by checking the reference lists or personal communications were also reviewed. We kept a record of all rejected papers and the reasons for rejection. We used this information to construct a PRISMA flow diagram (<a href="#CD008012-fig-0001">Figure 1</a>), and reported the reasons for exclusion of excluded studies in the <a href="./references#CD008012-sec-0118" title="">Characteristics of excluded studies</a> table. Important parts of foreign language papers of included studies (i.e. not English, German, or Chinese) were translated into English. If the two review authors disagreed about the inclusion of an article, a third review author (original review: JB; update: PJT) was asked to review the article. Any disagreements were resolved by consensus discussion. </p> <div class="figure" id="CD008012-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Summary of the 2020 literature search update and study selection." data-id="CD008012-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary of the 2020 literature search update and study selection.</p> </div> </div> </div> </section> <section id="CD008012-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (original review: HB, NH; update: PJT, SYA, EJLL, NB, EB) independently in pairs extracted data from the full copies of primary studies using a data extraction form. We extracted study characteristics including participants (sample size at baseline and follow‐up, type of CAD, gender, age), type of depression (major depression, minor depression or dysthymic disorder), assessment method (standardised diagnostic interview, self‐report questionnaire, medical record or physician’s diagnosis), cut‐off used to indicate depression on self‐report questionnaire, type of intervention (type of psychological treatment versus type of pharmacological treatment), comparison group (usual care, other control, another psychological treatment or pharmacological treatment), length of follow‐up, descriptive statistics of primary and secondary outcomes, effect sizes and confidence intervals. </p> </section> <section id="CD008012-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (original review HB, NH; update: PJT, SYA, EJLL, EB, NB) independently in pairs assessed risk of bias in the included studies using Cochrane's tool for assessing risk of bias (<a href="./references#CD008012-bbs2-0188" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS , editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>). We described sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias. With regard to psychological interventions, blinding of healthcare providers or participants to the treatment is not feasible. In pharmacological trials blinding is possible for participants, personnel, and outcome assessors, and was evaluated accordingly. We considered a trial as having an overall high risk of bias when four domains out of six were assessed as high or unclear for: allocation (sequence generation and concealment), blinding (participants, personnel, and outcome assessors), incomplete outcome data, and selective reporting. In the event that we identified an other source of bias at high risk, this also contributed to the overall adjudication of a trial at high risk of bias. </p> </section> <section id="CD008012-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>Continuous outcomes measured using different scales necessitated the standardisation of the results of the studies to a uniform scale. We computed standardised mean differences (SMD) with 95% confidence intervals (CIs) for continuous outcomes measured using different scales. As a first preference we analysed the mean scores of final assessment, followed by mean change scores from baseline to final assessment if only these scores were available. If no measures of variability were provided in the study reports, we used exact P values as well as t‐statistic or Chi<sup>2</sup> statistic to compute an SMD. </p> <p>For dichotomous variables, we computed odds ratios (OR) with 95% CI. For continuous primary and secondary outcomes assessed by the same method (i.e. Hamilton Depression Rating Scale (HAM‐D), BP, heart rate, ECG parameters), we used a mean difference (non‐standardised). </p> <p>Several strategies have been proposed to help readers interpret results presented as SMDs (e.g. re‐expressing SMDs using Cohen's rules of thumb for effect sizes (<a href="./references#CD008012-bbs2-0162" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. New York, NY: Routledge Academic, 1988.">Cohen 1988</a>), re‐expressing SMDs by transformation to OR, re‐expressing SMDs using a familiar instrument, reporting the ratio of the means, or expressing as minimal important difference units; see also Section 15.5.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>) (<a href="./references#CD008012-bbs2-0188" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS , editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>). However, all of these strategies have substantial disadvantages and introduce imprecision. For example, re‐expressing SMDs by means of familiar instruments does not account for between‐study heterogeneity. An SMD of a specific magnitude translates into different scores (e.g. on the Beck Depression Inventory (BDI)) depending on, for example, the baseline severity of depression. Conclusions based on this strategy might thus be substantially misleading. We decided to use the rule of thumb proposed by <a href="./references#CD008012-bbs2-0162" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. New York, NY: Routledge Academic, 1988.">Cohen 1988</a> and suggested by the <i>Cochrane Handbook</i> to re‐express SMDs (<a href="./references#CD008012-bbs2-0188" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS , editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>). Based on the assumptions of <a href="./references#CD008012-bbs2-0162" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. New York, NY: Routledge Academic, 1988.">Cohen 1988</a>, SMDs around 0.2 must be regarded as small, 0.5 as moderate, and 0.8 as large. As previously mentioned, this strategy also comprises substantial disadvantages, as a small, moderate, or large effect size depends on the specific outcome and the assessment instrument being used. Moreover, <i>patient</i> importance of a finding is context‐dependent and not amenable to generic statements (<a href="./references#CD008012-bbs2-0188" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS , editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>). When interpreting the results (<a href="./references#CD008012-bbs2-0152" title="BaumeisterH , HutterN , BengelJ . Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD008381. [DOI: 10.1002/14651858.CD008381.pub2]">Baumeister 2012b</a>), readers should keep this limitation of the rules of thumb in mind (<a href="./references#CD008012-bbs2-0162" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. New York, NY: Routledge Academic, 1988.">Cohen 1988</a>). </p> </section> <section id="CD008012-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis in the primary studies was the participant, which is randomised to either the treatment or control group. The number of observations thus matches the number of units that are randomised. In instances where observational units were correlated (e.g. by cluster), we planned to reduce the sample to an 'effective sample size', dividing the original sample size by the ‘design effect’ (<a href="./references#CD008012-bbs2-0189" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> </section> <section id="CD008012-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We requested missing information from published RCTs from the corresponding authors or obtained it from trial data repositories. Of 18 authors contacted for missing data, five replied, and three were able to provide at least some of the requested data. No imputation methods were used due to the small amount of trials per outcome. </p> </section> <section id="CD008012-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested for statistically significant heterogeneity using the Q‐statistics with a 95% CI. We computed the I<sup>2</sup> to examine the extent of heterogeneity. Meta‐analytically pooled effect estimates should be interpreted in accordance with any substantial clinical or methodological or statistical heterogeneity. We planned to specifically examine heterogeneity with the I<sup>2</sup> statistic quantifying inconsistency across studies to assess the impact of heterogeneity on the meta‐analysis. Interpretation of heterogeneity would include the magnitude and direction of effects, the strength of evidence for heterogeneity (e.g. P value from the Chi<sup>2</sup> test), and the I<sup>2</sup> statistic where: </p> <p> <ul id="CD008012-list-0010"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity (<a href="./references#CD008012-bbs2-0189" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> </li> </ul> </p> <p>A meta‐regression was considered to explore potential sources of heterogeneity but was not performed owing to the small amount of trials per outcome. </p> </section> <section id="CD008012-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not create funnel plots to investigate reporting bias due to the limited number of trials per outcome (<a href="./references#CD008012-bbs2-0189" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). To examine outcome reporting bias, we analysed discrepancies in reported outcomes between published protocols and original papers. Where no protocol was available, we contacted the corresponding trial authors for published or unpublished protocols. </p> </section> <section id="CD008012-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We performed random‐effects meta‐analyses to compute overall estimates of treatment outcomes based on the assumption of high clinical and methodological heterogeneity between RCTs. Both SMD and OR effect sizes were pooled using the inverse‐variance method, which is best suited to random‐effects meta‐analysis (<a href="./references#CD008012-bbs2-0188" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS , editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.">Higgins 2011</a>). The effect sizes of the primary studies are presented in forest plots. In the case of considerable methodological heterogeneity owing to different intervention types and their heterogenous comparators, we abstained from meta‐analytical pooling of trial results (Comparison 2: psychological versus psychological/CM; Comparison 4: pharmacological versus pharmacological). Where no dichotomous events occurred in both arms of a trial, we described the finding narratively in the text and in the summary of findings tables. </p> <p>In the case of multiple assessment tools used for the same outcome, we followed a hierarchical approach to decide which assessment to use in the meta‐analyses. Clinician‐rated assessments were given priority over patient self‐report questionnaires. In the case of assessment tools on the same hierarchical level, we chose the most frequently used assessment tool across the included studies, followed by the measure with the least missing data (per‐protocol), followed by random selection of one of the assessment tools. </p> </section> <section id="CD008012-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses to examine the impact of sex (men versus women), CAD subtype, time of onset of depression (pre‐existing versus new‐onset depression), CAD severity, and risk of bias of included studies on the results, but did not conduct them due to the sparseness of trial data. We will reconsider these subgroup analyses in future updates of the review. </p> </section> <section id="CD008012-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>Because pooling results across different types of psychological interventions may level out specific treatment effects and be potentially misleading (<a href="./references#CD008012-bbs2-0238" title="BaumeisterH , HutterN , BengelJ . Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD008012. [DOI: 10.1002/14651858.CD008012.pub3]">Baumeister 2011c</a>), we conducted sensitivity analysis on depression symptoms at end of treatment to update the results of <a href="./references#CD008012-bbs2-0238" title="BaumeisterH , HutterN , BengelJ . Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD008012. [DOI: 10.1002/14651858.CD008012.pub3]">Baumeister 2011c</a> for Comparison 1: psychological versus control and Comparison 3: pharmacological versus placebo. For Comparison 1, we performed sensitivity analysis in CBT‐only trials, and similarly in Comparison 3 conducted sensitivity analysis restricted to serotonergic antidepressant interventions. Specifically, the sensitivity analysis included SSRIs and mirtazepine, which can be classed as a noradrenergic and specific serotonergic antidepressant and tetracyclic analogue (see <a href="#CD008012-sec-0019">Types of interventions</a>) (<a href="./references#CD008012-bbs2-0171" title="deBoerT . The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. International Clinical Psychopharmacology1995;10:19-23.">de Boer 1995</a>). We also performed sensitivity analyses according to depressive disorders and secondly by depression‐only trials (e.g. excluding mixed depression/anxiety studies). </p> </section> <section id="CD008012-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We assessed the certainty of the evidence for the primary outcomes (short‐term) using the GRADE approach (<a href="./references#CD008012-bbs2-0182" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), (accessed prior to 7 December 2021). Available at gradepro.org.">GRADEpro GDT</a>), which takes into consideration risk of bias (see <a href="#CD008012-sec-0029">Assessment of risk of bias in included studies</a>), consistency of effect, imprecision, indirectness, and publication bias (<a href="./references#CD008012-bbs2-0222" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Schünemann 2019</a>). We constructed a summary of findings table for the primary outcomes (short‐term, end of treatment) for five outcomes: depression symptoms, depression remission, all‐cause mortality, cardiovascular mortality, and occurrence of MI. We made comments narratively to qualitatively describe the certainty of the evidence for the five end‐of‐treatment outcomes per comparison. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008012-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008012-sec-0039"></div> <section id="CD008012-sec-0040"> <h3 class="title">Description of studies</h3> <p>See: PRISMA flow chart (<a href="#CD008012-fig-0001">Figure 1</a>), <a href="./references#CD008012-sec-0117" title="">Characteristics of included studies</a>; <a href="#CD008012-tbl-0005">Table 1</a>; <a href="./references#CD008012-sec-0118" title="">Characteristics of excluded studies</a>; <a href="./references#CD008012-sec-0119" title="">Characteristics of studies awaiting classification</a>; <a href="./references#CD008012-sec-0120" title="">Characteristics of ongoing studies</a>. </p> <div class="table" id="CD008012-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of study population</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>[n]</b> <b>screened</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>[n] randomised</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>[n] ITT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>[n] finishing study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>[%] of randomised participants</b> <br/><b>finishing study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): simvastatin</p> <p>Intervention 2 (I2): atorvastatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 29</p> <p>I2: 29</p> <p>Total: 58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: NR</p> <p>I2: NR</p> <p>Total: NR</p> <p>(per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 23</p> <p>I2: 23</p> <p>Total: 46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 79.3%</p> <p>I2: 79.3%</p> <p>Total: 79.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0002" title="NCT02463110. Acute myocardial necrosis and depression: antiplatelet effect of reuptake inhibition of serotonin. clinicaltrials.gov/show/nct02463110 (first posted 4 June 2015). ">ANDROS 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): sertraline</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: trial terminated early, no results posted</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): resource‐orientated psychotherapy</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 27</p> <p>C: 32</p> <p>Total: 59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 27</p> <p>C: 32</p> <p>Total: 59</p> <p>(per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 27</p> <p>C: 28</p> <p>Total: 55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 100%</p> <p>C: 87.5%</p> <p>Total: 93.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): behaviour therapy</p> <p>Intervention 2 (I2): person‐centred therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: NR</p> <p>I2: NR</p> <p>Total: 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: NR</p> <p>I2: NR</p> <p>Total: NR</p> <p>(per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 20</p> <p>I2: 20</p> <p>Total: 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: ?</p> <p>I2: ?</p> <p>Total: 74.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: dropout reported in text, no flow chart</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): interpersonal psychotherapy, citalopram, clinical management</p> <p>Intervention 2 (I2): citalopram, clinical management</p> <p>Control 1 (C1): interpersonal psychotherapy, placebo, clinical management</p> <p>Control 2 (C2): placebo, clinical management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 1897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 67</p> <p>I2: 75</p> <p>C1: 75</p> <p>C2: 67</p> <p>Total: 284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 67</p> <p>I2: 75</p> <p>C1: 75</p> <p>C2: 67</p> <p>Total: 284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 59</p> <p>I2: 72</p> <p>C1: 59</p> <p>C2: 47</p> <p>Total: 237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 88.1%</p> <p>I2: 96.0%</p> <p>C1: 78.7%</p> <p>C2: 70.1%</p> <p>Total: 83.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: 2 x 2 factorial trial; only I2 and C2 data are eligible for this review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): sertraline plus omega‐3</p> <p>Intervention 2 (I2): sertraline plus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 62</p> <p>I2: 60</p> <p>Total: 122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 62</p> <p>I2: 60</p> <p>Total: 122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 59</p> <p>I2: 56</p> <p>Total: 115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 95.2%</p> <p>I2: 93.3%</p> <p>Total: 94.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): cognitive‐ behavioural therapy</p> <p>C: usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 50</p> <p>C: 50</p> <p>Total: 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR</p> <p>(per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 48</p> <p>C: 48:</p> <p>Total: 96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 96%</p> <p>C: 96%</p> <p>Total: 96%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): sertraline plus red yeast rice</p> <p>Intervention 2 (I2): sertraline plus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 28</p> <p>I2: 28</p> <p>Total: 56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: NR</p> <p>I2: NR</p> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 25</p> <p>I2: 25</p> <p>Total: 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 89.3%</p> <p>I2: 89.3%</p> <p>Total: 89.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): cognitive‐ behavioural therapy</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR</p> <p>(per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 7</p> <p>C: 8</p> <p>Total: 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: reasons for dropout not stated, no flow chart</p> <p>Comment: nested trial within observational study (non‐depressed cohort)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): escitalopram</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 4809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I:149</p> <p>C: 151</p> <p>Total: 300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 108</p> <p>C: 109</p> <p>Total: 217 (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 78</p> <p>C: 79</p> <p>Total: 157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 52.3%</p> <p>C: 52.3%</p> <p>Total: 52.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: nested trial within observational study (depressed cohort receiving usual care) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): cognitive‐ behavioural therapy</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 33780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 1238</p> <p>C: 1243</p> <p>Total: 2481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 1238</p> <p>C: 1243</p> <p>Total: 2481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 983</p> <p>C: 985</p> <p>Total: 1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 79.4%</p> <p>C: 79.2%</p> <p>Total: 79.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): health education and psychological intervention</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 27</p> <p>C: 30</p> <p>Total: 57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: translated paper</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): cognitive‐ behavioural therapy</p> <p>Intervention 2 (I2): supportive stress management</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 2955</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 41</p> <p>I2: 42</p> <p>C1: 40</p> <p>Total: 123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 41</p> <p>I2: 42</p> <p>C1: 40</p> <p>Total: 123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 40</p> <p>I2: 33</p> <p>C1: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 98%</p> <p>I2: 79%</p> <p>C1: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0014" title="FreemanAM , FleeceL , FolksDG , SokolRS , HallKR , PacificoAD , et al. Alprazolam treatment of postcoronary bypass anxiety and depression. Journal of Clinical Psychopharmacology1986;6:39-41. ">Freeman 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): alprazolam</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 54</p> <p>C: 53</p> <p>Total: 107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 32</p> <p>C: 28</p> <p>Total: 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 59.3%</p> <p>C: 52.8%</p> <p>Total: 56.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: no flow chart</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): escitalopram</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 9</p> <p>C: 10</p> <p>Total: 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR</p> <p>(per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 2</p> <p>C: 2</p> <p>Total: 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 22.2%</p> <p>C: 20.0%</p> <p>Total: 21.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: trial terminated early, redacted results posted</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): St John's wort extract</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: 87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 43</p> <p>C: 39</p> <p>Total: 82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: 94.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: translated paper</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): fluoxetine</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 31</p> <p>C: 37</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: translated paper</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): sertraline and Shugan Jieyu</p> <p>Intervention 2 (I2): sertraline and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 3907</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 76</p> <p>I2: 73</p> <p>Total: 149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 76</p> <p>I2: 73</p> <p>Total: 149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 48</p> <p>I2: 46</p> <p>Total: 94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 63.2%</p> <p>I2: 63.0%</p> <p>Total: 63.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: no flow chart, reasons for dropout reported in text</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): mirtazapine</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 2177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 47</p> <p>C: 44</p> <p>Total: 91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 47</p> <p>C: 44</p> <p>Total: 91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 22</p> <p>C: 18</p> <p>Total: 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 46.8%</p> <p>C: 40.9%</p> <p>Total: 44.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: nested trial within observational study (depressed cohort receiving usual care) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): Xinkeshu</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 30</p> <p>C: 30</p> <p>Total: 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 28</p> <p>C: 27</p> <p>Total: 55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 93.3%</p> <p>C: 90%</p> <p>Total: 91.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): sertraline</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 18</p> <p>C: 20</p> <p>Total: 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 12</p> <p>C: 15</p> <p>Total: 27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 66.7%</p> <p>C: 75.0%</p> <p>Total: 71.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: no flow chart, reasons for dropout reported in text</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I1): telephone counselling</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 53</p> <p>C: 47</p> <p>Total: 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 45</p> <p>C: 34</p> <p>Total: 79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 84.9%</p> <p>C: 72.3%</p> <p>Total: 79%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): cognitive‐ behavioural therapy<br/>Control (C): usual care </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 3071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 61</p> <p>C: 60</p> <p>Total: 121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 53</p> <p>C: 53</p> <p>Total: 106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 86.9%</p> <p>C: 88.3%</p> <p>Total: 87.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): sertraline</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 50</p> <p>C: 50</p> <p>Total: 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 47</p> <p>C: 48</p> <p>Total: 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 94%</p> <p>C: 96%</p> <p>Total: 95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): paroxetine</p> <p>Intervention 2 (I2): nortriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 41</p> <p>I2: 40</p> <p>Total: 81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 41</p> <p>I2: 40</p> <p>Total: 81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 37</p> <p>I2: 30</p> <p>Total: 67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 90.2%</p> <p>I2: 75.0%</p> <p>Total: 82.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: no flow chart, reasons for dropout reported in text</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): sertraline</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 11546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 186</p> <p>C: 183</p> <p>Total: 369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 186</p> <p>C: 183</p> <p>Total: 169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 133</p> <p>C: 137</p> <p>Total: 270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 71.5%</p> <p>C: 74.9%</p> <p>Total: 73.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): stepwise psychotherapy intervention</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 21780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 285</p> <p>C: 285</p> <p>Total: 570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 284</p> <p>C: 284</p> <p>Total: 568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 110</p> <p>C: 194</p> <p>Total: 304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 38.6%</p> <p>C: 68.1%</p> <p>Total: 53.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): fluoxetine</p> <p>Intervention 2 (I2): <i>Crocus sativus</i> L. (saffron) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 22</p> <p>I2: 22</p> <p>Total: 44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: NR</p> <p>I2: NR</p> <p>Total: NR (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 20</p> <p>I2: 20</p> <p>Total: 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 90.9%</p> <p>I2: 90.9%</p> <p>Total: 90.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): fluoxetine</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 27</p> <p>C: 27</p> <p>Total: 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 27</p> <p>C: 27</p> <p>Total: 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 22</p> <p>C: 18</p> <p>Total: 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 81.5%</p> <p>C: 66.7%</p> <p>Total: 74.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): paroxetine</p> <p>Intervention 2 (I2): fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 23</p> <p>I2: 23</p> <p>Total: 46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 23</p> <p>I2: 23</p> <p>Total: 46 (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 23</p> <p>I2: 23</p> <p>Total: 46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 100%</p> <p>I2: 100%</p> <p>Total: 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: no flow chart was reported. It is unclear whether 16 participants who did not finish the study were from I1 or I2 groups, or non‐treatment or non‐depressed groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): cognitive‐behavioural therapy and well‐being therapy</p> <p>Intervention 2 (I2): clinical management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 50</p> <p>I2: 50</p> <p>Total: 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 50</p> <p>I2: 50</p> <p>Total: 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 42</p> <p>I2: 40</p> <p>Total: 82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 84%</p> <p>I2: 80%</p> <p>Total: 82%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): internet cognitive‐behavioural therapy</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 3928</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 117</p> <p>C: 122</p> <p>Total: 239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 117</p> <p>C: 122</p> <p>Total: 239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 96</p> <p>C: 115</p> <p>Total: 211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 82.1%</p> <p>C: 94.3%</p> <p>Total: 88.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): sertraline</p> <p>Intervention 2 (I2): exercise</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 1680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 40</p> <p>I2: 37</p> <p>C: 24</p> <p>Total: 101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: NR</p> <p>I2: NR</p> <p>C: NR</p> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 36</p> <p>I2: 36</p> <p>C: 23</p> <p>Total: 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 90%</p> <p>I2: 97.3%</p> <p>C: 95.8%</p> <p>Total: 94.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: only I1 sertraline and C placebo are eligible for this review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): escitalopram</p> <p>Intervention 2 (I2):</p> <p>Bu Xin Qi decoction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 140</p> <p>I2: 140</p> <p>Total: 280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: NR</p> <p>I2: NR</p> <p>Total: NR (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 113</p> <p>I2: 115</p> <p>Total: 228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 80.7%</p> <p>I2: 82.1%</p> <p>Total: 81.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: reasons for dropout not stated in flow chart</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): internet cognitive‐behavioural therapy</p> <p>Control (C): wait‐list control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 18</p> <p>C: 16</p> <p>Total: 34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 18</p> <p>C: 16</p> <p>Total: 34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 13</p> <p>C: 13</p> <p>Total: 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 72.2%</p> <p>C: 81.3%</p> <p>Total: 76.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): intensive telephone‐based care</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 112</p> <p>C: 112</p> <p>Total: 224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 107</p> <p>C: 105</p> <p>Total: 212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 95.5%</p> <p>C: 93.8%</p> <p>Total: 94.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): Peplau's therapeutic communication model</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ? (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 37</p> <p>C: 37</p> <p>Total: 74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: total sample estimated from degrees of freedom in Table 3</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ITT = intention‐to‐treat; NR = not reported; ? = unclear</p> </div> </div> <section id="CD008012-sec-0041"> <h4 class="title">Results of the search</h4> <p>The database and trial registry search resulted in 7407 references (101 from trial registries), 5387 of which were unique references. We excluded 5245 articles at the title/abstract level, and 80 studies (97 articles) after full‐text review, most commonly because the study did not investigate participants without comorbid depression (25 studies, 30 articles), the intervention for depression was not a predefined comparison of this review (13 studies, 19 articles), the sample was not restricted to CAD (10 studies, 13 articles), the intervention not specifically psychological or pharmacological intervention for treating depression (4 studies, 4 articles), the study was not an RCT (4 studies, 4 articles), the control group was unclear or there was no control group (1 study, 1 reference), or new citations to studies already excluded in the previous review (2 studies, 4 references). We also identified 17 ongoing studies (17 references) and 4 trials awaiting classification (5 references). Twenty‐one new studies were found to be eligible in this updated review (45 new references) and included in the narrative review or synthesis. See the study flow chart for details of the study selection process (<a href="#CD008012-fig-0001">Figure 1</a>). </p> </section> <section id="CD008012-sec-0042"> <h4 class="title">Included studies</h4> <p>Thirty‐seven trials fulfilled the inclusion criteria of the review (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>; <a href="./references#CD008012-bbs2-0002" title="NCT02463110. Acute myocardial necrosis and depression: antiplatelet effect of reuptake inhibition of serotonin. clinicaltrials.gov/show/nct02463110 (first posted 4 June 2015). ">ANDROS 2015</a>; <a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a>; <a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>; <a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0014" title="FreemanAM , FleeceL , FolksDG , SokolRS , HallKR , PacificoAD , et al. Alprazolam treatment of postcoronary bypass anxiety and depression. Journal of Clinical Psychopharmacology1986;6:39-41. ">Freeman 1986</a>; <a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>; <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>; <a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>; <a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>; <a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>; <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a>). </p> <p>Fifteen trials investigated psychological interventions, which comprised CBT (<a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>; <a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>), resource‐orientated psychotherapy (<a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>), telephone counselling (<a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>), individual and group psychotherapy (<a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>), therapeutic communication sessions (<a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a>), and an intervention comprising health education and various psychological treatments (<a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>). One three‐arm trial examined CBT, supportive stress management, and usual care (<a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>). One trial examined eight sessions of CBT in combination with four sessions of well‐being therapy versus CM (<a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>). One trial examined behaviour therapy versus person‐centred therapy (<a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>). Two psychological therapy trials delivered the CBT intervention entirely online with therapist or eCoach support (<a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>); all others delivered the intervention face‐to‐face. </p> <p>Twenty‐one trials investigated the effects of pharmacological depression treatments with sertraline (<a href="./references#CD008012-bbs2-0002" title="NCT02463110. Acute myocardial necrosis and depression: antiplatelet effect of reuptake inhibition of serotonin. clinicaltrials.gov/show/nct02463110 (first posted 4 June 2015). ">ANDROS 2015</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>), mirtazapine (<a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>), fluoxetine (<a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>), escitalopram (<a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>), paroxetine and nortriptyline (<a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>), paroxetine and fluoxetine (<a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>), alprazolam (<a href="./references#CD008012-bbs2-0014" title="FreemanAM , FleeceL , FolksDG , SokolRS , HallKR , PacificoAD , et al. Alprazolam treatment of postcoronary bypass anxiety and depression. Journal of Clinical Psychopharmacology1986;6:39-41. ">Freeman 1986</a>), sertraline plus omega‐3 (<a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>), sertraline plus red yeast rice (<a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a>), St John's wort (<a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>), simvastatin compared to atorvastatin (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>), Xinkeshu (<a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>), saffron compared to fluoxetine (<a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>), Shugan Jieyu compared to sertraline (<a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>), Bu Xin Qi compared to escitalopram (<a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>). </p> <p>One trial had a 2 x 2 factorial design (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>). In accordance with our inclusion criteria, we restricted analyses to the citalopram and CM versus placebo and CM arms of the trial. The IPT plus citalopram plus CM, and IPT plus placebo plus CM arms of the trial were ineligible and are not described further. </p> <p>The trial size in psychological intervention studies ranged from 15 participants in <a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a> to 2481 participants in <a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>. In the pharmacological intervention studies, the trial size ranged from 2 participants in <a href="./references#CD008012-bbs2-0002" title="NCT02463110. Acute myocardial necrosis and depression: antiplatelet effect of reuptake inhibition of serotonin. clinicaltrials.gov/show/nct02463110 (first posted 4 June 2015). ">ANDROS 2015</a> to 369 participants in <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>. </p> <p>The mean age of participants ranged from 52.6 in <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a> to 64.0 years in <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>. The percentage of female participants ranged from 10% in <a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a> to 56.8% in <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>. One study was restricted to female participants only (<a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>). </p> <p>Ten studies originated from the USA (<a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>; <a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0014" title="FreemanAM , FleeceL , FolksDG , SokolRS , HallKR , PacificoAD , et al. Alprazolam treatment of postcoronary bypass anxiety and depression. Journal of Clinical Psychopharmacology1986;6:39-41. ">Freeman 1986</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>), eight from China (<a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>; <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>; <a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>; <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>), four from Iran (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>; <a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a>), three from Germany (<a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>), two from Canada (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>), two from the Netherlands (<a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>), two from Italy (<a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>), one from Australia (<a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>), one from Korea (<a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>), one from France (<a href="./references#CD008012-bbs2-0002" title="NCT02463110. Acute myocardial necrosis and depression: antiplatelet effect of reuptake inhibition of serotonin. clinicaltrials.gov/show/nct02463110 (first posted 4 June 2015). ">ANDROS 2015</a>), and one from Sweden (<a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>). Two studies were performed across multiple sites in different countries, taking place in the USA, Europe, Canada, and Australia in <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a> and Denmark, Estonia, and Norway in <a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>. </p> <p>Sixteen studies investigated individuals with MI or acute coronary syndromes (<a href="./references#CD008012-bbs2-0002" title="NCT02463110. Acute myocardial necrosis and depression: antiplatelet effect of reuptake inhibition of serotonin. clinicaltrials.gov/show/nct02463110 (first posted 4 June 2015). ">ANDROS 2015</a>; <a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>; <a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>; <a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>). Twelve trials studied diverse CAD populations comprising MI, angina pectoris, and patients undergoing cardiac procedures (<a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>; <a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>; <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>). Seven trials investigated patients awaiting or after CABG (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>; <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0014" title="FreemanAM , FleeceL , FolksDG , SokolRS , HallKR , PacificoAD , et al. Alprazolam treatment of postcoronary bypass anxiety and depression. Journal of Clinical Psychopharmacology1986;6:39-41. ">Freeman 1986</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a>), and two trials investigated patients after PCI (<a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>). </p> <p>We also identified 17 ongoing trials (<a href="./references#CD008012-bbs2-0116" title="IRCT20180312039056N2. Effectiveness of rumination-focused cognitive-behavioral therapy on improvement depression and anxiety in patients with coronary heart disease. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20180312039056N2 (first received 14 October 2018). ">Ahmadi 2018</a>; <a href="./references#CD008012-bbs2-0117" title="IRCT20140126016374N2. The study of of escitalopram's effectiveness on treatment of mild to moderate depressive disorder and improvement of quality of life in patients who are undergone coronary artery bypass graft surgery (CABG) – a randomized double blind placebo controlled trial. en.irct.ir/trial/49571?revision=159827 (first received 11 November 2020). [IRCT: 20140126016374N2]">Ardakani 2020</a>; <a href="./references#CD008012-bbs2-0118" title="NCT04986969. Online Cognitive Behavioral Therapy for Depressive Symptoms in Rural Patients With Cardiac Disease (COMBAT-DS). clinicaltrials.gov/ct2/show/NCT04986969 (first received 3 August 2021). ">COMBAT‐DS 2021</a>; <a href="./references#CD008012-bbs2-0119" title="PedersenSS , AndersenCM , AhmR , SkovbakkeSJ , KokR , HelmarkC , et al. Efficacy and cost-effectiveness of a therapist-assisted web-based intervention for depression and anxiety in patients with ischemic heart disease attending cardiac rehabilitation (eMindYourHeart trial): a randomised controlled trial protocol. BMC Cardiovascular Disorders2021;21:20. [HTTPS://CLINICALTRIALS.GOV/: NCT04172974]">eMindYourHeart 2021</a>; <a href="./references#CD008012-bbs2-0120" title="IRCT2017080835568N1. The effectiveness of cognitive behavioral therapy on symptoms of depression, dysfunctional attitudes and level of social support in patients with cardiovascular disease. en.irct.ir/trial/26838 (first received 13 August 2017). [WHO CLINICAL TRIAL ID: IRCT2017080835568N1]">Firouzjaei 2017</a>; <a href="./references#CD008012-bbs2-0121" title="ChiCTR1800014291. Effect of guanxin danshen dropping pill on clinical anxiety, depression, heart rate variability and cardiovascular prognosis in patients with coronary heart disease after PCI combined with anxiety or depression. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR1800014291 (first received 4 January 2018). [WHO CLINICAL TRIAL ID: chictr1800014291]">Geng 2018</a>; <a href="./references#CD008012-bbs2-0122" title="HamzehpourR . Comparison of bupropion and ecitalopram efficacy on depressive symptoms after coronary artery bypass graft surgery. en.irct.ir/trial/49626 (registration date 25 July 2020). ">Hamzehpour 2020</a>; <a href="./references#CD008012-bbs2-0123" title="NCT04347525. The effect of culturally adapted cognitive behaviour therapy (CaCBT)-based guided self help in depressed patients with myocardial infarction. A randomised controlled trial. clinicaltrials.gov/show/NCT04347525 (first received 15 April 2020). ">Irfan 2020</a>; <a href="./references#CD008012-bbs2-0124" title="JazayeriS . Effect of hesperidin supplementation on depressive symptoms, serum levels of BDNF and cortisol in patients after myocardial infarction. www.irct.ir/trial/2090 (registration date 26 April 2017). [IRCT: 201702262394N36]">Jazayeri 2017</a>; <a href="./references#CD008012-bbs2-0125" title="MBCT via group videoconferencing for acute coronary syndrome patients with depressive symptoms: a pilot RCT. Ongoing study. April 2021. Contact author for more information.">Luberto 2021</a>; <a href="./references#CD008012-bbs2-0126" title="MaWL . The therapeutic effect of statins on patients with depression after acute coronary syndrome. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR-IPR-14005672 (date of registration 15 December 2014). [WHO CLINICAL TRIAL ID: ChiCTR-IPR-14005672]">Ma 2014</a>; <a href="./references#CD008012-bbs2-0127" title="MohammadianR . The efficacy of cognitive-behavioral therapy based on rumination on depression, anxiety and hostility in cardiac patients. https://www.irct.ir/trial/36370 (registration date 27 March 2019)). ">Mohammadian 2018</a>; <a href="./references#CD008012-bbs2-0128" title="MoudiS . The efficacy of citalopram in depression and quality of life in the patients with cardiac disease. en.irct.ir/trial/19730 (registration date 30 September 2016). [WHO CLINICAL TRIAL ID: IRCT2016091722991N6]">Moudi 2016</a>; <a href="./references#CD008012-bbs2-0129" title="Effect of guanxindanshen dropping pills on quality of life and cardiovascular prognosis of patients with depression or anxiety after PCI for coronary heart disease. Ongoing study. 1 March 2017. Contact author for more information.">Qiaoning 2019</a>; <a href="./references#CD008012-bbs2-0130" title="SourizahiM . Comparison of therapeutic effect of sertraline and supportive psychotherapy in comparison with placebo in coronary heart disease patients with mild to moderate depression. en.irct.ir/trial/27596 (registration date 26 December 2017). [WHO CLINICAL TRIAL ID: IRCT20171105037241N2]">Sourizahi 2017</a>; <a href="./references#CD008012-bbs2-0131" title="WangZ . Intervention study of the patients with mild depressive mood after percutaneous coronary intervention in the treatment of the patients with collateral vessels based on the hypothesis of. trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR-INR-15007378 (date of registration 11 November 2015). [WHO CLINICAL TRIAL ID: ChiCTR-INR-15007378]">Wang 2015</a>; <a href="./references#CD008012-bbs2-0132" title="The efficacy and safety of Ginkgo biloba dropping pills in the treatment of coronary heart disease with stable angina pectoris and depression. Ongoing study. 20 September 2020. Contact author for more information.">Yang 2020</a>). Three studies are awaiting classification, two of which were identified as conference abstracts in our search of the databases, without any contact information available (<a href="./references#CD008012-bbs2-0112" title="AhangarezaiezadehS , OladrostamN , NemotplahiA . The effect of positive thinking on stress, anxiety and depression in coronary heart disease. Nursing and Midwifery Journal2017;15:339-48. IRCT2016022026347N2. The effect of positive thinking on stress, anxiety and depression in coronary patients. www.who.int/trialsearch/trial2.aspx?Trialid=irct2016022026347n2 (first received 13 July 2016). ">Ahangarezaiezadeh 2017</a>; <a href="./references#CD008012-bbs2-0113" title="CaiJM , XieDY . Clinical analysis on deanxit treating unstable angina patients with anxiety-depression. Heart2012;98 Suppl 2:GW23-e1783. ">Cai 2012</a>; <a href="./references#CD008012-bbs2-0115" title="GuY , ZhuY . Effects of mindfulness-based stress reduction on markers of cardiovascular risk in patients with ischemic heart disease a randomized controlled trial. Journal of the American College of Cardiology2017;70(16):C166. [DOI: DOI: 10.1016/j.jacc.2017.07.592]">Gu 2017</a>). </p> </section> <section id="CD008012-sec-0043"> <h4 class="title">Excluded studies</h4> <p>A total of 96 studies (118 articles) that appeared to be relevant to the review were excluded after careful examination of eligibility criteria (see <a href="./references#CD008012-sec-0118" title="">Characteristics of excluded studies</a> for reasons for exclusion). Sixteen studies (21 references) were excluded in the previous review reported by <a href="./references#CD008012-bbs2-0238" title="BaumeisterH , HutterN , BengelJ . Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD008012. [DOI: 10.1002/14651858.CD008012.pub3]">Baumeister 2011c</a>, and 80 studies (97 references) were excluded from the 2020 updated literature search. </p> </section> </section> <section id="CD008012-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias in the included studies varied across studies (see <a href="#CD008012-fig-0002">Figure 2</a>; <a href="#CD008012-fig-0003">Figure 3</a>). The information available after translating parts of three trials published in Chinese was insufficient to determine risk of bias in these studies (<a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>). We assessed risk of bias for the two trials that were terminated early by the investigators based on information reported in the clinical trial registries (<a href="./references#CD008012-bbs2-0002" title="NCT02463110. Acute myocardial necrosis and depression: antiplatelet effect of reuptake inhibition of serotonin. clinicaltrials.gov/show/nct02463110 (first posted 4 June 2015). ">ANDROS 2015</a>; <a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>). </p> <div class="figure" id="CD008012-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008012-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008012-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008012-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008012-sec-0045"> <h4 class="title">Allocation</h4> <p>Twelve trials used an appropriately generated and adequately concealed randomisation procedure (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>; <a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a>; <a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>). The generation of the randomisation sequence appeared to be appropriate in eight trials; however, they did not sufficiently describe the concealment of the allocation, <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>; <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>, or failed to conceal the allocation adequately (<a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>). Two trials used an inappropriate randomisation procedure and provided insufficient information on concealment (<a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a>). One trial described a sufficient sequence generation but was an open‐label trial (<a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>). Details regarding sequence generation and allocation concealment were unclear for the remaining 14 trials (<a href="./references#CD008012-bbs2-0002" title="NCT02463110. Acute myocardial necrosis and depression: antiplatelet effect of reuptake inhibition of serotonin. clinicaltrials.gov/show/nct02463110 (first posted 4 June 2015). ">ANDROS 2015</a>; <a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>; <a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0014" title="FreemanAM , FleeceL , FolksDG , SokolRS , HallKR , PacificoAD , et al. Alprazolam treatment of postcoronary bypass anxiety and depression. Journal of Clinical Psychopharmacology1986;6:39-41. ">Freeman 1986</a>; <a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>; <a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>; <a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>). </p> </section> <section id="CD008012-sec-0046"> <h4 class="title">Blinding</h4> <p>No trial of psychological interventions utilised an attention‐control design, thus we judged participants in all psychological intervention trials as unblinded to treatment allocation. The outcome assessor was blinded in seven psychological intervention trials (<a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>; <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>). Seven trials did not report sufficient details regarding blinding to make a judgement of low or high risk (<a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a>). We assessed one psychological trial as high risk and unblinded, as the outcome was assessed using patient self‐report without sufficient information regarding blinding (<a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>). </p> <p>In six pharmacological trials blinding was adequately realised and described (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>; <a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>). Four pharmacological trials reported using a double‐blind method but did not describe who was blinded (<a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>). One trial was described as open‐label trial and hence unblinded (<a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>). The remaining 11 trials did not report sufficient information regarding blinding of staff, participants, and outcome assessors (<a href="./references#CD008012-bbs2-0002" title="NCT02463110. Acute myocardial necrosis and depression: antiplatelet effect of reuptake inhibition of serotonin. clinicaltrials.gov/show/nct02463110 (first posted 4 June 2015). ">ANDROS 2015</a>; <a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0014" title="FreemanAM , FleeceL , FolksDG , SokolRS , HallKR , PacificoAD , et al. Alprazolam treatment of postcoronary bypass anxiety and depression. Journal of Clinical Psychopharmacology1986;6:39-41. ">Freeman 1986</a>; <a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>; <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>). </p> </section> <section id="CD008012-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>Fourteen trials provided intention‐to‐treat (ITT) analyses for primary outcomes (<a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>; <a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>; <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>). One trial reported both ITT and per‐protocol analyses simultaneously (<a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>). Depression outcomes were analysed per‐protocol in two trials that reported cardiovascular mortality and cardiac events as ITT (<a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>). Conversely, <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a> reported ITT analyses for depression outcomes and per‐protocol analyses for cardiac events, cardiovascular vital signs, and ECG waves. Fourteen trials reported per‐protocol analyses (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>; <a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0014" title="FreemanAM , FleeceL , FolksDG , SokolRS , HallKR , PacificoAD , et al. Alprazolam treatment of postcoronary bypass anxiety and depression. Journal of Clinical Psychopharmacology1986;6:39-41. ">Freeman 1986</a>; <a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>; <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>; <a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>; <a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>). The remaining seven studies provided insufficient information to make a determination (<a href="./references#CD008012-bbs2-0002" title="NCT02463110. Acute myocardial necrosis and depression: antiplatelet effect of reuptake inhibition of serotonin. clinicaltrials.gov/show/nct02463110 (first posted 4 June 2015). ">ANDROS 2015</a>; <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a>). </p> </section> <section id="CD008012-sec-0048"> <h4 class="title">Selective reporting</h4> <p>We judged eight studies as free of selective reporting based on the comparison of outcomes reported in published study protocols, methods sections, and original papers (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>; <a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>). Three trials have as yet not reported the results of all the outcomes mentioned in published protocols (<a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>). We assessed four trials as high risk of bias due to incomplete or inadequate outcome reporting (<a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>; <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>). Furthermore, in <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>, we rated selective reporting as unclear risk bias, as measures of variance (standard deviation (SD) or standard error (SE)) were not reported, and P values were reported for active treatment (sertraline group, exercise group), thereby combining two separate interventions. No published or unpublished trial protocols were available other than trial registries for the remaining 21 trials (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>; <a href="./references#CD008012-bbs2-0002" title="NCT02463110. Acute myocardial necrosis and depression: antiplatelet effect of reuptake inhibition of serotonin. clinicaltrials.gov/show/nct02463110 (first posted 4 June 2015). ">ANDROS 2015</a>; <a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a>; <a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>; <a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0014" title="FreemanAM , FleeceL , FolksDG , SokolRS , HallKR , PacificoAD , et al. Alprazolam treatment of postcoronary bypass anxiety and depression. Journal of Clinical Psychopharmacology1986;6:39-41. ">Freeman 1986</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>; <a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>; <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a>), thus it remains unclear whether or not there is a risk of selective reporting in these trials. </p> </section> <section id="CD008012-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>We judged eight studies as free of other sources of bias (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>; <a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>). The risk of other sources of bias remains unclear for the three trials translated from Chinese (<a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>). Ten psychotherapy studies may exhibit performance bias because the adherence of therapists in the treatment group was unclear (<a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>; <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a>), or was undertaken differently from the protocol (<a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>). In two trials there was evidence of statistically significant differences between groups at baseline on depression (<a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>), or differences at baseline were not established (<a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>). In <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a> (p 619 and p 620) and <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a> (discrepancy between text and figure of depression score on Hospital Anxiety and Depression Scale (HADS)), results were inconsistently reported. In three trials (<a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>), there was a change in the inclusion criteria. </p> <p>In two trials there was evidence of high risk of bias (selection bias), with eligible participants not recruited (<a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>). There was evidence of high risk of other bias in two internet CBT interventions that were terminated early by investigators with ITT results reported (<a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>). Similarly, a high risk of other bias was evident in two drug trials terminated early with results not reported (<a href="./references#CD008012-bbs2-0002" title="NCT02463110. Acute myocardial necrosis and depression: antiplatelet effect of reuptake inhibition of serotonin. clinicaltrials.gov/show/nct02463110 (first posted 4 June 2015). ">ANDROS 2015</a>), or partially reported per protocol in redacted form (<a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>). A high risk of other bias was evident in two trials that either did not register the trial (<a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>), or did so retrospectively after recruitment had commenced (<a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>). A high risk of other bias was evident in two drug trials that included pharmaceutical company employees in the trial design, conduct, analysis, and reporting of results (<a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>). A high risk of other bias was evident in <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>, where the primary results were reported mid‐treatment. </p> </section> </section> <section id="CD008012-sec-0050"> <h3 class="title" id="CD008012-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD008012-tbl-0001"><b>Summary of findings 1</b> Summary of findings table ‐ Psychological treatment compared to control for depression in patients with coronary artery disease</a>; <a href="./full#CD008012-tbl-0002"><b>Summary of findings 2</b> Summary of findings table ‐ Psychological treatment 1 compared to psychological treatment 2 for depression in patients with coronary artery disease</a>; <a href="./full#CD008012-tbl-0003"><b>Summary of findings 3</b> Summary of findings table ‐ Pharmacological treatment compared to placebo for depression in patients with coronary artery disease</a>; <a href="./full#CD008012-tbl-0004"><b>Summary of findings 4</b> Summary of findings table ‐ Pharmacological treatment 1 compared to pharmacological treatment 2 for depression in patients with coronary artery disease</a> </p> <section id="CD008012-sec-0051"> <h4 class="title">Comparison 1: Psychological intervention versus control</h4> <p>Thirteen trials studied the effects of a psychological intervention versus control (<a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>; <a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>; <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a>). </p> <section id="CD008012-sec-0052"> <h5 class="title">1.1 Primary outcome: depression symptoms</h5> <p>Twelve studies investigated the effects of psychological interventions on short‐term depression symptoms (i.e. the end of treatment) (<a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>; <a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>; <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a>). One study did not report sufficient information to compute effect sizes (<a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>). Three studies reported data as change scores (<a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>), of which two studies reported end‐of‐treatment scores that could be pooled in analysis of standardised mean difference (SMD) (<a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>). Meta‐analysis of 10 trials showed that psychological interventions may result in a reduction in depression symptoms at the end of treatment compared to control groups (pooled SMD −0.55, 95% confidence interval (CI) −0.92 to −0.19) (n = 1226) (<a href="./references#CD008012-fig-0004" title="">Analysis 1.1</a>) (<a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a>). Heterogeneity was considerable (I<sup>2</sup> = 88%). One trial reported a significant change in the depression subscale of the HADS for patients' intensive telephone‐based care (Δ −2.20, SD 2.61) compared to usual care (Δ −1.04, SD 2.89) (n = 212) (<a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>), which could not be pooled. Sensitivity analyses for <a href="./references#CD008012-fig-0004" title="">Analysis 1.1</a> (<a href="#CD008012-tbl-0006">Table 2</a>) indicate minimal change to the pooled SMD and heterogeneity in analyses restricted to non‐major depressive disorder trials and CBT trials. By contrast, analyses restricted to depression‐only trials resulted in an attenuation of the SMD that was no longer significant. </p> <div class="table" id="CD008012-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analyses for depression symptoms at end of treatment in psychological versus control trials</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study references [n]</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SMD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>I</b><sup>2</sup> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychological vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (<a href="./references#CD008012-fig-0004" title="">Analysis 1.1</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a> (n = 1226) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.55 (95% CI −0.92 to −0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychological vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constrained to trials without depression disorders as part of the inclusion criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a> (n = 1145) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.53 (95% CI −0.92 to −0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychological vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constrained to depression (e.g. excluding trials with mixed depression and/or anxiety as part of the inclusion criteria) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a> (n = 681) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.27 (95% CI −0.58 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychological vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constrained to cognitive‐behavioural therapy trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a> (n = 571) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.48 (95% CI −0.77 to −0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI = confidence interval; SMD = standardised mean difference</p> </div> </div> <p>Eight studies investigated the effects of psychological interventions on medium‐term depression symptoms (i.e. one to six months after treatment) (<a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>; <a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a>). One study did not report sufficient information to compute effect sizes (<a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>). Meta‐analysis of seven psychotherapy trials showed no benefit compared to control on medium‐term depression symptoms (pooled SMD −0.20, 95% CI −0.42 to 0.01) (n = 2620) (<a href="./references#CD008012-fig-0005" title="">Analysis 1.2</a>) (<a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a>). Heterogeneity was substantial (I<sup>2</sup> = 69%). </p> <p>Two trials investigated the effects of psychological interventions on long‐term depression symptoms (i.e. more than six months after treatment) (<a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>). CBT was not superior to control on long‐term depression symptoms (SMD −0.46, 95% CI −0.96 to 0.04) (n = 282) (<a href="./references#CD008012-fig-0006" title="">Analysis 1.3</a>). There was evidence of considerable heterogeneity (I<sup>2</sup> = 72%). </p> </section> <section id="CD008012-sec-0053"> <h5 class="title">1.2 Primary outcome: depression remission and response</h5> <p>Three studies reported on depression remission in the short term (i.e. end of treatment) (n = 862) (<a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>). CBT was beneficial compared to usual care (odds ratio (OR) 5.02, 95% CI 1.95 to 12.90) in the study by <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>. An intensive telephone‐based care programme was beneficial compared to usual care (OR 2.25, 95% CI 1.22 to 4.15) in the study by <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>. Stepwise, fully manualised individual and group psychotherapy was not superior compared to usual care (n = 569) (<a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>). A pooled analysis suggests that psychological intervention results in little to no difference in depression remission at the end of treatment (OR 2.02, 95% CI 0.78 to 5.19) (n = 862) (<a href="./references#CD008012-fig-0007" title="">Analysis 1.4</a>). Statistical heterogeneity remained considerable between studies (I<sup>2</sup> = 87%). </p> <p>One trial included only participants with depressive disorders and re‐evaluated participants in the medium term (four months) for depression disorders, but did not report these data (<a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a>). Only <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a> (n = 81) reported on medium‐ and long‐term depression remission. No effect was observed in the medium term (i.e. one to six months after end of treatment) (<a href="./references#CD008012-fig-0008" title="">Analysis 1.5</a>). In the same trial, the effect was significant in the long term (i.e. more than six months after end of treatment; OR 5.06, 95% CI 1.96 to 13.08) (<a href="./references#CD008012-fig-0009" title="">Analysis 1.6</a>). </p> <p>No trials reported depression response at any time point.</p> </section> <section id="CD008012-sec-0054"> <h5 class="title">1.3 Primary outcome: all‐cause and cardiovascular mortality</h5> <p>Two trials reported loss to follow‐up attributable to all‐cause mortality in the short term (<a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>). Few events were recorded (five deaths), and neither trial showed a significant increase or decrease in probability of mortality in the short term. Pooled analysis of the two trials was very uncertain regarding the effect of psychological interventions on all‐cause mortality at end of treatment (OR 0.31, 95% CI 0.05 to 2.02; I<sup>2</sup> = 0%) (n = 324) (<a href="./references#CD008012-fig-0010" title="">Analysis 1.7</a>). </p> <p>The <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a> trial reported all‐cause mortality in the medium term and did not find a significant increase or decrease in probability of mortality (OR 0.66, 95% CI 0.23 to 1.88) (n = 570) (<a href="./references#CD008012-fig-0011" title="">Analysis 1.8</a>). </p> <p>The <a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a> (n = 2481) and <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a> (n = 189) trials reported all‐cause mortality in the long term as an endpoint. No effect between psychotherapy versus usual care was observed in the two trials, and the pooled effect was not significant (OR 0.83, 95% CI 0.48 to 1.42) (n = 2670) (<a href="./references#CD008012-fig-0012" title="">Analysis 1.9</a>). There was evidence of moderate heterogeneity (I<sup>2</sup> = 46%). </p> <p>No psychological intervention trial reported the short‐term cardiovascular mortality outcome. The <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a> trial (n = 570) reported cardiovascular mortality in the medium term and did not find a significant increase or decrease in probability of cardiovascular mortality (<a href="./references#CD008012-fig-0013" title="">Analysis 1.10</a>). Two trials reported on cardiovascular mortality in the long term (<a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>). No effect between CBT versus usual control was observed (OR 0.83, 95% CI 0.62 to 1.10) (n = 2720) (<a href="./references#CD008012-fig-0014" title="">Analysis 1.11</a>). There was no evidence of heterogeneity (I<sup>2</sup> = 0%). </p> </section> <section id="CD008012-sec-0055"> <h5 class="title">1.4 Primary outcome: cardiac events</h5> <p>No psychological intervention trial reported MI as an outcome in the short or medium term. Two trials (n = 2720) reported on MI (<a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>). In <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>, the endpoint was inclusive of acute coronary syndromes (ST and non‐ST elevated MI, and unstable angina). No effect between CBT and control was observed on MI outcome in the long term (OR 1.09, 95% CI 0.73 to 1.65) (n = 2720) (<a href="./references#CD008012-fig-0015" title="">Analysis 1.12</a>). There was no evidence of heterogeneity (I<sup>2</sup> = 27%). Only <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a> reported the primary outcomes of heart failure and stroke in the long term (n = 239). <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a> did not report a significant increase or decrease in probability of heart failure (OR 3.82, 95% CI 0.78 to 18.77) (<a href="./references#CD008012-fig-0016" title="">Analysis 1.13</a>) or stroke (OR 2.10, 95% CI 0.19 to 23.52) (<a href="./references#CD008012-fig-0017" title="">Analysis 1.14</a>) in the long term (n = 239), though the number of events were sparse. Two trials reported coronary revascularisation procedure as an outcome in the long term (OR 0.91, 95% CI 0.75 to 1.11) (n = 2780) (<a href="./references#CD008012-fig-0018" title="">Analysis 1.15</a>) without heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>). No psychological intervention trial reported angina or arrhythmia as an outcome in the short, medium, or longer term. </p> </section> <section id="CD008012-sec-0056"> <h5 class="title">1.5 Secondary outcome: healthcare and resource utilisation</h5> <p>One trial reported data on the effect of a brief CBT intervention compared to usual care on hospital length of stay after a CABG procedure (mean difference (MD) −1.30, 95% CI −2.53 to −0.07) (n = 97) (<a href="./references#CD008012-fig-0020" title="">Analysis 1.17</a>) (<a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>). One trial reported data on the effect of a CBT intervention compared to usual care on hospitalisation for cardiovascular causes (OR 0.92, 95% CI 0.78 to 1.09) (n = 2481) (<a href="./references#CD008012-fig-0019" title="">Analysis 1.16</a>) (<a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>). </p> </section> <section id="CD008012-sec-0057"> <h5 class="title">1.6 Secondary outcome: quality of life</h5> <p>Three studies investigated the effects of psychological interventions on short‐term quality of life (QoL) (<a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>). The Physical Component Summary (PCS) and Mental Component Summary (MCS) scores of the Medical Outcomes Study Short‐Form 12/36‐item Health Survey (SF‐12 and SF‐36) were used in <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a> and <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>, respectively. The <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a> trial utilised the Assessment of Quality of Life scale (AQoL‐8D) at end of treatment, where higher scores indicate lower QoL, therefore these data were not pooled with data from the trials utilising the SF‐12 and SF‐36 (<a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>). </p> <p>There was no beneficial effect of CBT versus usual care on PCS score (SMD 0.22, 95% CI −0.06 to 0.50) (n = 202) (I<sup>2</sup> = 0%). (<a href="./references#CD008012-fig-0021" title="">Analysis 1.18</a>). There was an effect favouring CBT versus usual care on MCS in <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>. No effect on MCS was reported in <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>. The pooled effect of the two trials indicated a moderate effect on MCS favouring CBT versus usual care (SMD 0.51, 95% CI 0.07 to 0.94) (n = 202), with substantial heterogeneity (I<sup>2</sup> = 57%) (<a href="./references#CD008012-fig-0022" title="">Analysis 1.19</a>). There was no difference between internet CBT (M = 63.87 ± 16.43) and wait‐list control (M = 63.78 ± 14.42; Cohen's <i>d</i> = 0.00) on total AQoL‐8D scores at end of treatment in the <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a> trial (n = 34). </p> <p>Three studies investigated the effects of psychological interventions on medium‐term QoL, using the PCS and MCS scores of the SF‐12/36 (<a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>), and the overall score of the SF‐12 (<a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>). The pooled effect of two trials indicated no effect on PCS for psychotherapy (both CBT) versus usual care (SMD 0.18, 95% CI −1.29 to 1.65) (n = 202), without evidence of heterogeneity (I<sup>2</sup> = 25%) (<a href="./references#CD008012-fig-0023" title="">Analysis 1.20</a>) (<a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>). The pooled effect of two trials indicated no effect on MCS for psychotherapy (both CBT) versus usual care (SMD 1.21, 95% CI −1.09 to 3.52) (n = 202), with evidence of moderate heterogeneity (I<sup>2</sup> = 41%) (<a href="./references#CD008012-fig-0024" title="">Analysis 1.21</a>) (<a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>). In the trial by <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>, no effect for brief CBT versus usual care was found for the SF‐12 overall score (MD −4.00, 95% CI −8.48 to 0.48) (n = 96) (<a href="./references#CD008012-fig-0025" title="">Analysis 1.22</a>). One trial investigated the effects of psychological interventions on long‐term QoL using the PCS and MCS scores of the SF‐36 quantified at nine months (n = 81) (<a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>). No effect was observed on the PCS score in the long term (MD 0.70, 95% CI −3.60 to 5.00) (<a href="./references#CD008012-fig-0026" title="">Analysis 1.23</a>). An effect was reported for the MCS score of the SF‐36 QoL measure (MD 6.70, 95% CI 1.29 to 12.11) (n = 81) (<a href="./references#CD008012-fig-0027" title="">Analysis 1.24</a>). One further study did not report sufficient information to compute effects sizes regarding QoL (<a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>). </p> </section> <section id="CD008012-sec-0058"> <h5 class="title">1.7 Secondary outcome: cardiovascular vital signs, biomarkers of platelet activation, ECG wave recording </h5> <p>No trial comparing psychological interventions with control reported cardiovascular vital signs, biomarkers of platelet activation, or ECG wave recording at any follow‐up time point. </p> </section> <section id="CD008012-sec-0059"> <h5 class="title">1.8 Post hoc outcome: non‐cardiac adverse events</h5> <p>One trial comparing CBT with wait‐list control reported a non‐cardiac adverse event (suicide intent) during the eight‐week intervention and did not attribute this to the intervention (<a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>). One trial reported insufficient information on newly diagnosed severe mental illness (e.g. severe depression, suicide attempt, and psychosis) (<a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>). Otherwise, data were sparse for non‐cardiac adverse effects of psychological interventions for depression in individuals with CAD. </p> </section> </section> <section id="CD008012-sec-0060"> <h4 class="title">Comparison 2: Psychological intervention versus psychological intervention</h4> <p>In three trials with a total of 219 participants the effects of a specific psychological intervention were compared with the effects of another psychological intervention or clinical management (<a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>). <a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a> compared 12 weekly sessions of behaviour therapy for patients and their partners by Lewinsohn versus 12 weekly sessions of person‐centred therapy by Rogers. <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a> compared 12 weekly sessions of CBT versus 12 weekly sessions of supportive stress management. <a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a> compared an intervention comprising eight sessions of CBT and four sessions of well‐being therapy versus CM. We could not report pooled estimates for this comparison due to the heterogeneous interventions and different comparators examined in the trials (see <a href="#CD008012-sec-0019">Types of interventions</a>). Data are therefore reported as mean differences and described qualitatively in text. </p> <section id="CD008012-sec-0061"> <h5 class="title">2.1 Primary outcome: depression score</h5> <p>Three studies investigated the effects of psychological intervention compared to another psychological intervention on short‐term depression symptoms (i.e. end of treatment) (<a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>). The evidence is very uncertain regarding the effect on end‐of‐treatment depression symptoms for behaviour therapy compared to person‐centred therapy on the BDI (n = 40) (<a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>); CBT compared to supportive stress management on the HAM‐D (n = 83) (<a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>); and the combination of CBT and well‐being therapy compared to CM on symptoms measured by the Clinical Interview for Depression (CID) (n = 100) (<a href="./references#CD008012-fig-0028" title="">Analysis 2.1</a>) (<a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>). </p> <p>Three studies investigated the effects of psychological intervention compared to another psychological intervention or CM on medium‐term depression symptoms (i.e. one to six months after treatment) (<a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>). No effect was observed for CBT compared to supportive stress management on symptoms measured by the HAM‐D depression score (n = 83) (<a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>). Behaviour therapy showed a beneficial effect compared to person‐centred therapy on symptoms measured by the BDI (SMD −0.65, 95% CI −1.28 to −0.01) (n = 40) (<a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>). No effect was observed for the combination of CBT and well‐being therapy compared to CM on symptoms measured by the CID (n = 100) (<a href="./references#CD008012-fig-0029" title="">Analysis 2.2</a>) (<a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>). </p> <p>Three studies investigated the effects of psychological intervention compared to another psychological intervention or CM on long‐term depression symptoms (i.e. more than six months after treatment) (<a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>). No effect was observed for CBT compared to supportive stress management on symptoms measured by the HAM‐D (n = 83) (<a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>). Behaviour therapy resulted in a large effect compared to person‐centred therapy on symptoms measured by the BDI (SMD −0.69, 95% CI −1.33 to −0.05) (n = 40) (<a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>). No effect was observed for the combination of CBT and well‐being therapy compared to CM on symptoms measured by the CID (n = 100) (<a href="./references#CD008012-fig-0030" title="">Analysis 2.3</a>) (<a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>). </p> </section> <section id="CD008012-sec-0062"> <h5 class="title">2.2 Primary outcome: depression remission and response</h5> <p>One trial investigated the effects of psychological intervention compared to another psychological intervention on short‐term depression remission (i.e. end of treatment) (<a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>). No effect was observed for CBT compared to supportive stress management on the HAM‐D (n = 83) (<a href="./references#CD008012-fig-0031" title="">Analysis 2.4</a>) (<a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>). No effect was observed for CBT compared to supportive stress management on HAM‐D depression remission in one study (n = 83) in the medium term (i.e. one to six months after end of treatment) (<a href="./references#CD008012-fig-0032" title="">Analysis 2.5</a>) and the long term (i.e. more than six months after end of treatment) (<a href="./references#CD008012-fig-0033" title="">Analysis 2.6</a>) (<a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>). One trial reported depression relapse, but as remission and response rate was unclear data were not extracted (<a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>). </p> </section> <section id="CD008012-sec-0063"> <h5 class="title">2.3 Primary outcome: all‐cause and cardiovascular mortality</h5> <p>No trials reported all‐cause mortality at any length of follow‐up for this comparison. One trial comparing the combination of CBT and well‐being therapy versus CM reported cardiac death as a cause of attrition or dropout from the study from 18 to 30 months (<a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>), though events were sparse (<a href="./references#CD008012-fig-0034" title="">Analysis 2.7</a>) (n = 100). </p> </section> <section id="CD008012-sec-0064"> <h5 class="title">2.4 Primary outcome: cardiac events</h5> <p>One trial reported composite cardiac events to 30 months of follow‐up but did not differentiate cardiac events, therefore data could not be analysed (n = 100) (<a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>). </p> </section> <section id="CD008012-sec-0065"> <h5 class="title">2.5 Secondary outcome: healthcare and resource utilisation</h5> <p>No trials reported healthcare and resource utilisation at any length of follow‐up for this comparison. </p> </section> <section id="CD008012-sec-0066"> <h5 class="title">2.6 Secondary outcome: quality of life</h5> <p>Only <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a> (n = 83) reported QoL using mean final scores of the SF‐36 subscales PCS and MCS. No effects were observed for CBT compared to supportive stress management in the short term (i.e. end of treatment) for the PCS (<a href="./references#CD008012-fig-0035" title="">Analysis 2.8</a>) (n = 83) and MCS (<a href="./references#CD008012-fig-0036" title="">Analysis 2.9</a>) (n = 83). No effects were observed for CBT compared to supportive stress management in the medium term (i.e. one to six months after end of treatment) for the PCS (<a href="./references#CD008012-fig-0037" title="">Analysis 2.10</a>) (n = 83) and MCS (<a href="./references#CD008012-fig-0038" title="">Analysis 2.11</a>) (n = 83). Likewise, no effects were reported for the PCS (<a href="./references#CD008012-fig-0039" title="">Analysis 2.12</a>) and MCS (<a href="./references#CD008012-fig-0040" title="">Analysis 2.13</a>) in the long term (i.e. more than six months after end of treatment) (n = 83). </p> </section> <section id="CD008012-sec-0067"> <h5 class="title">2.7 Secondary outcome: cardiovascular vital signs, biomarkers of platelet activation, ECG wave recording </h5> <p>One trial quantified biomarkers of platelet activation (i.e. platelet count, D‐dimer level) at three months but did not report sufficient information to compute effect sizes (<a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>). </p> </section> <section id="CD008012-sec-0068"> <h5 class="title">2.8 Post hoc outcome: non‐cardiac adverse events</h5> <p>Non‐cardiac adverse events were inconsistently and sparsely reported for this comparison. In <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>, one participant in the supportive stress management group dropped out due to psychiatric complications. </p> </section> </section> <section id="CD008012-sec-0069"> <h4 class="title">Comparison 3: Pharmacological intervention versus placebo</h4> <p>Thirteen trials studied the effects of a pharmacological intervention versus placebo (<a href="./references#CD008012-bbs2-0002" title="NCT02463110. Acute myocardial necrosis and depression: antiplatelet effect of reuptake inhibition of serotonin. clinicaltrials.gov/show/nct02463110 (first posted 4 June 2015). ">ANDROS 2015</a>; <a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0014" title="FreemanAM , FleeceL , FolksDG , SokolRS , HallKR , PacificoAD , et al. Alprazolam treatment of postcoronary bypass anxiety and depression. Journal of Clinical Psychopharmacology1986;6:39-41. ">Freeman 1986</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>). Minimal information could be extracted from the trial registry of the two trials that were terminated early (<a href="./references#CD008012-bbs2-0002" title="NCT02463110. Acute myocardial necrosis and depression: antiplatelet effect of reuptake inhibition of serotonin. clinicaltrials.gov/show/nct02463110 (first posted 4 June 2015). ">ANDROS 2015</a>; <a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>). Data from <a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a> were restricted to the citalopram and CM versus placebo and CM arms of this trial, thereby excluding data from the arms randomised to psychotherapy (IPT). </p> <section id="CD008012-sec-0070"> <h5 class="title">3.1 Primary outcome: depression score</h5> <p>Twelve studies investigated the effects of pharmacological interventions on short‐term depression symptoms (i.e. end of treatment) (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0014" title="FreemanAM , FleeceL , FolksDG , SokolRS , HallKR , PacificoAD , et al. Alprazolam treatment of postcoronary bypass anxiety and depression. Journal of Clinical Psychopharmacology1986;6:39-41. ">Freeman 1986</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>). Two trials did not report sufficient information to compute effects sizes (<a href="./references#CD008012-bbs2-0014" title="FreemanAM , FleeceL , FolksDG , SokolRS , HallKR , PacificoAD , et al. Alprazolam treatment of postcoronary bypass anxiety and depression. Journal of Clinical Psychopharmacology1986;6:39-41. ">Freeman 1986</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>). A pooled analysis of eight trials indicated that pharmacological intervention may result in a large reduction in depression symptoms at the end of treatment versus placebo (SMD −0.83, 95% CI −1.33 to −0.32) (n = 750) (<a href="./references#CD008012-fig-0041" title="">Analysis 3.1</a>) (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>). There was evidence of considerable heterogeneity between studies (I<sup>2</sup> = 90%). Sensitivity analyses for <a href="./references#CD008012-fig-0041" title="">Analysis 3.1</a> (<a href="#CD008012-tbl-0007">Table 3</a>) indicated that heterogeneity remained. The pooled SMD was attenuated and no longer significant in three trials undertaken in participants with depressive disorders. There was no attenuation of the pooled SMD in analyses restricted to seven trials undertaken in depression‐only samples (i.e. excluding mixed depression/anxiety). The pooled SMD was modestly attenuated in analyses restricted to six serotonergic antidepressant trials. </p> <div class="table" id="CD008012-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analyses for depression symptoms at end of treatment in pharmacological versus placebo trials</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study references [n]</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SMD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>I<sup>2</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacological vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (<a href="./references#CD008012-fig-0041" title="">Analysis 3.1</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a> (n = 750) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD −0.83 (95% CI −1.33 to −0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacological vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constrained to trials with major depressive disorders as part of the inclusion criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a> </p> <p>(n = 427)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD −0.48 (95% CI −1.38 to 0.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacological vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constrained to depression (e.g. excluding trials with mixed depression and/or anxiety as part of the inclusion criteria) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a> (n = 695) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD −0.76 (95% CI −1.29 to −0.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacological vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constrained to serotonergic antidepressant trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a> (n = 613) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD −0.69 (95% CI −1.27 to −0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI = confidence interval; SMD = standardised mean difference</p> </div> </div> <p>Two studies reported depression change scores that could not be pooled in the main meta‐analysis of end‐of‐treatment SMDs (<a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>), and one trial reported both end‐of‐treatment scores and change scores (<a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>). A pooled analysis of change scores suggested a small change in depression symptoms (SMD −0.18, 95% CI −0.36 to −0.00) compared to placebo (<a href="./references#CD008012-fig-0042" title="">Analysis 3.2</a>) (n = 482). Heterogeneity was low (I<sup>2</sup> = 0%). No trials reported depression symptoms in the medium or long term. </p> </section> <section id="CD008012-sec-0071"> <h5 class="title">3.2 Primary outcome: depression remission and response</h5> <p>Four studies investigated the effects of pharmacological interventions on short‐term depression remission (i.e. end of treatment) (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>). One study reported insufficient information on "depressive reductive rate" which was unclear and not extracted (<a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>). Citalopram showed a beneficial effect compared to placebo in two studies (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>). Mirtazapine, <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a> (n = 91), and fluoxetine, <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a> (n = 54), did not show a beneficial effect compared to placebo. Pooled meta‐analysis of four studies indicated that pharmacological intervention probably results in a moderate to large increase in depression remission at the end of treatment versus placebo (OR 2.06, 95% CI 1.47 to 2.89; I<sup>2</sup> = 0%) (<a href="./references#CD008012-fig-0043" title="">Analysis 3.3</a>) (n = 646) (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>). </p> <p>Five trials investigated the effects of pharmacological intervention on depression response, defined as a 50% reduction in depression scores, in the short term (i.e. end of treatment) (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>). No significant effect was found in one trial (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>). An effect favouring pharmacological intervention for depression response versus placebo was found in the other four trials (<a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>). The pooled effect from five trials indicated an effect favouring pharmacological intervention treatment versus placebo (OR 2.73, 95% CI 1.65 to 4.54) (n = 891) with considerable heterogeneity (I<sup>2</sup> = 62%) (<a href="./references#CD008012-fig-0044" title="">Analysis 3.4</a>). No trials reported depression remission or depression response in the medium or long term for this comparison. </p> </section> <section id="CD008012-sec-0072"> <h5 class="title">3.3 Primary outcome: all‐cause and cardiovascular mortality</h5> <p>Five studies reported all‐cause mortality (<a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>). No deaths occurred in two studies in the short term (<a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a> (n = 91); (<a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>) (n = 27)), and in two trials no effect was observed (<a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>). Data from one trial after translation remained unclear and could not be extracted (<a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>). The evidence is very uncertain regarding the effect of pharmacological intervention on all‐cause mortality at end of treatment in two trials (OR 0.38, 95% CI 0.10 to 1.47; I<sup>2</sup> = 0%) (n = 437) (<a href="./references#CD008012-fig-0045" title="">Analysis 3.5</a>). Medium‐term all‐cause mortality data was not reported. Two studies reported long‐term all‐cause mortality (<a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a> (n = 300); <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a> (n = 361)), neither of which showed a survival benefit from pharmacological intervention versus placebo. The pooled effect was not significant (OR 0.89, 95% CI 0.64 to 1.25) (n = 661) (<a href="./references#CD008012-fig-0046" title="">Analysis 3.6</a>) and without heterogeneity (I<sup>2</sup> = 0%). One trial reported long‐term cardiovascular mortality and did not find a survival benefit from escitalopram versus placebo (<a href="./references#CD008012-fig-0047" title="">Analysis 3.7</a>) (n = 300) (<a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>). </p> </section> <section id="CD008012-sec-0073"> <h5 class="title">3.4 Primary outcome: cardiac events</h5> <p>Four studies analysed cardiac events (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>). One trial reported specific cardiac events occurring by the end of treatment in groups randomised to mirtazapine or placebo (<a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>). Serious adverse events were described in the terminated trial (<a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>). Insufficient information was provided in one trial to adjudicate whether cardiac events were assessed or had occurred (<a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>). Three studies reported the occurrence of MI in the short term (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>). The evidence is very uncertain regarding the effects of pharmacological intervention on MI at end of treatment from tree trials (OR 0.74, 95% CI 0.26 to 2.09; I<sup>2</sup> = 0%) (n = 728) (<a href="./references#CD008012-fig-0048" title="">Analysis 3.8</a>). Longer‐term MI was not significantly decreased in one trial comparing escitalopram versus placebo (<a href="./references#CD008012-fig-0049" title="">Analysis 3.9</a>) (n = 300) (<a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>). </p> <p>There was little to no difference in angina at the end of treatment in trials of sertraline (<a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>) (n = 369), mirtazapine (<a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>) (n = 91), citalopram (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>) (n = 142), and escitalopram (<a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>) (n = 217). Meta‐analysis of four studies indicated little to no difference with pharmacological intervention versus placebo in angina pectoris (OR 0.75, 95% CI 0.44 to 1.28; I<sup>2</sup> = 0%) (<a href="./references#CD008012-fig-0050" title="">Analysis 3.10</a>) (n = 819) (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>). Angina was not reported in the medium to long term for this comparison. </p> <p>There was little to no difference in heart failure in trials of sertraline (<a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>) (n = 369), mirtazapine (<a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>) (n = 91), and citalopram (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>) (n = 142), though the number of events was sparse. Meta‐analysis of three studies indicated little to no difference with pharmacological intervention versus placebo in heart failure in the short term (OR 0.93, 95% CI 0.33 to 2.62; I<sup>2</sup> = 0%) (<a href="./references#CD008012-fig-0051" title="">Analysis 3.11</a>) (n = 602) (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>). </p> <p>Arrhythmias were decreased in one trial of fluoxetine compared to placebo at the end of treatment (<a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>). Atrial fibrillation was reported as a serious adverse event in the terminated trial (<a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>). The pooled estimate from two trials showed little to no difference in arrhythmia at end of treatment (OR 0.46, 95% CI 0.01 to 17.06) (<a href="./references#CD008012-fig-0052" title="">Analysis 3.12</a>) (n = 87). The number of events was sparse, and there was considerable heterogeneity between studies (I<sup>2</sup> = 71%). Changes to ECG waves, <a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>, and heart rate variability, <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>, were reported but could not be extracted due to uncertainty in the assessment of arrhythmia endpoints. Ventricular function assessment and endpoints were unclear after translation of one trial, and data could not be extracted (<a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>). </p> <p>There was little to no difference in stroke in one trial comparing sertraline to placebo, <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a> (n = 369), and one trial comparing escitalopram to placebo, <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a> (n = 217). One trial of citalopram compared to placebo reported no stroke events in either group (n = 142) (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>). The pooled probability estimate of stroke at the end of treatment from the two trials with events indicated little to no difference in stroke (OR 0.99, 95% CI 0.20 to 4.96) (<a href="./references#CD008012-fig-0053" title="">Analysis 3.13</a>) (n = 586). The number of events was sparse, and there was no heterogeneity between studies (I<sup>2</sup> = 0%). There was little to no difference in percutaneous coronary intervention procedures in the long term in one trial of escitalopram versus placebo (<a href="./references#CD008012-fig-0054" title="">Analysis 3.14</a>) (n = 300) (<a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>). Evidence of coronary revascularisation interventions for CAD was sparse and not reported in the short and medium term. </p> </section> <section id="CD008012-sec-0074"> <h5 class="title">3.5 Secondary outcome: healthcare and resource utilisation</h5> <p>There was little to no difference in healthcare costs at the end of treatment, excluding antidepressant medication with sertraline, in <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a> (<a href="./references#CD008012-fig-0055" title="">Analysis 3.15</a>) (n = 369). Meta‐analysis of three studies (n = 514) indicated that pharmacological interventions may reduce hospitalisations compared to placebo (OR 0.58, 95% CI 0.39 to 0.85) (<a href="./references#CD008012-fig-0056" title="">Analysis 3.16</a>) without evidence of heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>). Any possible effect on hospitalisation was largely attributed to a trial of sertraline (OR 0.59, 95% CI 0.38 to 0.91) (n = 369) (<a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>), whereas no effect was observed in the trials of mirtazapine, <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a> (n = 91), and fluoxetine, <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a> (n = 54). Emergency room visits at the end of treatment were not reduced in a trial of sertraline (OR 0.58, 95% CI 0.34 to 1.00) (<a href="./references#CD008012-fig-0057" title="">Analysis 3.17</a>) (n = 369) (<a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>). </p> </section> <section id="CD008012-sec-0075"> <h5 class="title">3.6 Secondary outcome: quality of life</h5> <p>Two trials examined quality of life (<a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>). The <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a> trial (n = 369) investigated quality of life using the Quality of Life Enjoyment and Satisfaction Questionnaire (Q‐LES‐Q) and the SF‐36 comparing sertraline with placebo. Data for the SF‐36 were not reported sufficiently to compute effects sizes. No effect was observed for the Q‐LES‐Q (<a href="./references#CD008012-fig-0058" title="">Analysis 3.18</a>). <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a> (n = 213) examined short‐ and medium‐term QoL using the WHOQOL‐BREF questionnaire. Escitalopram compared to placebo (n = 213) showed possible short‐term end‐of‐treatment effects on the following WHOQOL‐BREF subscales: physical (MD 6.80, 95% CI 2.77 to 10.83) (<a href="./references#CD008012-fig-0059" title="">Analysis 3.19</a>), psychological (MD 5.60, 95% CI 1.54 to 9.66) (<a href="./references#CD008012-fig-0060" title="">Analysis 3.20</a>), social relationship (MD 4.00, 95% CI 0.03 to 7.97) (<a href="./references#CD008012-fig-0061" title="">Analysis 3.21</a>), and environmental (MD 6.50, 95% CI 2.90 to 10.10) (<a href="./references#CD008012-fig-0062" title="">Analysis 3.22</a>) (<a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>). End‐of‐treatment effects on social and occupational functioning, as well as disability, were reported for a subset of participants in <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a> (n = 217), but were not extracted here. </p> <p>Escitalopram compared to placebo showed possible medium‐term treatment effects on the WHOQOL‐BREF subscales physical (MD 6.10, 95% CI 1.25 to 10.95) (<a href="./references#CD008012-fig-0063" title="">Analysis 3.23</a>), social relationship (MD 4.80, 95% CI 0.17 to 9.43) (<a href="./references#CD008012-fig-0065" title="">Analysis 3.25</a>), and environmental (MD 5.80, 95% CI 1.54 to 10.06) (<a href="./references#CD008012-fig-0066" title="">Analysis 3.26</a>), but not on the psychological subscale (MD 4.70, 95% CI −0.33 to 9.73) (n = 213) (<a href="./references#CD008012-fig-0064" title="">Analysis 3.24</a>) (<a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>). </p> </section> <section id="CD008012-sec-0076"> <h5 class="title">3.7 Secondary outcome: cardiovascular vital signs, biomarkers of platelet activation, ECG wave recording </h5> <p>Three trials reported all BP and heart rate cardiovascular vital signs post‐treatment (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>), and a fourth trial reported heart rate and not BP (<a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>). Pooled analysis from three trials indicated that pharmacological intervention may result in little to no difference in end‐of‐treatment systolic BP versus placebo (MD −0.24, 95% CI −3.52 to 3.05) (<a href="./references#CD008012-fig-0067" title="">Analysis 3.27</a>) in three trials (n = 675) without substantial heterogeneity (I<sup>2</sup> = 32%). Likewise, pharmacological intervention may result in little to no difference in end‐of‐treatment diastolic BP (MD 0.60, 95% CI −1.55 to 2.74) (<a href="./references#CD008012-fig-0068" title="">Analysis 3.28</a>) in three trials (n = 675). There was evidence of moderate heterogeneity between studies (I<sup>2</sup> = 43%). Pharmacological intervention may result in little to no difference in end‐of‐treatment heart rate (MD −0.80, 95% CI −2.40 to 0.79) (<a href="./references#CD008012-fig-0069" title="">Analysis 3.29</a>) in four trials (n = 662). There was no evidence of heterogeneity between studies (I<sup>2</sup> = 0%). </p> <p>Seven studies reported platelet biomarkers post‐treatment (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>), generally from a smaller subset of participants from each trial arm. Two studies reported insufficient data to calculate effect sizes (<a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>), and additional data for PF4 could be extracted from an online trial data repository (<a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>). Two studies reported platelet biomarkers outside of the outcomes of this review (<a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>), which may be considered in a future update. Meta‐analysis of three trials showed that pharmacological treatment may reduce βTG at end of treatment (SMD −0.54, 95% CI −0.99 to −0.09) versus placebo (n = 141) (<a href="./references#CD008012-fig-0070" title="">Analysis 3.30</a>). There was evidence of possible heterogeneity (I<sup>2</sup> = 36%). </p> <p>Meta‐analysis of three trials showed that pharmacological treatment may result in little to no difference in reduction in PF4 (SMD −0.14, 95% CI −0.48 to 0.19) versus placebo (n = 144) (<a href="./references#CD008012-fig-0071" title="">Analysis 3.31</a>). There was no evidence of heterogeneity between studies (I<sup>2</sup> = 0%). Meta‐analysis of two trials showed that pharmacological treatment may result in little to no difference in P‐selectin (SMD −0.31, 95% CI −1.12 to 0.50) versus placebo (n = 121) (<a href="./references#CD008012-fig-0072" title="">Analysis 3.32</a>). There was evidence of considerable between‐study effect sizes (I<sup>2</sup> = 79%). Only <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a> reported PECAM‐1 and TxB<sub>2</sub> in a subset of trial participants. <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a> did not find an effect of pharmacological treatment versus placebo on PECAM‐1 (MD −8.30, 95% CI −18.12 to 1.52) (n = 64) (<a href="./references#CD008012-fig-0073" title="">Analysis 3.33</a>). No effect was observed in <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a> of pharmacological treatment versus placebo in TxB<sub>2</sub> (MD −6.20, 95% CI −15.78 to 3.38) (n = 64) (<a href="./references#CD008012-fig-0074" title="">Analysis 3.34</a>). </p> <p>Six studies performed end‐of‐treatment ECGs and reported wave parameters comparing pharmacological intervention versus placebo at end of treatment (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>). Three studies reported insufficient data to calculate effect sizes (<a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>). A reduction in PR interval was found in the <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a> trial of sertraline when compared to placebo (MD −6.00, 95% CI −11.84 to −0.16). The pooled effect for PR interval from three studies indicated that pharmacological intervention may result in a small reduction in PR interval (MD −4.35, 95% CI −8.40 to −0.31) (<a href="./references#CD008012-fig-0075" title="">Analysis 3.35</a>) (n = 635) without evidence of heterogeneity (I<sup>2</sup> = 0%) (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>). The pooled effect of ECG findings also suggested that pharmacological intervention may result in little to no difference in the QRS interval at the end of treatment (MD 2.37, 95% CI −0.41 to 5.15) (<a href="./references#CD008012-fig-0076" title="">Analysis 3.36</a>) (n = 635) without evidence of heterogeneity (I<sup>2</sup> = 0%). Only <a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a> (n = 142) reported the QT interval, finding no evidence of a difference between citalopram and placebo (MD 2.40, 95% CI −9.11 to 13.91). Pooled meta‐analysis from three trials indicated that pharmacological intervention probably results in little to no difference in QTc interval at the end of treatment (MD 2.76, 95% CI −1.96 to 7.47) (<a href="./references#CD008012-fig-0078" title="">Analysis 3.38</a>) (n = 635) without evidence of heterogeneity between studies (I<sup>2</sup> = 20%). </p> </section> <section id="CD008012-sec-0077"> <h5 class="title">3.8 Post hoc outcome: non‐cardiac adverse events and pharmacological side effects</h5> <p>One trial reported worsening depression in one participant receiving placebo and CM (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>). Otherwise, non‐cardiac adverse events were sparsely reported. Ten studies reported pharmacological side effects (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>). Two studies reported insufficient data to calculate effect sizes (<a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>). Pharmacological intervention may be associated with an increase in side effects (OR 1.44, 95% CI 1.07 to 1.92) versus placebo (<a href="./references#CD008012-fig-0079" title="">Analysis 3.39</a>) in eight trials (n = 1193) (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a>), without evidence of heterogeneity (I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD008012-sec-0078"> <h4 class="title">Comparison 4: Pharmacological intervention versus pharmacological intervention</h4> <section id="CD008012-sec-0079"> <h5 class="title">4.1 Primary outcome: depression symptoms</h5> <p>Eight trials compared two active pharmacological interventions against each other (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>; <a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a>; <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>; <a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>; <a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>). We did not report pooled estimates for this comparison due to the heterogeneous interventions and comparators examined in the trials. The trials made the following comparisons: </p> <p> <ul id="CD008012-list-0011"> <li> <p><a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a> (n = 46) simvastatin versus atorvastatin (each 20 mg/d); </p> </li> <li> <p><a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a> (n = 122) the add‐on effect of sertraline (50 mg/d) plus omega‐3 (2 g/d) versus sertraline (50 mg/d) and placebo; </p> </li> <li> <p><a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a> (n = 56) sertraline (200 mg/d) plus red yeast rice (2400 mg/d) versus sertraline (200 mg/d) plus placebo; </p> </li> <li> <p><a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a> (n = 146) Shugan Jieyu plus sertraline placebo versus sertraline plus Shugan Jieyu placebo; </p> </li> <li> <p><a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a> (n = 81) paroxetine versus nortriptyline; </p> </li> <li> <p><a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a> (n = 40) saffron (15 to 30 mg/d) versus fluoxetine (20 to 40 mg/d); </p> </li> <li> <p><a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a> (n = 46) paroxetine versus fluoxetine (each 20 mg/d); and </p> </li> <li> <p><a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a> (n = 228) escitalopram (5 to 10 mg/d) versus Bu Xin Qi concoction (400 mL twice a day). </p> </li> </ul> </p> <p>Eight studies examined the differential effects of two pharmacological interventions on short‐term depression symptoms, all using the HAM‐D clinician rating scale (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>; <a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a>; <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>; <a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>; <a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>). The evidence is very uncertain as to whether different pharmacological interventions may result in a reduction in depression symptoms at end of treatment (<a href="./references#CD008012-fig-0080" title="">Analysis 4.1</a>) for: simvastatin versus atorvastatin (SMD −0.66, 95% CI −1.25 to −0.06) (n = 46) (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>); paroxetine versus fluoxetine (SMD −1.05, 95% CI −1.67 to −0.43) (n = 46) (<a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>); and escitalopram versus Bu Xin Qi (SMD −1.02, 95% CI −1.30 to −0.74) (n = 228) (<a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>). The evidence is very uncertain as to whether the add‐on effect of sertraline (50 mg/d) plus omega‐3 (2 g/d) versus sertraline (50 mg/d) and placebo may result in a reduction in depression symptoms at end of treatment (n = 122) (<a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>). </p> <p>Four trials reported end‐of‐treatment depression change scores (<a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a>; <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>). In the study by <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>, we assumed the data were reported as standard errors and not standard deviation as stated in the article to remain consistent with the P values reported. The evidence is very uncertain regarding the effects of different pharmacological strategies on end‐of‐treatment depression change scores in the four trials (<a href="./references#CD008012-fig-0081" title="">Analysis 4.2</a>) (<a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a> (n = 50), <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a> (n = 149), <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a> (n = 81), and <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a> (n = 40)). No trials for this comparison reported medium‐ or longer‐term durability of interventions on depression symptoms. </p> </section> <section id="CD008012-sec-0080"> <h5 class="title">4.2 Primary outcome: depression remission and response</h5> <p>Three studies examined the differential effects of two pharmacological interventions on depression remission (<a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>). In all three trials no differences were observed between groups using the clinician‐rated HAM‐D, <a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>, or the BDI‐II, <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a> (<a href="./references#CD008012-fig-0082" title="">Analysis 4.3</a>), and the evidence is very uncertain regarding the effects of different pharmacological strategies on end‐of‐treatment depression remission. Four studies examined the differential effects of two pharmacological interventions on depression response (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>; <a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>). No differences were observed using the clinician‐rated HAM‐D, <a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>; <a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>, or the BDI‐II, <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a> (<a href="./references#CD008012-fig-0083" title="">Analysis 4.4</a>). The study by <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a> (n = 149) reported the number needed for treatment for non‐inferiority, but not depression response nor remission, therefore no data were extracted. </p> </section> <section id="CD008012-sec-0081"> <h5 class="title">4.3 Primary outcome: all‐cause and cardiovascular mortality</h5> <p>The evidence from one trial is very uncertain regarding the effect of Shugan Jieyu plus sertraline placebo compared to sertraline plus Shugan Jieyu placebo on all‐cause mortality at the end of treatment (n = 149) (<a href="./references#CD008012-fig-0084" title="">Analysis 4.5</a>) (<a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>). No trials for this comparison reported medium‐ or longer‐term all‐cause mortality. Likewise, no trials for this comparison reported cardiovascular mortality at any time point. </p> </section> <section id="CD008012-sec-0082"> <h5 class="title">4.4 Primary outcome: cardiac events</h5> <p>Four studies reported the differential effects of two pharmacological interventions on cardiac events at the end of treatment (i.e. short term) (<a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>; <a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>). The number of events were sparse for MI, heart failure, and arrhythmia, whilst no study reported stroke. The evidence is very uncertain regarding the occurrence of MI at end of treatment in trials of: sertraline plus omega‐3 versus sertraline plus placebo (n = 122) (<a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>); paroxetine versus fluoxetine (n = 46) (<a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>); and escitalopram versus Bu Xin Qi concoction (n = 228) (<a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>) (<a href="./references#CD008012-fig-0085" title="">Analysis 4.6</a>). No differences were reported between different pharmacological strategies on end‐of‐treatment angina in the trials by <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a> (n = 81), <a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a> (n = 46), or <a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a> (n = 228) (<a href="./references#CD008012-fig-0086" title="">Analysis 4.7</a>). No differences were observed between pharmacological interventions in end‐of‐treatment heart failure in the trials reported by <a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a> (n = 122) and <a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a> (n = 228) (<a href="./references#CD008012-fig-0087" title="">Analysis 4.8</a>). Likewise, no differences were observed between pharmacological interventions in end‐of‐treatment arrhythmia in the trials reported by <a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a> (n = 122), <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a> (n = 81), and <a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a> (n = 228) (<a href="./references#CD008012-fig-0088" title="">Analysis 4.9</a>). No studies reported the occurrence of MI, angina, heart failure, arrhythmia, or stroke in the medium to longer term. Coronary revascularisation procedure for CAD (angioplasty) at end of treatment did not differ between groups in the trial reported by <a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a> (<a href="./references#CD008012-fig-0089" title="">Analysis 4.10</a>) (n = 122). </p> </section> <section id="CD008012-sec-0083"> <h5 class="title">4.5 Secondary outcome: healthcare and resource utilisation</h5> <p>One trial reported emergency room visits, finding no effect for sertraline plus omega‐3 versus sertraline plus placebo (n = 122) (<a href="./references#CD008012-fig-0090" title="">Analysis 4.11</a>) (<a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>). </p> </section> <section id="CD008012-sec-0084"> <h5 class="title">4.6 Secondary outcome: quality of life</h5> <p>No trials evaluating this comparison reported QoL at any time point.</p> </section> <section id="CD008012-sec-0085"> <h5 class="title">4.7 Secondary outcome: cardiovascular vital signs, biomarkers of platelet activation, ECG wave recording </h5> <p>Three studies reported the differential effects of pharmacological interventions on cardiovascular vital signs in the short term (<a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>). Paroxetine may result in a lower systolic BP (MD −10.00, 95% CI −17.10 to −2.90) compared to nortriptyline (n = 63) (<a href="./references#CD008012-fig-0091" title="">Analysis 4.12</a>) (<a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>). Systolic BP may not differ for pharmacological strategies employing paroxetine versus fluoxetine (n = 46) (<a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>), or Shugan Jieyu versus sertraline (n = 149) (<a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>). No differential effects were evident between pharmacological interventions for diastolic BP in the trials by <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a> (n = 63), <a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a> (n = 46), and <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a> (n = 149) (<a href="./references#CD008012-fig-0092" title="">Analysis 4.13</a>). Two studies reported heart rate. Paroxetine may result in a lower heart rate (MD −11.00, 95% CI −14.31 to −7.69) compared to nortriptyline (n = 63) (<a href="./references#CD008012-fig-0093" title="">Analysis 4.14</a>) (<a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>). No difference in heart rate was observed between Shugan Jieyu plus sertraline placebo and sertraline plus Shugan Jieyu placebo (n = 149) (<a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>). No trials reported medium‐ to longer‐term assessment of cardiovascular vital signs for this comparison. </p> <p>No head‐to‐head comparison of two pharmacological interventions reported on biomarkers of platelet activation. </p> <p>Two studies reported the differential effects of two pharmacological interventions on ECG waves in the short term (<a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>). Paroxetine may result in a lower PR interval (MD −9.00, 95% CI −16.77 to −1.23) compared to nortriptyline (n = 63) (<a href="./references#CD008012-fig-0094" title="">Analysis 4.15</a>) (<a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>). Shugan Jieyu plus sertraline placebo versus sertraline plus Shugan Jieyu placebo was not associated with differences in PR interval (n = 146) (<a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>). There may be little to no differences between pharmacological interventions for the QRS (<a href="./references#CD008012-fig-0095" title="">Analysis 4.16</a>) and QTc intervals (<a href="./references#CD008012-fig-0096" title="">Analysis 4.17</a>). No trial reported end‐of‐treatment QT intervals. One trial reported ventricular premature depolarisations (<a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>), which was not considered in this review. </p> </section> <section id="CD008012-sec-0086"> <h5 class="title">4.8 Post hoc outcome: non‐cardiac adverse events and pharmacological side effects</h5> <p>In <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>, one participant allocated to fluoxetine withdrew from treatment due to suicidal ideation. In two trials (<a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a> ; <a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>), the definition of non‐cardiac adverse events was unclear. Otherwise, non‐cardiac adverse events were sparsely reported. Seven studies reported pharmacological side effects (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>; <a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>; <a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a>; <a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a>; <a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a>; <a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a>; <a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>). There may be little to no difference between different pharmacological intervention strategies on side effects at end of treatment in seven trials (<a href="./references#CD008012-fig-0097" title="">Analysis 4.18</a>) (n = 716). </p> </section> </section> <section id="CD008012-sec-0087"> <h4 class="title">Comparison 5: Psychological intervention versus pharmacological intervention</h4> <p>We found no trials evaluating psychological intervention versus pharmacological intervention. No analyses were performed. </p> </section> <section id="CD008012-sec-0088"> <h4 class="title">Subgroup analyses</h4> <p>We planned subgroup analyses to take into account variables such as the population, sex, CAD subtype, time of onset of depression, CAD severity, and risk of bias. Lack of primary data per outcome precluded these analyses. However, as Cochrane Reviews are meant to be updated on a regular basis, these analyses may be feasible in future updates of this review. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008012-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008012-sec-0089"></div> <p>The current systematic review investigated the effects of psychological and pharmacological interventions on depression outcomes, mortality, cardiac events, healthcare costs and utilisation, health‐related QoL, cardiovascular vital signs, biomarkers of platelet activation, ECG wave parameters, non‐cardiac adverse events, and side effects in CAD patients with comorbid depressive disorder. Our comprehensive search strategy identified 37 RCTs fulfilling the inclusion criteria of the review. Fifteen trials examined psychological interventions, and 21 trials examined pharmacological interventions. </p> <section id="CD008012-sec-0090"> <h3 class="title" id="CD008012-sec-0090">Summary of main results</h3> <p>The results of the current review provide evidence that psychological interventions may result in lower depression symptoms compared to control at end of treatment. However, psychological intervention may result in little to no difference in depression remission in the short term based on three trials. The findings of one trial favoured psychological intervention for depression remission in the long term but not in the medium term. Based on one to two trials per outcome, the evidence is uncertain or sparse for the effects of psychological interventions versus usual care on mortality and cardiac events in the short to longer term. Regarding our secondary outcomes, one trial reported that psychological intervention may result in a reduction in resource utilisation (i.e. length of hospital stay). Though an improved mental QoL favouring psychological intervention versus usual care was found in the short term, no effect on end‐of‐treatment physical QoL was observed. </p> <p>The evidence base for the comparison of psychological intervention versus other psychological intervention or CM was sparse, and the evidence is very uncertain. Based on four trials, the evidence is very uncertain as to whether there may be differences between the varying approaches (behavioural therapy versus person‐centred therapy; CBT versus supportive stress management; IPT versus CM; CBT and well‐being therapy versus CM) on our primary outcomes. Statistical and methodological heterogeneity precluded the pooling of results to determine effect sizes. </p> <p>Regarding the comparison pharmacological intervention versus placebo, we found low‐certainty evidence that pharmacological intervention may result in a large reduction in depression symptoms at the end of treatment. There was moderate‐certainty evidence that pharmacological intervention probably results in a moderate to large increase in depression remission at the end of treatment. The evidence is very uncertain regarding the effects of pharmacological intervention on mortality and cardiac events, and no consistent findings were reported. The evidence for our secondary outcomes of hospitalisation rates, emergency room visits, and QoL was sparse but points in the direction of a possible beneficial effect of pharmacological intervention compared to placebo. Evidence on cardiovascular vital signs, platelet biomarkers, and ECG waves was mixed and based on small substudies from the main trials. Pooled meta‐analysis of one to three trials indicated a possible small beneficial effect of pharmacological interventions for βTG and lower PR interval on ECG at the end of treatment. A possible increase in non‐cardiovascular side effects was observed with the pharmacological intervention compared with placebo. </p> <p>The comparison of pharmacological intervention versus other pharmacological intervention comprised eight trials. The evidence was very uncertain for the effect of different pharmacological agents on depression symptoms at the end of treatment for: simvastatin compared to atorvastatin (<a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a>); sertraline plus omega‐3 compared to sertraline plus placebo (<a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a>); paroxetine compared to fluoxetine (<a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a>); and escitalopram compared to Bu Xin Qi (<a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a>). Statistical and methodological heterogeneity precluded the pooling of results to determine effect sizes. </p> <p>Overall, there is evidence for a possible beneficial effect of both psychological and pharmacological interventions on depression outcomes at end of treatment. However, the evidence base is still small and did not permit conclusions about the effects of these interventions on most other outcomes, as well as on specific types of psychological approaches and pharmacological agents. Moreover, the settings, samples, interventions, and outcome measures were heterogeneous across the included studies, which hampered the interpretation of meta‐analytical synthesis. Sensitivity analyses for end‐of‐treatment depression symptoms provided mixed results that could not explain heterogeneity between psychological trials (versus control) and pharmacological trials (versus placebo). Moreover, our pre‐planned subgroup analyses were not feasible due to the low number of studies per outcome and methodological and clinical heterogeneity between studies. </p> </section> <section id="CD008012-sec-0091"> <h3 class="title" id="CD008012-sec-0091">Overall completeness and applicability of evidence</h3> <p>This review summarises the evidence regarding depression treatments in a variety of settings. The included trials comprised different CAD samples (MI, CABG, PCI); investigated various types of psychological and pharmacologic interventions; and were located in different countries with different healthcare systems, thus increasing the generalisability of the results. However, the overall completeness is limited, and the applicability of evidence restricted due to four aspects. </p> <p>Firstly, most of the primary and secondary outcomes were investigated or reported insufficiently. Hence, evidence of treatment effects on these outcomes needs to be interpreted carefully. Moreover, most trials were underpowered to detect effects of depression treatments on mortality and specific cardiac events and were below the optimal information size. </p> <p>Secondly, we found no studies comparing psychological and pharmacological interventions. Consequently, no conclusions could be drawn on the differential effects of these treatment approaches. A systematic review experimentally comparing the two approaches indicated that overall psychological and pharmacological interventions were equally effective for treating depression, with pharmacotherapy seemingly superior in dysthymia (g = 0.3), as well as compared to non‐directive counselling (g = 0.33), and psychotherapy superior to tricyclic antidepressants (g = 0.21) (<a href="./references#CD008012-bbs2-0167" title="CuijpersP , SijbrandijM , KooleSL , AnderssonG , BeekmanAT , ReynoldsCF . The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry2013;12:137-48.">Cuijpers 2013</a>). Combining both pharmacotherapy and psychotherapy was superior to pharmacotherapy alone at six months or longer postrandomisation (OR = 2.93), whilst psychotherapy alone resulted in equal depression effects when compared to combined therapy at six months and longer follow‐up (<a href="./references#CD008012-bbs2-0193" title="KaryotakiE , SmitY , Holdt HenningsenK , HuibersMJ , RobaysJ , deBeursD , et al. Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects. Journal of Affective Disorders2016;194:144-52.">Karyotaki 2016</a>). However, the National Institute for Health and Care Excellence (NICE) guideline on depression in adults with a chronic physical health problem favours the use of psychological interventions as first‐line interventions in patients with minor and mild to moderate depression due to adverse effects of antidepressants and the resulting poor risk‐benefit ratio (<a href="./references#CD008012-bbs2-0207" title="National Institute for Health and Clinical Excellence. Depression in adults with a chronic physical health problem: recognition and management Clinical guideline [CG91]. www.nice.org.uk/guidance/CG91 (accessed 26 July 2011).">NICE 2009</a>). An increase in side effects was observed in trials of antidepressants versus placebo for patients with CAD and depression symptoms. </p> <p>Thirdly, the samples of the included trials most likely differed regarding subtypes and severity of depression. The included trials comprised participants with a wide range of depressive symptomatology and different aetiology (e.g. dysthymia, minor and major depression, adjustment disorder with depressed mood; <a href="./references#CD008012-bbs2-0151" title="BaumeisterH , ParkerG . Meta-review of depressive subtyping models. Journal of Affective Disorders2012;139:126-40.">Baumeister 2012a</a>). Depressive disorders were present immediately following the cardiac event or up to 12 months after the event. Furthermore, diverse methods and cut‐off points were used to determine trial eligibility and determine depression remission and depression response. The inclusion of mixed samples and those with different depression disorders may have levelled potential effects of depression treatments in participants with specific subtypes of depression (<a href="./references#CD008012-bbs2-0151" title="BaumeisterH , ParkerG . Meta-review of depressive subtyping models. Journal of Affective Disorders2012;139:126-40.">Baumeister 2012a</a>; <a href="./references#CD008012-bbs2-0154" title="BauneB , StuartM , GilmourA , WerschingH , HeindelW , AroltV , et al. The relationship between subtypes of depression and cardiovascular disease: a systematic review of biological models.. Translational Psychiatry2012;2:e92.">Baune 2012</a>). For example, when these factors were considered, sensitivity analyses showed changes to the strength and significance of end‐of‐treatment depression symptoms effect sizes. Other research suggests that the onset of depression was previously shown to be a moderator of treatment outcomes in CAD patients (<a href="./references#CD008012-bbs2-0173" title="DickensC , McGowanL , PercivalC , TomensonB , CotterL , HeagertyA , et al. New onset depression following myocardial infarction predicts cardiac mortality. Psychosomatic Medicine2008;70:450-5.">Dickens 2008</a>). Another trial on depression treatment in general highlighted differential responses to psychotherapy versus pharmacotherapy in chronic depressed patients with childhood trauma compared to those without a history of childhood trauma (<a href="./references#CD008012-bbs2-0206" title="NemeroffCB , HeimCM , ThaseME , KleinDN , RushAJ , SchatzbergAF , et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. PNAS2003;100:14293-6.">Nemeroff 2003</a>). Moreover, a patient‐level meta‐analysis concluded that the effects of antidepressant medication are associated with the severity of depressive symptoms, showing minimal effects in mild to moderate depression and substantial benefit in severe depression (<a href="./references#CD008012-bbs2-0176" title="FournierJC , DeRubeisRJ , HollonSD , DimidjianS , AmsterdamJD , SheltonRC , et al. Antidepressant drug effects and depression severity. A patient-level meta-analysis. JAMA2010;303:47-53.">Fournier 2010</a>). </p> <p>Fourthly, the length of psychotherapies examined in the included trials ranged from short‐term four‐session therapies, <a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>, to 12 sessions, <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a>; single‐ and group‐therapies, <a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; and 12‐month telephone support counselling, <a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a>. The number and intensity of sessions needed to show substantial benefit in psychotherapy should be higher or more specifically tailored to the needs, problems and treatment response of individual patients in order to exploit the full potential of psychological interventions (<a href="./references#CD008012-bbs2-0159" title="CarrMM , SaulesKK , KochEI , WaltzTJ . Testing the dose-response curve in a training clinic setting: use of client pretreatment factors to minimize bias in estimates. Training and Education in Professional Psychology2017;11:26-32.">Carr 2017</a>; <a href="./references#CD008012-bbs2-0183" title="HarnettP , O'DonovanA , LambertMJ . The dose response relationship in psychotherapy: implications for social policy. Clinical Psychologist2010;14:39-44.">Harnett 2010</a>). Hence, the effects found in the included psychological intervention trials may be limited in part due to an insufficient number or intensity of sessions. </p> </section> <section id="CD008012-sec-0092"> <h3 class="title" id="CD008012-sec-0092">Quality of the evidence</h3> <p>The included trials differed with regard to methodological shortcomings (see <a href="#CD008012-sec-0044">Risk of bias in included studies</a>) and quality of reporting. Many trials did not adequately describe design aspects such as randomisation procedure, allocation concealment, and blinding. Furthermore, some trials did not report ITT analyses, missing data was common, and selective reporting may have occurred. However, published protocols were not always available, and we were unable to quantify publication bias for our primary outcomes. Low‐quality studies have been associated with exaggerated effects (<a href="./references#CD008012-bbs2-0166" title="CuijpersP , vanStratenA , BohlmeijerE , HollonSD , AnderssonG . The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size. Psychological Medicine2010;40:211-23.">Cuijpers 2010</a>; <a href="./references#CD008012-bbs2-0204" title="MoherD , CookDJ , JadadAR . Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technology Assessment1999;29:823-32.">Moher 1999</a>). The treatment effects summarised in this review may therefore be overestimated due to poor methodological quality of some of the included trials as well as uncertainty in study quality. </p> <p>Most pharmacological studies were supported by pharmaceutical industry, and two trials included pharmaceutical company employees in the design, conduct, analysis, and reporting of trial outcomes. It has been shown that studies sponsored by pharmaceutical companies are more likely to have outcomes favouring the sponsor than studies with other sponsors (<a href="./references#CD008012-bbs2-0198" title="LexchinJ , BeroLA , DjulbegovicB , ClarkO . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ (Clinical Research Ed.)2003;326(7400):1167-70.">Lexchin 2003</a>). Furthermore, selective reporting of null findings in industry‐funded RCTs of antidepressant trials has been documented (<a href="./references#CD008012-bbs2-0232" title="TurnerEH , MatthewsAM , LinardatosE , TellRA , RosenthalR . Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine2008;358:252-60.">Turner 2008</a>). Despite our comprehensive search strategy, there may be unpublished trials with non‐significant results or additional trials terminated prematurely. </p> <p>Another source of bias results from selective reporting of negative findings for prespecified primary outcomes, whilst emphasising positive results from secondary or new outcomes of antidepressant medication trials (<a href="./references#CD008012-bbs2-0212" title="PigottHE , LeventhalAM , AlterGS , BorenJJ . Efficacy and effectiveness of antidepressants: current status of research. Psychotherapy and Psychosomatics2010;79:267-79.">Pigott 2010</a>). We were not able to obtain published protocols for all trials included in this review and thus were not able to judge the risk of selective reporting for these studies. </p> <p>Meta‐analyses regarding depressive outcomes were hampered because depressive symptoms were assessed by a heterogeneous set of clinician‐rated tools and self‐report questionnaires. Furthermore, the included trials reported either final mean scores or mean change scores from baseline to final assessment or did not report sufficient information to compute effect estimates. </p> <p>The GRADE assessment of primary outcomes in the short term resulted in a range of ratings of certainty of evidence. We assessed the evidence for only one outcome as moderate certainty (depression remission at end of treatment in pharmacological versus placebo trials). Otherwise, the certainty of evidence was very low, low, or could not be determined. The certainty of evidence must be taken into consideration when interpreting the findings of the review (<a href="./full#CD008012-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD008012-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD008012-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD008012-tbl-0004">summary of findings Table 4</a>). </p> </section> <section id="CD008012-sec-0093"> <h3 class="title" id="CD008012-sec-0093">Potential biases in the review process</h3> <p>In the review process we decided to consider the <a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a> and <a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a> studies as psychological intervention trials, disregarding the fact that participants in these trials were allowed to receive adjunct pharmacologic treatments in addition to the assigned psychological intervention. Hence, it remains unclear to what degree the effects of these studies were impacted by additional pharmacological treatments. Conversely, we excluded the psychological arms (IPT) in the <a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a> trial who received citalopram, placebo, or CM. The results might also be biased by the inclusion of mixed study samples of CAD patients with depression and/or low social support, <a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>, and patients with depression and/or anxiety (<a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0014" title="FreemanAM , FleeceL , FolksDG , SokolRS , HallKR , PacificoAD , et al. Alprazolam treatment of postcoronary bypass anxiety and depression. Journal of Clinical Psychopharmacology1986;6:39-41. ">Freeman 1986</a>; <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a>). As a result of including these trials with mixed study samples and methodological uncertainties, the presented findings might be biased. Moreover, the inclusion of such heterogeneous samples without depression may spuriously increase or decrease the pooled effect sizes. Another source of potential bias may result from the translation process of the included Chinese trials (<a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>). Despite our efforts to translate the Chinese trials accurately, the translations did not result in unambiguous results. Moreover, the limited information provided resulted in unclear risk of bias for these trials (<a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>). Another potential source of bias in the review process concerns the pooling of outcomes by time frame (short, medium, and long term) in accordance with the original review (<a href="./references#CD008012-bbs2-0238" title="BaumeisterH , HutterN , BengelJ . Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD008012. [DOI: 10.1002/14651858.CD008012.pub3]">Baumeister 2011c</a>). This likely results in data below the optimal information size when pooling uncommon cardiovascular events (e.g. stroke). Future updates to this review may consider pooling all time frames together in dichotomous but infrequent primary outcomes of mortality and cardiovascular events. Likewise, combining end‐of‐treatment depression symptom effect sizes with the medium‐term data may result in increased certainty of evidence. </p> </section> <section id="CD008012-sec-0094"> <h3 class="title" id="CD008012-sec-0094">Agreements and disagreements with other studies or reviews</h3> <p>Differences in the trials included in this review compared to previous reviews are attributable to our focus on trials investigating depression treatments in CAD patients with depression. Two psychological intervention trials included in the current review, <a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>, were also included in the review of <a href="./references#CD008012-bbs2-0233" title="Van StratenA , GeraedtsA , Verdonck-de LeeuwI , AnderssonG , CuijpersP . Psychological treatment of depressive symptoms in patients with medical disorders: a meta-analysis. Journal of Psychosomatic Research2010;69:23-32.">Van Straten 2010</a>, which investigated the effects of psychological treatments on depressive symptoms in medical diseases. The authors conducted a meta‐analysis of 23 studies with 10 different medical diseases and concluded that depressive symptoms could be effectively treated with psychological interventions. The results of our review were in a similar direction for CAD patients with depression. However, the evidence is still sparse given the high within‐review variance of findings regarding psychological interventions. </p> <p><a href="./references#CD008012-bbs2-0213" title="RaynerL , PriceA , EvansA , ValsrajK , HigginsonIJ , HotopfM . Antidepressants for depression in physically ill people. Cochrane Database of Systematic Reviews2010, Issue 3. Art. No: CD007503. [DOI: 10.1002/14651858.CD007503.pub2]">Rayner 2010</a>, a Cochrane Review, systematically reviewed trials investigating the effects of antidepressant medication in treating depression in physically ill people. They concluded that antidepressants were superior to placebo in a meta‐analysis of 51 studies. The evidence of the current review agrees with this finding for the specific group of CAD patients with comorbid depression. Four trials were included in both reviews (<a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a>; <a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a>; <a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a>). </p> <p>One systematic review examined collaborative care interventions for patients with CAD and depression (<a href="./references#CD008012-bbs2-0231" title="TullyPJ , BaumeisterH . Collaborative care for comorbid depression and coronary heart disease: a systematic review and meta-analysis of randomised controlled trials. BMJ Open2015;5:e009128.">Tully 2015</a>). Based on six included trials, the authors reported a reduction in major cardiac events in the short but not long term, and a small‐to‐moderate effect on depression severity and an increased depression remission rate. A direct comparison of the findings on collaborative care (<a href="./references#CD008012-bbs2-0231" title="TullyPJ , BaumeisterH . Collaborative care for comorbid depression and coronary heart disease: a systematic review and meta-analysis of randomised controlled trials. BMJ Open2015;5:e009128.">Tully 2015</a>) with the stand‐alone psychological or pharmacological interventions here is difficult since the methodological heterogeneity between the respective included trials is substantial. There is as yet insufficient evidence to recommend one treatment option over another, suggesting that psychological interventions and pharmacological interventions and more complex collaborative care are recommendable for the treatment of depression in patients with CAD and depression. A network meta‐analysis compared different depression interventions for CAD patients at eight weeks from baseline (<a href="./references#CD008012-bbs2-0174" title="DoyleF , FreedlandKE , CarneyRM , deJongeP , DickensC , PedersenSS , et al. Hybrid systematic review and network meta-analysis of randomized controlled trials of interventions for depressive symptoms in patients with coronary artery disease. Psychosomatic Medicine2021;83:423-31.">Doyle 2021</a>). Both psychological therapy (versus usual care) and antidepressant therapy (versus placebo and usual care) displayed significantly better effects. The strongest effects were evident for combination therapy and exercise; however, only single trials were available. Moreover, the network meta‐analysis included antidepressant versus usual care interventions, which was a prespecified exclusion criterion for the current review, where we only included pharmacological versus placebo trials (<a href="./references#CD008012-bbs2-0174" title="DoyleF , FreedlandKE , CarneyRM , deJongeP , DickensC , PedersenSS , et al. Hybrid systematic review and network meta-analysis of randomized controlled trials of interventions for depressive symptoms in patients with coronary artery disease. Psychosomatic Medicine2021;83:423-31.">Doyle 2021</a>). </p> <p>Several trials included in our review, <a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a>; <a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>, were included in a Cochrane Review on the effects of psychological interventions in CAD patients in general (i.e. not restricted to depressed CAD patients) (<a href="./references#CD008012-bbs2-0214" title="RichardsSH , AndersonL , JenkinsonCE , WhalleyB , ReesK , DaviesP , et al. Psychological interventions for coronary heart disease. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD002902. [DOI: 10.1002/14651858.CD002902.pub4]">Richards 2017</a>). Overall, psychological interventions had no effect on mortality, but a beneficial effect on depression symptoms (<a href="./references#CD008012-bbs2-0214" title="RichardsSH , AndersonL , JenkinsonCE , WhalleyB , ReesK , DaviesP , et al. Psychological interventions for coronary heart disease. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD002902. [DOI: 10.1002/14651858.CD002902.pub4]">Richards 2017</a>), which is comparable to the current review. Also, <a href="./references#CD008012-bbs2-0214" title="RichardsSH , AndersonL , JenkinsonCE , WhalleyB , ReesK , DaviesP , et al. Psychological interventions for coronary heart disease. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD002902. [DOI: 10.1002/14651858.CD002902.pub4]">Richards 2017</a> found a 22% reduction in MI for psychological interventions, which cannot be confirmed for the depression‐specific interventions for depressed CAD patients examined in the current review. </p> <p>The systematic review by <a href="./references#CD008012-bbs2-0226" title="SwensonJR , DoucetteS , FergussonD . Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Canadian Journal of Psychiatry2006;51(14):923-9.">Swenson 2006</a> reported the side effects from antidepressant drug versus placebo trials performed in individuals with chronic illness. No difference was observed between SSRI and placebo for serious and non‐serious cardiovascular events. <a href="./references#CD008012-bbs2-0226" title="SwensonJR , DoucetteS , FergussonD . Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Canadian Journal of Psychiatry2006;51(14):923-9.">Swenson 2006</a> also reported higher dropout due to side effects in participants receiving SSRIs versus placebo. A direct comparison with the current review indicates some consistent results on pharmacological side effects. We found evidence that pharmacological intervention may result in an increase in side effects compared to placebo at end of treatment. However, the evidence is very uncertain as to whether there are differences between different pharmacological agents in end‐of‐treatment side effects. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008012-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Summary of the 2020 literature search update and study selection." data-id="CD008012-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Summary of the 2020 literature search update and study selection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008012-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008012-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 1: Depression symptoms ‐ short term" data-id="CD008012-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 1: Depression symptoms ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 2: Depression symptoms ‐ medium term" data-id="CD008012-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 2: Depression symptoms ‐ medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 3: Depression symptoms ‐ long term" data-id="CD008012-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 3: Depression symptoms ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 4: Depression remission ‐ short term" data-id="CD008012-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 4: Depression remission ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 5: Depression remission ‐ medium term" data-id="CD008012-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 5: Depression remission ‐ medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 6: Depression remission ‐ long term" data-id="CD008012-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 6: Depression remission ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 7: All‐cause mortality ‐ short term" data-id="CD008012-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 7: All‐cause mortality ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 8: All‐cause mortality ‐ medium term" data-id="CD008012-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 8: All‐cause mortality ‐ medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 9: All‐cause mortality ‐ long term" data-id="CD008012-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 9: All‐cause mortality ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 10: Cardiovascular mortality ‐ medium term" data-id="CD008012-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 10: Cardiovascular mortality ‐ medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 11: Cardiovascular mortality ‐ long term" data-id="CD008012-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 11: Cardiovascular mortality ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 12: Myocardial infarction ‐ long term" data-id="CD008012-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 12: Myocardial infarction ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 13: Heart failure ‐ long term" data-id="CD008012-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 13: Heart failure ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 14: Stroke ‐ long term" data-id="CD008012-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 14: Stroke ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 15: Coronary revascularisation procedure ‐ long term" data-id="CD008012-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 15: Coronary revascularisation procedure ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 16: Hospitalisations ‐ long term" data-id="CD008012-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 16: Hospitalisations ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 17: Length of stay ‐ short term" data-id="CD008012-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 17: Length of stay ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 18: Quality of life SF‐12/36 physical ‐ short term" data-id="CD008012-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 18: Quality of life SF‐12/36 physical ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 19: Quality of life SF‐12/36 mental ‐ short term" data-id="CD008012-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 19: Quality of life SF‐12/36 mental ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 20: Quality of life SF‐12/36 physical ‐ medium term" data-id="CD008012-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 20: Quality of life SF‐12/36 physical ‐ medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 21: Quality of life SF‐12/36 mental ‐ medium term" data-id="CD008012-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 21: Quality of life SF‐12/36 mental ‐ medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 22: Quality of life SF‐12 total ‐ medium term" data-id="CD008012-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 22: Quality of life SF‐12 total ‐ medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 23: Quality of life SF‐36 physical ‐ long term" data-id="CD008012-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 23: Quality of life SF‐36 physical ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Psychological intervention versus control, Outcome 24: Quality of life SF‐36 mental ‐ long term" data-id="CD008012-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Psychological intervention versus control, Outcome 24: Quality of life SF‐36 mental ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 1: Depression symptoms ‐ short term" data-id="CD008012-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 1: Depression symptoms ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 2: Depression symptoms ‐ medium term" data-id="CD008012-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 2: Depression symptoms ‐ medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 3: Depression symptoms ‐ long term" data-id="CD008012-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 3: Depression symptoms ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 4: Depression remission ‐ short term" data-id="CD008012-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 4: Depression remission ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 5: Depression remission ‐ medium term" data-id="CD008012-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 5: Depression remission ‐ medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 6: Depression remission ‐ long term" data-id="CD008012-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 6: Depression remission ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 7: Cardiovascular mortality ‐ long term" data-id="CD008012-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 7: Cardiovascular mortality ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 8: Quality of life SF‐36 physical ‐ short term" data-id="CD008012-fig-0035" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 8: Quality of life SF‐36 physical ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 9: Quality of life SF‐36 mental ‐ short term" data-id="CD008012-fig-0036" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 9: Quality of life SF‐36 mental ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 10: Quality of life SF‐36 physical ‐ medium term" data-id="CD008012-fig-0037" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 10: Quality of life SF‐36 physical ‐ medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 11: Quality of life SF‐36 mental ‐ medium term" data-id="CD008012-fig-0038" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 11: Quality of life SF‐36 mental ‐ medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 12: Quality of life SF‐36 physical ‐ long term" data-id="CD008012-fig-0039" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 12: Quality of life SF‐36 physical ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 13: Quality of life SF‐36 mental ‐ long term" data-id="CD008012-fig-0040" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Psychological intervention versus psychological intervention/clinical management, Outcome 13: Quality of life SF‐36 mental ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 1: Depression symptoms ‐ short term" data-id="CD008012-fig-0041" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 1: Depression symptoms ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 2: Depression symptoms change score ‐ short term" data-id="CD008012-fig-0042" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 2: Depression symptoms change score ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 3: Depression remission ‐ short term" data-id="CD008012-fig-0043" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 3: Depression remission ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 4: Depression response ‐ short term" data-id="CD008012-fig-0044" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 4: Depression response ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 5: All‐cause mortality ‐ short term" data-id="CD008012-fig-0045" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 5: All‐cause mortality ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 6: All‐cause mortality ‐ long term" data-id="CD008012-fig-0046" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 6: All‐cause mortality ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 7: Cardiovascular mortality ‐ long term" data-id="CD008012-fig-0047" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 7: Cardiovascular mortality ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 8: Myocardial infarction ‐ short term" data-id="CD008012-fig-0048" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 8: Myocardial infarction ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 9: Myocardial infarction ‐ long term" data-id="CD008012-fig-0049" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 9: Myocardial infarction ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 10: Angina ‐ short term" data-id="CD008012-fig-0050" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 10: Angina ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 11: Heart failure ‐ short term" data-id="CD008012-fig-0051" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 11: Heart failure ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 12: Arrhythmia ‐ short term" data-id="CD008012-fig-0052" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 12: Arrhythmia ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 13: Stroke ‐ short term" data-id="CD008012-fig-0053" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 13: Stroke ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 14: Coronary revascularisation procedure ‐ long term" data-id="CD008012-fig-0054" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 14: Coronary revascularisation procedure ‐ long term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 15: Healthcare costs ‐ short term" data-id="CD008012-fig-0055" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 15: Healthcare costs ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 16: Hospitalisations ‐ short term" data-id="CD008012-fig-0056" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 16: Hospitalisations ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 17: Emergency department visits ‐ short term" data-id="CD008012-fig-0057" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 17: Emergency department visits ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 18: Quality of life Q‐LES‐Q ‐ short term" data-id="CD008012-fig-0058" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 18: Quality of life Q‐LES‐Q ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 19: Quality of life WHOQOL‐BREF Physical ‐ short term" data-id="CD008012-fig-0059" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 19: Quality of life WHOQOL‐BREF Physical ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 20: Quality of life WHOQOL‐BREF Psychological ‐ short term" data-id="CD008012-fig-0060" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 20: Quality of life WHOQOL‐BREF Psychological ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 21: Quality of life WHOQOL‐BREF Social relationships ‐ short term" data-id="CD008012-fig-0061" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 21: Quality of life WHOQOL‐BREF Social relationships ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 22: Quality of life WHOQOL‐BREF Environmental ‐ short term" data-id="CD008012-fig-0062" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 22: Quality of life WHOQOL‐BREF Environmental ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 23: Quality of life WHOQOL‐BREF Physical ‐ medium term" data-id="CD008012-fig-0063" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.23</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 23: Quality of life WHOQOL‐BREF Physical ‐ medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 24: Quality of life WHOQOL‐BREF Psychological ‐ medium term" data-id="CD008012-fig-0064" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.24</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 24: Quality of life WHOQOL‐BREF Psychological ‐ medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 25: Quality of life WHOQOL‐BREF Social Relationships ‐ medium term" data-id="CD008012-fig-0065" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.25</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 25: Quality of life WHOQOL‐BREF Social Relationships ‐ medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 26: Quality of life WHOQOL‐BREF Environmental ‐ medium term" data-id="CD008012-fig-0066" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.26</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 26: Quality of life WHOQOL‐BREF Environmental ‐ medium term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 27: Systolic BP ‐ short term" data-id="CD008012-fig-0067" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.27</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 27: Systolic BP ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 28: Diastolic BP ‐ short term" data-id="CD008012-fig-0068" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.28</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 28: Diastolic BP ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 29: Heart rate ‐ short term" data-id="CD008012-fig-0069" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.29</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 29: Heart rate ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 30: Platelet biomarker βTG ‐ short term" data-id="CD008012-fig-0070" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.30</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 30: Platelet biomarker βTG ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 31: Platelet biomarker PF4 ‐ short term" data-id="CD008012-fig-0071" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.31</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 31: Platelet biomarker PF4 ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 32: Platelet biomarker P‐selectin ‐ short term" data-id="CD008012-fig-0072" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.32</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 32: Platelet biomarker P‐selectin ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 33: Platelet biomarker PECAM‐1 ‐ short term" data-id="CD008012-fig-0073" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.33</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 33: Platelet biomarker PECAM‐1 ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 34: Platelet biomarker TxB 2 ‐ short term" data-id="CD008012-fig-0074" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.34</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 34: Platelet biomarker TxB <sub>2</sub> ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.35" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 35: ECG PR interval ‐ short term" data-id="CD008012-fig-0075" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.35.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.35.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.35</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 35: ECG PR interval ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.35.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.36" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 36: ECG QRS interval ‐ short term" data-id="CD008012-fig-0076" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.36.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.36.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.36</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 36: ECG QRS interval ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.36.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.37" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 37: ECG QT interval ‐ short term" data-id="CD008012-fig-0077" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.37.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.37.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.37</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 37: ECG QT interval ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.37.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.38" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 38: ECG QTc interval ‐ short term" data-id="CD008012-fig-0078" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.38.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.38.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.38</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 38: ECG QTc interval ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.38.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-003.39" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Pharmacological intervention versus placebo, Outcome 39: Non‐cardiac adverse events and side effects ‐ short term" data-id="CD008012-fig-0079" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.39.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-003.39.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.39</div> <div class="figure-caption"> <p>Comparison 3: Pharmacological intervention versus placebo, Outcome 39: Non‐cardiac adverse events and side effects ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-003.39.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 1: Depression symptoms ‐ short term" data-id="CD008012-fig-0080" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 1: Depression symptoms ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 2: Depression symptoms change score ‐ short term" data-id="CD008012-fig-0081" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 2: Depression symptoms change score ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 3: Depression remission ‐ short term" data-id="CD008012-fig-0082" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 3: Depression remission ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 4: Depression response ‐ short term" data-id="CD008012-fig-0083" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 4: Depression response ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 5: All‐cause mortality ‐ short term" data-id="CD008012-fig-0084" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 5: All‐cause mortality ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 6: Myocardial infarction ‐ short term" data-id="CD008012-fig-0085" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 6: Myocardial infarction ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 7: Angina ‐ short term" data-id="CD008012-fig-0086" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 7: Angina ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 8: Heart failure ‐ short term" data-id="CD008012-fig-0087" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 8: Heart failure ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 9: Arrhythmia ‐ short term" data-id="CD008012-fig-0088" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 9: Arrhythmia ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 10: Coronary revascularisation procedure ‐ short term" data-id="CD008012-fig-0089" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 10: Coronary revascularisation procedure ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 11: Emergency department visits ‐ short term" data-id="CD008012-fig-0090" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 11: Emergency department visits ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 12: Systolic BP ‐ short term" data-id="CD008012-fig-0091" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 12: Systolic BP ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 13: Diastolic BP ‐ short term" data-id="CD008012-fig-0092" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 13: Diastolic BP ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 14: Heart rate ‐ short term" data-id="CD008012-fig-0093" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 14: Heart rate ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 15: ECG PR interval ‐ short term" data-id="CD008012-fig-0094" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 15: ECG PR interval ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 16: ECG QRS interval ‐ short term" data-id="CD008012-fig-0095" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 16: ECG QRS interval ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 17: ECG QTc interval ‐ short term" data-id="CD008012-fig-0096" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 17: ECG QTc interval ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008012-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/urn:x-wiley:14651858:media:CD008012:CD008012-CMP-004.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 18: Non‐cardiac adverse events and side effects ‐ short term" data-id="CD008012-fig-0097" src="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_t/tCD008012-CMP-004.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.18</div> <div class="figure-caption"> <p>Comparison 4: Pharmacological intervention versus pharmacological intervention, Outcome 18: Non‐cardiac adverse events and side effects ‐ short term </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/media/CDSR/CD008012/image_n/nCD008012-CMP-004.18.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008012-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Psychological treatment compared to control for depression in patients with coronary artery disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Psychological treatment compared to control for depression in patients with coronary artery disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> health problem or population<br/><b>Setting:</b> cardiology in‐ and outpatient<br/><b>Intervention:</b> Psychological treatment<br/><b>Comparison:</b> Control </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Psychological treatment</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression symptoms ‐ short‐term<br/>assessed with: objective and self‐reported measures of depression symptoms, higher scores indicate more severe symptoms </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.55 SD lower</b><br/>(0.92 lower to 0.19 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1226<br/>(10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is low certainty evidence that psychological treatment may result in a moderate reduction in depression symptoms at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression remission ‐ short term<br/>assessed with: below cut‐points on objective and self‐report measures of depression </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>319 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>486 per 1000</b><br/>(267 to 708) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.02</b><br/>(0.78 to 5.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>862<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is low certainty evidence that psychological treatment may result in no difference in depression remission at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ short‐term<br/>assessed with: mortality records </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/>(1 to 50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.31</b><br/>(0.05 to 2.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>324<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d,</sup><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of psychological treatment on all‐cause mortality at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality ‐ long‐term<br/>assessed with: cause of death according to standardised criteria on mortality records </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b><br/>(54 to 93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.83</b><br/>(0.62 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2720<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data for cardiovascular mortality at end of treatment in trials comparing psychological interventions versus usual care </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myocardial infarction ‐ short term (end of treatment) ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data for occurrence of myocardial infarction at end of treatment in trials comparing psychological interventions versus usual care </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_427596582080189491" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_427596582080189491</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Risk of bias rated down one level ‐ trials that contributed to this outcome were rated as unclear risk of bias<br/><sup>b</sup> Inconsistency rated down one level ‐ though confidence intervals generally overlapped, there was considerable unexplained statistical heterogeneity<br/><sup>c</sup> Imprecision rated down one level ‐ confidence intervals encompass an adverse effect to beneficial effect<br/><sup>d</sup> Risk of bias rated down two levels ‐ most trials that contributed to this outcome were rated as high or unclear risk of bias<br/><sup>e</sup> Imprecision rated down two levels ‐ sparse events and wide confidence intervals encompass an adverse effect to beneficial effect </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table ‐ Psychological treatment compared to control for depression in patients with coronary artery disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008012-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Psychological treatment 1 compared to psychological treatment 2 for depression in patients with coronary artery disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Psychological treatment 1 compared to psychological treatment 2 for depression in patients with coronary artery disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> health problem or population<br/><b>Setting:</b> cardiology outpatient settings<br/><b>Intervention:</b> Psychological Treatment 1<br/><b>Comparison:</b> Psychological Treatment 2 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Psychological Treatment 2</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Psychological Treatment 1</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression symptoms ‐ short term (end of treatment)<br/>assessed with: objective and self‐reported measures of depression symptoms; higher scores indicate more severe symptoms </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No meta‐analysis performed due to clinical heterogeneity. The evidence is very uncertain as to whether different psychological interventions may result in a reduction in depression symptoms at the end of treatment for: cognitive‐behavioural therapy compared to supportive stress management (Freedland 2009); behaviour therapy compared to person‐centred therapy (Brown 1993); cognitive‐behavioural therapy and well‐being therapy compared to clinical management (TREATED‐ACS 2020). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression remission ‐ short term (end of treatment)<br/>assessed with: below cut‐off on Hamilton Rating Scale for Depression </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>571 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>707 per 1000</b><br/>(493 to 857) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.81</b><br/>(0.73 to 4.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is low certainty evidence from one trial that cognitive‐behavioural therapy may result in no difference in depression remission at the end of treatment compared to supportive stress management (Freedland 2009). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ short term (end of treatment) ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data for all‐cause mortality at end of treatment in trials comparing psychological intervention versus another psychological intervention/clinical management </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality ‐ short term (end of treatment) ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data for cardiovascular mortality at end of treatment in trials comparing psychological intervention versus another psychological intervention/clinical management </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myocardial infarction ‐ short term (end of treatment) ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data for the occurrence of myocardial infarction at end of treatment in trials comparing psychological intervention versus another psychological intervention/clinical management </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_427665509108780589" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_427665509108780589</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Imprecision rated down two levels ‐ wide confidence intervals from one trial encompass an adverse effect to beneficial effect </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings table ‐ Psychological treatment 1 compared to psychological treatment 2 for depression in patients with coronary artery disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008012-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ Pharmacological treatment compared to placebo for depression in patients with coronary artery disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pharmacological treatment compared to placebo for depression in patients with coronary artery disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> health problem or population<br/><b>Setting:</b> cardiology in‐ and outpatient settings<br/><b>Intervention:</b> Pharmacological<br/><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Pharmacological</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression symptoms ‐ short term<br/>assessed with: objective and self‐reported measures of depression; higher scores indicate more severe symptoms </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD <b>0.83 lower</b><br/>(1.33 lower to 0.32 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>750<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is low certainty evidence that pharmacological intervention may result in a large reduction in depression symptoms at the end of treatment </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression remission ‐ short term<br/>assessed with: below cut‐point on objective measure of depression (Hamilton Rating Scale for Depression) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>323 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>496 per 1000</b><br/>(412 to 580) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.06</b><br/>(1.47 to 2.89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>646<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There is moderate certainty evidence that pharmacological intervention probably results in a moderate to large increase in depression remission at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ short term<br/>assessed with: mortality records </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b><br/>(4 to 53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.38</b><br/>(0.10 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>437<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of pharmacological intervention on all‐cause mortality at the end of treatment. In addition to the pooled results, data could not be extracted from 2 studies where no deaths occurred and from 1 trial which remained unclear. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality ‐ short term (end of treatment) ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data for cardiovascular mortality at end of treatment in trials comparing pharmacological intervention versus placebo </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myocardial infarction ‐ short term<br/>assessed with: standardised criteria for fatal or non‐fatal myocardial infarction </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b><br/>(6 to 45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.74</b><br/>(0.26 to 2.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>728<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effect of pharmacological intervention on myocardial infarction at the end of treatment. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_427666962988765745" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_427666962988765745</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Risk of bias rated down one level ‐ trials that contributed to this outcome were rated as unclear or high risk of bias<br/><sup>b</sup> Inconsistency rated down one level ‐ though confidence intervals generally overlapped, there was considerable unexplained statistical heterogeneity<br/><sup>c</sup> Imprecision rated down two levels ‐ sparse events and wide confidence intervals encompass an adverse effect to beneficial effect </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings table ‐ Pharmacological treatment compared to placebo for depression in patients with coronary artery disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008012-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings table ‐ Pharmacological treatment 1 compared to pharmacological treatment 2 for depression in patients with coronary artery disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Pharmacological treatment 1 compared to pharmacological treatment 2 for depression in patients with coronary artery disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> health problem or population<br/><b>Setting:</b> cardiology in‐ and outpatient settings<br/><b>Intervention:</b> Pharmacological intervention 1<br/><b>Comparison:</b> Pharmacological intervention 2 </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Pharmacological intervention 2</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Pharmacological intervention 1</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression symptoms ‐ short term (end of treatment)<br/>assessed with: objective measure of depression (Hamilton Rating Scale for Depression); higher scores indicate more severe symptoms </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>442<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No meta‐analysis performed due to clinical heterogeneity. The evidence is very uncertain as to whether different pharmacological interventions may result in a reduction in depression symptoms at the end of treatment for: simvastatin compared to atorvastatin (Abbasi 2015); sertraline plus omega‐3 compared to sertraline plus placebo (Carney 2009); paroxetine compared to fluoxetine (Tian 2016); escitalopram compared to Bu Xin Qi (Wang 2020). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression remission ‐ short term (end of treatment)<br/>assessed with: below cut‐points on objective and self‐report measures of depression </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No meta‐analysis performed due to clinical heterogeneity. The evidence is very uncertain about the effect of pharmacological treatment compared to another pharmacological treatment on depression remission at the end of treatment . </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ short term (end of treatment)<br/>assessed with: mortality records </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b><br/>(14 to 281) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.72</b><br/>(0.51 to 14.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence from 1 trial is very uncertain about the effect of sertraline vs Shugan Jieyu on all‐cause mortality at the end of treatment (Liu 2016). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiovascular mortality ‐ short term (end of treatment) ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data for cardiovascular mortality at end of treatment in trials comparing a pharmacological intervention versus another pharmacological intervention </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myocardial infarction ‐ short term (end of treatment)<br/>assessed with: standardised criteria for fatal and non‐fatal myocardial infarction </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>396<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No meta‐analysis performed due to clinical heterogeneity. The evidence is very uncertain about the effect of pharmacological treatment compared to another pharmacological treatment on the occurrence of myocardial infarction at end of treatment for: sertraline plus omega‐3 compared to sertraline plus placebo (Carney 2009); paroxetine compared to fluoxetine (Tian 2016); escitalopram compared to Bu Xin Qi (Wang 2020). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_428037497253281678" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_428037497253281678</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Risk of bias rated down one level ‐ the trial(s) that contributed to this outcome were rated as unclear or high risk of bias<br/><sup>b</sup> Imprecision rated down two levels ‐ sparse events and wide confidence intervals encompass an adverse effect to beneficial effect </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings table ‐ Pharmacological treatment 1 compared to pharmacological treatment 2 for depression in patients with coronary artery disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008012-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of study population</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>[n]</b> <b>screened</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>[n] randomised</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>[n] ITT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>[n] finishing study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>[%] of randomised participants</b> <br/><b>finishing study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0001" title="AbbasiSH , MohammadinejadP , ShahmansouriN , SalehiomranA , BeglarAA , ZeinoddiniA , et al. Simvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trial. Journal of Affective Disorders2015;183:149-55. ">Abbasi 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): simvastatin</p> <p>Intervention 2 (I2): atorvastatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 29</p> <p>I2: 29</p> <p>Total: 58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: NR</p> <p>I2: NR</p> <p>Total: NR</p> <p>(per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 23</p> <p>I2: 23</p> <p>Total: 46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 79.3%</p> <p>I2: 79.3%</p> <p>Total: 79.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0002" title="NCT02463110. Acute myocardial necrosis and depression: antiplatelet effect of reuptake inhibition of serotonin. clinicaltrials.gov/show/nct02463110 (first posted 4 June 2015). ">ANDROS 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): sertraline</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: trial terminated early, no results posted</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): resource‐orientated psychotherapy</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 27</p> <p>C: 32</p> <p>Total: 59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 27</p> <p>C: 32</p> <p>Total: 59</p> <p>(per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 27</p> <p>C: 28</p> <p>Total: 55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 100%</p> <p>C: 87.5%</p> <p>Total: 93.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0004" title="BrownMA , MunfordAM , MunfordPR . Behavior therapy of psychological distress in patients after myocardial infarction or coronary bypass. Journal of Cardiopulmonary Rehabilitation and Prevention1993;13:201-10. ">Brown 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): behaviour therapy</p> <p>Intervention 2 (I2): person‐centred therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: NR</p> <p>I2: NR</p> <p>Total: 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: NR</p> <p>I2: NR</p> <p>Total: NR</p> <p>(per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 20</p> <p>I2: 20</p> <p>Total: 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: ?</p> <p>I2: ?</p> <p>Total: 74.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: dropout reported in text, no flow chart</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): interpersonal psychotherapy, citalopram, clinical management</p> <p>Intervention 2 (I2): citalopram, clinical management</p> <p>Control 1 (C1): interpersonal psychotherapy, placebo, clinical management</p> <p>Control 2 (C2): placebo, clinical management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 1897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 67</p> <p>I2: 75</p> <p>C1: 75</p> <p>C2: 67</p> <p>Total: 284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 67</p> <p>I2: 75</p> <p>C1: 75</p> <p>C2: 67</p> <p>Total: 284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 59</p> <p>I2: 72</p> <p>C1: 59</p> <p>C2: 47</p> <p>Total: 237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 88.1%</p> <p>I2: 96.0%</p> <p>C1: 78.7%</p> <p>C2: 70.1%</p> <p>Total: 83.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: 2 x 2 factorial trial; only I2 and C2 data are eligible for this review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0005" title="BotM , CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , et al. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research2011;71:13-7. CarneyRM , FreedlandKE , RubinEH , RichMW , SteinmeyerBC , HarrisWS . Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. JAMA2009;302:1651-7. CarneyRM , SteinmeyerBC , FreedlandKE , RubinEH , RichMW , HarrisWS . Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements. Journal of Clinical Psychiatry2016;77:e138-43. ">Carney 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): sertraline plus omega‐3</p> <p>Intervention 2 (I2): sertraline plus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 62</p> <p>I2: 60</p> <p>Total: 122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 62</p> <p>I2: 60</p> <p>Total: 122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 59</p> <p>I2: 56</p> <p>Total: 115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 95.2%</p> <p>I2: 93.3%</p> <p>Total: 94.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): cognitive‐ behavioural therapy</p> <p>C: usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 50</p> <p>C: 50</p> <p>Total: 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR</p> <p>(per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 48</p> <p>C: 48:</p> <p>Total: 96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 96%</p> <p>C: 96%</p> <p>Total: 96%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0008" title="DivsalarP , NoorbalaAA , ZadehEM , JafariniaM , ShakibaM , ShahmansouriN , et al. Red yeast rice as an adjunct to sertraline for treatment of depression in patients with percutaneous coronary intervention: placebo-controlled trial. Advances in Integrative Medicine2018;5(2):69-74. [DOI: 10.1016/j.aimed.2018.01.001]">Divsalar 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): sertraline plus red yeast rice</p> <p>Intervention 2 (I2): sertraline plus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 28</p> <p>I2: 28</p> <p>Total: 56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: NR</p> <p>I2: NR</p> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 25</p> <p>I2: 25</p> <p>Total: 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 89.3%</p> <p>I2: 89.3%</p> <p>Total: 89.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0009" title="DoeringLV , CrossR , VredevoeD , Martinez-MazaO , CowanMJ . Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine2007;13:18-21. ">Doering 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): cognitive‐ behavioural therapy</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR</p> <p>(per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 7</p> <p>C: 8</p> <p>Total: 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: reasons for dropout not stated, no flow chart</p> <p>Comment: nested trial within observational study (non‐depressed cohort)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): escitalopram</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 4809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I:149</p> <p>C: 151</p> <p>Total: 300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 108</p> <p>C: 109</p> <p>Total: 217 (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 78</p> <p>C: 79</p> <p>Total: 157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 52.3%</p> <p>C: 52.3%</p> <p>Total: 52.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: nested trial within observational study (depressed cohort receiving usual care) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0010" title="BerkmanLF , BlumenthalJ , BurgM , CarneyRM , CatellierD , CowanMJ , et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA2003;289:3106-16. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD): baseline characteristics. American Journal of Cardiology2001;88(3):316-22. ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosomatic Medicine2001;63(5):747-55. ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. American Heart Journal2000;139:1-9. Mendes de LeonCF , CzajkowskiSM , FreedlandKE , BangH , PowellLH , WuC , et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: the enhancing recovery in coronary heart disease (ENRICHD) clinical trial. Journal of Cardiopulmonary Rehabilitation and Prevention2006;26:9-13. SaabPG , BangH , WilliamsRB , PowellLH , SchneidermanN , ThoresenC , et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICHD experience. Journal of Psychosomatic Research2009;67:45-56. ">ENRICHD 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): cognitive‐ behavioural therapy</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 33780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 1238</p> <p>C: 1243</p> <p>Total: 2481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 1238</p> <p>C: 1243</p> <p>Total: 2481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 983</p> <p>C: 985</p> <p>Total: 1968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 79.4%</p> <p>C: 79.2%</p> <p>Total: 79.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): health education and psychological intervention</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 27</p> <p>C: 30</p> <p>Total: 57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: translated paper</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): cognitive‐ behavioural therapy</p> <p>Intervention 2 (I2): supportive stress management</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 2955</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 41</p> <p>I2: 42</p> <p>C1: 40</p> <p>Total: 123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 41</p> <p>I2: 42</p> <p>C1: 40</p> <p>Total: 123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 40</p> <p>I2: 33</p> <p>C1: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 98%</p> <p>I2: 79%</p> <p>C1: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0014" title="FreemanAM , FleeceL , FolksDG , SokolRS , HallKR , PacificoAD , et al. Alprazolam treatment of postcoronary bypass anxiety and depression. Journal of Clinical Psychopharmacology1986;6:39-41. ">Freeman 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): alprazolam</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 54</p> <p>C: 53</p> <p>Total: 107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 32</p> <p>C: 28</p> <p>Total: 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 59.3%</p> <p>C: 52.8%</p> <p>Total: 56.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: no flow chart</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0015" title="EUCTR2004-000990-78-AT. A double-blind, multicentre, randomised, parallel-group, placebo-controlled study assessing the efficacy and safety of escitalopram in post-myocardial infarction patients suffering from depressive symptoms. www.who.int/trialsearch/trial2.aspx?Trialid=euctr2004-000990-78-at (date of registration 23 September 2004). ">Kennedy 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): escitalopram</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 9</p> <p>C: 10</p> <p>Total: 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR</p> <p>(per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 2</p> <p>C: 2</p> <p>Total: 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 22.2%</p> <p>C: 20.0%</p> <p>Total: 21.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: trial terminated early, redacted results posted</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): St John's wort extract</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: 87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 43</p> <p>C: 39</p> <p>Total: 82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: 94.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: translated paper</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): fluoxetine</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 31</p> <p>C: 37</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: translated paper</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0018" title="LiuW , QinJ . Clinical efficacy and safety of the ShuganJieyu capsule in patients with acute myocardial infarction and depression. International Journal of Psychiatry in Medicine2016;51:534-43. ">Liu 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): sertraline and Shugan Jieyu</p> <p>Intervention 2 (I2): sertraline and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 3907</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 76</p> <p>I2: 73</p> <p>Total: 149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 76</p> <p>I2: 73</p> <p>Total: 149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 48</p> <p>I2: 46</p> <p>Total: 94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 63.2%</p> <p>I2: 63.0%</p> <p>Total: 63.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: no flow chart, reasons for dropout reported in text</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0022" title="HonigA , KuyperAM , ScheneAH , vanMelleJP , deJongeP , TulnerDM , et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosomatic Medicine2007;69:606-13. SchinsA , HamulyKK , ScharpS , LousbergR , Van MelleJ , CrijnsH , et al. Whole blood serotonin and platelet activation in depressed post-myocardial infarction patients. Life Sciences2004;76(6):637-50. Van den BrinkRH , vanMelleJP , HonigA , ScheneAH , CrijnsHJ , LambertFP , et al. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). American Heart Journal2002;144:219-25. Van MelleJP , deJongeP , HonigA , ScheneAH , KuyperAM , CrijnsHJ , et al. Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry2007;190:460-6. ZuidersmaM , ConradiHJ , vanMelleJP , OrmelJ , deJongeP . Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. Journal of Psychosomatic Research2013;74:25-30. ">MIND‐IT 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): mirtazapine</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 2177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 47</p> <p>C: 44</p> <p>Total: 91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 47</p> <p>C: 44</p> <p>Total: 91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 22</p> <p>C: 18</p> <p>Total: 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 46.8%</p> <p>C: 40.9%</p> <p>Total: 44.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: nested trial within observational study (depressed cohort receiving usual care) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): Xinkeshu</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 30</p> <p>C: 30</p> <p>Total: 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 28</p> <p>C: 27</p> <p>Total: 55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 93.3%</p> <p>C: 90%</p> <p>Total: 91.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): sertraline</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 18</p> <p>C: 20</p> <p>Total: 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 12</p> <p>C: 15</p> <p>Total: 27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 66.7%</p> <p>C: 75.0%</p> <p>Total: 71.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: no flow chart, reasons for dropout reported in text</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I1): telephone counselling</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 53</p> <p>C: 47</p> <p>Total: 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 45</p> <p>C: 34</p> <p>Total: 79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 84.9%</p> <p>C: 72.3%</p> <p>Total: 79%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): cognitive‐ behavioural therapy<br/>Control (C): usual care </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 3071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 61</p> <p>C: 60</p> <p>Total: 121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 53</p> <p>C: 53</p> <p>Total: 106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 86.9%</p> <p>C: 88.3%</p> <p>Total: 87.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): sertraline</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 50</p> <p>C: 50</p> <p>Total: 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 47</p> <p>C: 48</p> <p>Total: 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 94%</p> <p>C: 96%</p> <p>Total: 95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0025" title="NelsonJC , KennedyJS , PollockBG , Laghrissi-ThodeF , NarayanM , NoblerMS , et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. American Journal of Psychiatry1999;156:1024-8. PollockBG , Laghrissi-ThodeF , WagnerWR . Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology2000;20(2):137-40. RooseS , PollockB , KennedyJ , NelsonJ , GergelI , McCaffertyJ . Paroxetine in the treatment of depressed patients with ischaemic heart disease. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22 27. 1997. RooseS , PollockB , KennedyJ , NelsonJ , McCaffertyJ , GergelI . Paroxetine versus nortriptyline in ischemic disease. In: 150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17 22 May. 1997. RooseSP , Laghrissi-ThodeF , KennedyJS , NelsonJC , BiggerJT , PollockBG , et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA1998;279:287-91. YeraganiVK , PesceV , JayaramanA , RooseS . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological Psychiatry2002;52(5):418-29. YeraganiVK , RooseS , MallavarapuM , RadhakrishnaRK , PesceV . Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology2002;46(3):125-35. ">Roose 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): paroxetine</p> <p>Intervention 2 (I2): nortriptyline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 41</p> <p>I2: 40</p> <p>Total: 81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 41</p> <p>I2: 40</p> <p>Total: 81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 37</p> <p>I2: 30</p> <p>Total: 67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 90.2%</p> <p>I2: 75.0%</p> <p>Total: 82.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: no flow chart, reasons for dropout reported in text</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0026" title="GlassmanAH , Bigger T Jr, GaffneyM . Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression. Archives of General Psychiatry2009;66:1022-9. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina: ERRATUM. JAMA2002;288(14):1720. GlassmanAH , O'ConnorCM , CaliffRM , SwedbergK , SchwartzP , Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA2002;288:701-9. LattanzioF , CherubiniA , FurneriG , Di BariM , MarchionniN . Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian healthcare system. Aging: Clinical and Experimental Research2008;20(1):76-80. O'ConnorCM , GlassmanAH , HarrisonDJ . Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. Journal of Clinical Psychiatry2005;66:346-52. SerebruanyVL , GlassmanAH , MalininAI , NemeroffCB , MusselmanDL , vanZylLT , et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation2003;108(8):939-44. SerebruanyVL , SuckowRF , CooperTB , O'ConnorCM , MalininAI , KrishnanKR , et al. Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. American Journal of Psychiatry2005;162(6):1165-70. SwensonJR , O'ConnorCM , BartonD , vanZylLT , SwedbergK , FormanLM , et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. American Journal of Cardiology2003;92:1271-6. ">SADHART 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): sertraline</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 11546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 186</p> <p>C: 183</p> <p>Total: 369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 186</p> <p>C: 183</p> <p>Total: 169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 133</p> <p>C: 137</p> <p>Total: 270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 71.5%</p> <p>C: 74.9%</p> <p>Total: 73.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): stepwise psychotherapy intervention</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 21780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 285</p> <p>C: 285</p> <p>Total: 570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 284</p> <p>C: 284</p> <p>Total: 568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 110</p> <p>C: 194</p> <p>Total: 304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 38.6%</p> <p>C: 68.1%</p> <p>Total: 53.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0027" title="ShahmansouriS , FarokhniaM , AbbasiSH , KassaianSE , TaftiAA , GougolA , et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patient. Journal of Affective Disorders2013;155:216-22. ">Shahmansouri 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): fluoxetine</p> <p>Intervention 2 (I2): <i>Crocus sativus</i> L. (saffron) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 22</p> <p>I2: 22</p> <p>Total: 44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: NR</p> <p>I2: NR</p> <p>Total: NR (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 20</p> <p>I2: 20</p> <p>Total: 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 90.9%</p> <p>I2: 90.9%</p> <p>Total: 90.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0029" title="StrikJJ , HonigA , KlinkenbergE , DijkstraJ , JollesJ . Cognitive performance following fluoxetine treatment in depressed patients post myocardial infarction. Acta Neuropsychiatrica2006;18(1):1-6. StrikJJ , HonigA , LousbergR , LousbergAH , CheriexEC , Tuynman-QuaHG , et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine2000;62:783-9. StrikJJ , vanPraagHM , HonigA . Depression after first myocardial infarction. A prospective study on incidence, prognosis, risk factors and treatment. Tijdschrift Voor Gerontologie en Geriatrie2003;34(3):104-12. ">Strik 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): fluoxetine</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 27</p> <p>C: 27</p> <p>Total: 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 27</p> <p>C: 27</p> <p>Total: 54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 22</p> <p>C: 18</p> <p>Total: 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 81.5%</p> <p>C: 66.7%</p> <p>Total: 74.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0030" title="TianX , WangQ , GuoR , XuL , ChenQM , HouY . Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction. Neuropsychiatric Disease and Treatment2016;12:2333-41. ">Tian 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): paroxetine</p> <p>Intervention 2 (I2): fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 23</p> <p>I2: 23</p> <p>Total: 46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 23</p> <p>I2: 23</p> <p>Total: 46 (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 23</p> <p>I2: 23</p> <p>Total: 46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 100%</p> <p>I2: 100%</p> <p>Total: 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: no flow chart was reported. It is unclear whether 16 participants who did not finish the study were from I1 or I2 groups, or non‐treatment or non‐depressed groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0031" title="RafanelliC , GostoliS , BuzzichelliS , BergeroneS , GaitaF , RoncuzziR , et al. Results of the TREATED-ACS: a randomized controlled trial on the effectiveness of Cognitive Behavioral Therapy, combined with Well-Being Therapy, in improving depression and reducing cardiac risk among patients with acute coronary syndrome. Psychotherapy and Psychosomatics2019;88(Suppl 1):106-7. RafanelliC , GostoliS , BuzzichelliS , GuidiJ , SirriL , GalloP , et al. Sequential combination of cognitive-behavioral treatment and well-being therapy in depressed patients with acute coronary syndromes: a randomized controlled trial (TREATED-ACS Study). Psychotherapy and Psychosomatics2020;89(6):345-56. ">TREATED‐ACS 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): cognitive‐behavioural therapy and well‐being therapy</p> <p>Intervention 2 (I2): clinical management</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 50</p> <p>I2: 50</p> <p>Total: 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 50</p> <p>I2: 50</p> <p>Total: 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 42</p> <p>I2: 40</p> <p>Total: 82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 84%</p> <p>I2: 80%</p> <p>Total: 82%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): internet cognitive‐behavioural therapy</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 3928</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 117</p> <p>C: 122</p> <p>Total: 239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 117</p> <p>C: 122</p> <p>Total: 239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 96</p> <p>C: 115</p> <p>Total: 211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 82.1%</p> <p>C: 94.3%</p> <p>Total: 88.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): sertraline</p> <p>Intervention 2 (I2): exercise</p> <p>Control (C): placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 1680</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 40</p> <p>I2: 37</p> <p>C: 24</p> <p>Total: 101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: NR</p> <p>I2: NR</p> <p>C: NR</p> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 36</p> <p>I2: 36</p> <p>C: 23</p> <p>Total: 95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 90%</p> <p>I2: 97.3%</p> <p>C: 95.8%</p> <p>Total: 94.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: only I1 sertraline and C placebo are eligible for this review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0034" title="WangY , LiuYJ , Li F-E, GuoZ , WangJ , Comorbid Depression and Coronary Heart Disease Research Group of Cangzhou Central Hospital. A Chinese herbal formula shows beneficial effects on comorbid depression and coronary heart disease based on the philosophy of psycho-cardiology. Journal of Herbal Medicine2020;19:100303. [CHICTR-INC: 17012872] ">Wang 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1 (I1): escitalopram</p> <p>Intervention 2 (I2):</p> <p>Bu Xin Qi decoction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 140</p> <p>I2: 140</p> <p>Total: 280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: NR</p> <p>I2: NR</p> <p>Total: NR (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 113</p> <p>I2: 115</p> <p>Total: 228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: 80.7%</p> <p>I2: 82.1%</p> <p>Total: 81.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: reasons for dropout not stated in flow chart</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): internet cognitive‐behavioural therapy</p> <p>Control (C): wait‐list control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 18</p> <p>C: 16</p> <p>Total: 34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 18</p> <p>C: 16</p> <p>Total: 34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 13</p> <p>C: 13</p> <p>Total: 26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 72.2%</p> <p>C: 81.3%</p> <p>Total: 76.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0036" title="YangL , WangX , CuiX . Patients' intensive telephone-based care program reduces depression in coronary artery disease patients and may contribute to favorable overall survival by decreasing depression. Journal of Cardiovascular Nursing2019;34:236-43. ">Yang 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): intensive telephone‐based care</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: 354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 112</p> <p>C: 112</p> <p>Total: 224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NR</p> <p>C: NR</p> <p>Total: NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 107</p> <p>C: 105</p> <p>Total: 212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 95.5%</p> <p>C: 93.8%</p> <p>Total: 94.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention (I): Peplau's therapeutic communication model</p> <p>Control (C): usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ? (per‐protocol)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 37</p> <p>C: 37</p> <p>Total: 74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: ?</p> <p>C: ?</p> <p>Total: ?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comment: total sample estimated from degrees of freedom in Table 3</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>ITT = intention‐to‐treat; NR = not reported; ? = unclear</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of study population</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008012-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analyses for depression symptoms at end of treatment in psychological versus control trials</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study references [n]</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SMD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>I</b><sup>2</sup> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychological vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (<a href="./references#CD008012-fig-0004" title="">Analysis 1.1</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a> (n = 1226) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.55 (95% CI −0.92 to −0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychological vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constrained to trials without depression disorders as part of the inclusion criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0012" title="FangR , JiangY , SongJ , ChengG , XueG . Control study of general psychological intervention for patients with myocardial infarction. Chinese Journal of Clinical Rehabilitation2003;7:1382-3. ">Fang 2003</a>; <a href="./references#CD008012-bbs2-0021" title="BambauerKZ , AupontO , StonePH , LockeSE , MullanMG , ColagiovanniJ , et al. The effect of a telephone counseling intervention on self-rated health of cardiac patients. Psychosomatic Medicine2005;67:539-45. McLaughlinTJ , AupontO , BambauerKZ , StoneP , MullanMG , ColagiovanniJ . Improving psychologic adjustment to chronic illness in cardiac patients: the role of depression and anxiety. Journal of General Internal Medicine2005;20:1084-90. ">McLaughlin 2005</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a>; <a href="./references#CD008012-bbs2-0037" title="ZareaK , MaghsoudiS , DashtebozorgiB , HghighizadehMH , JavadiM . The impact of Peplau's therapeutic communication model on anxiety and depression in patients candidate for coronary artery bypass. Clinical Practice and Epidemiology in Mental Health2014;10:159-65. ">Zarea 2014</a> (n = 1145) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.53 (95% CI −0.92 to −0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychological vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constrained to depression (e.g. excluding trials with mixed depression and/or anxiety as part of the inclusion criteria) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0003" title="BarthJ , PaulJ , HärterM , BengelJ . Inpatient psychotherapeutic treatment for cardiac patients with depression in Germany: short-term results. GMS Psycho-Social-Medicine2005;2:1-8. ">Barth 2005</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0028" title="AlbusC , BeutelME , Deter H-C, FritzscheK , HellmichM , JordanH , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD) - rationale and design of a multicenter, randomized trial in depressed patients with CAD. Journal of Psychosomatic Research2011;71:215-22. FangaufSV , Herbeck BelnapB , MeyerT , AlbusC , BinderL , Deter H-C, et al. Associations of NT-proBNP and parameters of mental health in depressed coronary artery disease patients. Psychoneuroendocrinology2018;96:188-94. FritzscheK , AlbusC , JordanJ , BeutelME , WiltinkJ , Herrmann-LingenC . Individual and couple intervention for depressive coronary heart patients. Therapy manual, quality assurance and first experiences within the framework of a randomized controlled trial [Einzel- und Paarintervention für depressive Koronarpatienten. Therapiemanual, Qualitätssicherung und erste Erfahrungen im Rahmen einer randomisierten kontrollierten Interventionsstudie]. Psychotherapeut2011;56:325-36. Herrmann-LingenC , BeutelME , BosbachA , Deter H-C, FritzscheK , HellmichM , et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosomatic Medicine2016;78:704-15. ISRCTN76240576. A stepwise psychotherapy intervention for reducing risk in coronary artery disease - a randomised controlled trial (SPIRR-CAD). doi.org/10.1186/ISRCTN76240576 (date assigned 27 March 2008). ">SPIRR‐CAD 2011</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a> (n = 681) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.27 (95% CI −0.58 to 0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Psychological vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constrained to cognitive‐behavioural therapy trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0007" title="DaoTK , YoussefNA , ArmsworthM , WearE , PapathopoulosKN , GopaldasR . Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively inpatients undergoing coronary artery bypass graft surgery. Journal of Thoracic and Cardiovascular Surgery2011;142:109-15. ">Dao 2011</a>; <a href="./references#CD008012-bbs2-0013" title="FreedlandKE , SkalaJA , CarneyRM , RubinEH , LustmanPJ , Dávila-RomanVG , et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Archives of General Psychiatry2009;66:387-96. FreedlandKE . Treatment of depression after coronary bypass surgery. www.controlled-trials.com/mrct/trial/438737 (accessed 14 December 2009). ">Freedland 2009</a>; <a href="./references#CD008012-bbs2-0023" title="O'NeilA , HawkesAL , ChanB , SandersonK , ForbesA , HollingsworthB , et al. A randomised, feasibility trial of a tele-health intervention for acute coronary syndrome patients with depression (’MoodCare’): study protocol. BMC Cardiovascular Disorders2011;11:1471-2261. O'NeilA , TaylorB , HareDL , SandersonK , CyrilS , VenugopalK , et al. Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the MoodCare randomized controlled trial. Preventive Cardiology2015;22:1111-20. O'NeilA , TaylorB , SandersonK , CyrilS , ChanB , HawkesAL , et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the “MoodCare” randomized controlled trial. Annals of Behavioral Medicine2014;48:163-74. ">MoodCare 2011</a>; <a href="./references#CD008012-bbs2-0032" title="HumphriesSM , WallertJ , NorlundF , HeldC , OlssonE . 12-month follow-up of the U-CARE heart trial: using internet-based cognitive behavioural therapy to treat patients experiencing depression and anxiety after myocardial infarction. In: 25th World Congress of the International College of Psychosomatic Medicine, ICPM 2019 Italy , editors(s). Psychotherapy and Psychosomatics. Vol. 88. 2019. HumphriesSM , WallertJ , NorlundF , WallinE , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for patients reporting symptoms of anxiety and depression after myocardial infarction: U-CARE Heart randomized controlled trial twelve-month follow-up. Journal of Medical Internet Research2021;23:e25465. NorlundF , OlssonEM , BurellG , WallinE , HeldC . Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. Trials2015;16:154. [DOI: 10.1186/s13063-015-0689-y]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE Heart randomized controlled trial. European Journal of Preventive Cardiology2018;25(2 Suppl 1):S63-4. [DOI: 10.1177/2047487318786178]NorlundF , WallinE , OlssonEM , WallertJ , BurellG , vonEssenL , et al. Internet-based cognitive behavioral therapy for symptoms of depression and anxiety among patients with a recent myocardial infarction: the U-CARE heart randomized controlled trial. Journal of Medical Internet Research2018;20(3):e88. [DOI: 10.2196/jmir.9710]">U‐CARE 2018</a>; <a href="./references#CD008012-bbs2-0035" title="BendigE , BauereissN , BuntrockC , HabibovicM , EbertDD , BaumeisterH . Lessons learned from an attempted randomized-controlled feasibility trial on “WIDeCAD” - an internet-based depression treatment for people living with coronary artery disease (CAD). Internet Interventions2021;24:100375. ">WIDeCAD 2017</a> (n = 571) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.48 (95% CI −0.77 to −0.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI = confidence interval; SMD = standardised mean difference</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sensitivity analyses for depression symptoms at end of treatment in psychological versus control trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008012-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analyses for depression symptoms at end of treatment in pharmacological versus placebo trials</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study references [n]</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SMD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>I<sup>2</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacological vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None (<a href="./references#CD008012-fig-0041" title="">Analysis 3.1</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0019" title="MaH , WangY , XueY , HuangD , KongY , ZhaoX , et al. The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: results from a double-blind, randomized, placebo-controlled study. Biomedicine and Pharmacotherapy2019;112:108639. [DOI: 10.1016/j.biopha.2019.108639]">Ma 2019</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a> (n = 750) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD −0.83 (95% CI −1.33 to −0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacological vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constrained to trials with major depressive disorders as part of the inclusion criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a> </p> <p>(n = 427)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD −0.48 (95% CI −1.38 to 0.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacological vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constrained to depression (e.g. excluding trials with mixed depression and/or anxiety as part of the inclusion criteria) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0016" title="LiYM , LiGY , WangXL , YuLF . Rehabilitation effect of St John's wort extract on depression and myocardial function after coronary artery bypass grafting: a randomized grouping, placebo-control and blind evaluation. Zhongguo Linchuang Kangfu2005;9:38-9. ">Li 2005</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a> (n = 695) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD −0.76 (95% CI −1.29 to −0.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharmacological vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constrained to serotonergic antidepressant trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008012-bbs2-0006" title="Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylL . Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE): erratum. Psychosomatic Medicine2007;69(2):216. Frasure-SmithN , KoszyckiD , SwensonJR , BakerB , vanZylLT , LalibertéMA , et al. Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE). Psychosomatic Medicine2006;68:87-93. LespéranceF , Frasure-SmithN , KoszyckiD , LalibertéMA , vanZylLT , BakerB , et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA2007;29:367-79. vanZylLT , LesperanceF , Frasure-SmithN , MalininAI , AtarD , LaliberteMA , et al. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis2009;27(1):48-56. ">CREATE 2007</a>; <a href="./references#CD008012-bbs2-0011" title="KimJM , BaeKY , KangHJ , KimSW , ShinIS , HongYJ , et al. Design and methodology for the Korean observational and escitalopram treatment studies of depression in acute coronary syndrome: K-DEPACS and EsDEPACS. Psychiatry Investigations2014;11:89-94. KimJM , BaeKY , StewartR , JungBO , KangHJ , KimSW , et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2015;76(1):62-8. [DOI: 10.4088/JCP.14m09281]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Correlates and escitalopram treatment effects on sleep disturbance in patients with acute coronary syndrome: K-DEPACS and EsDEPACS. Sleep2015;38(7):1105-11. [DOI: 10.5665/sleep.4822]KimJM , StewartR , BaeKY , KangHJ , KimSW , ShinIS , et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychological Medicine2015;45:1641-52. [DOI: 10.1017/S003329171400275X]KimJM , StewartR , KangHJ , BaeKY , KimSW , ShinIS , et al. BDNF methylation and depressive disorder in acute coronary syndrome: the K-DEPACS and EsDEPACS studies. Psychoneuroendocrinology2015;62:159-65. [DOI: 10.1016/j.psyneuen.2015.08.013]KimJM , StewartR , KangHJ , KimSY , KimJW , LeeHJ , et al. Long-term cardiac outcomes of depression screening, diagnosis and treatment in patients with acute coronary syndrome: the DEPACS study. Psychological Medicine2021;51(6):964-74. KimJM , StewartR , LeeYS , LeeHJ , KimMC , KimJW , et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome: a randomized clinical trial. JAMA2018;320(4):350-8. [DOI: 10.1001/jama.2018.9422]KimJW , KangHJ , BaeKY , KimSW , ShinIS , YoonJS , et al. Social support deficit and depression treatment outcomes in patients with acute coronary syndrome: findings from the EsDEPACS study. International Journal of Psychiatry in Medicine2019;54(1):39-52. [DOI: 10.1177/0091217418791439]">EsDEPACS 2014</a>; <a href="./references#CD008012-bbs2-0017" title="LiuJD , ZhengH . Efficacy of fluoxetine in the treatment of depression in patients with acute myocardial infarction. Journal of Clinical Psychological Medicine1999;9:210-1. ">Liu 1999</a>; <a href="./references#CD008012-bbs2-0020" title="McFarlaneA , KamathMV , FallenEL , MalcolmV , CherianF , NormanG . Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. American Heart Journal2001;142(4):617-23. ">McFarlane 2001</a>; <a href="./references#CD008012-bbs2-0024" title="PizziC , ManciniS , AngeloniL , FontanaF , Costa GM. CORRIGENDUM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology &amp; Therapeutics2009;86:683. PizziC , ManciniS , AngeloniL , FontanaF , CostaGM . Sertraline ameliorates endothelial dysfunction and inflammation in coronary heart disease patients with depression. European Heart Journal2009;30(Suppl 1):520. PizziC , ManciniS , AngeloniL , FontanaF , ManzoliL , CostaGM . Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clinical Pharmacology and Therapeutics2009;86:527-32. ">Pizzi 2009</a>; <a href="./references#CD008012-bbs2-0033" title="BlumenthalJA , SherwoodA , BabyakMA , WatkinsLL , SmithPJ , HoffmanBM , et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. Journal of the American College of Cardiology2012;60:1053-63. BlumenthalJA , SherwoodA , RogersSD , BabyakMA , DoraiswamyPM , WatkinsL , et al. Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study - rationale, design, and methodological issues. Clinical Trials2007;4:548-59. ">UPBEAT 2012</a> (n = 613) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD −0.69 (95% CI −1.27 to −0.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI = confidence interval; SMD = standardised mean difference</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Sensitivity analyses for depression symptoms at end of treatment in pharmacological versus placebo trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/full#CD008012-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008012-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Psychological intervention versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Depression symptoms ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐0.92, ‐0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Depression symptoms ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.42, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Depression symptoms ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.96, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Depression remission ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [0.78, 5.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Depression remission ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Depression remission ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 All‐cause mortality ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.05, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 All‐cause mortality ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 All‐cause mortality ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.48, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Cardiovascular mortality ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Cardiovascular mortality ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.62, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Myocardial infarction ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.73, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Heart failure ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Stroke ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Coronary revascularisation procedure ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.75, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Hospitalisations ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Length of stay ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Quality of life SF‐12/36 physical ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [‐0.06, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Quality of life SF‐12/36 mental ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.07, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Quality of life SF‐12/36 physical ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐1.29, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Quality of life SF‐12/36 mental ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [‐1.09, 3.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Quality of life SF‐12 total ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Quality of life SF‐36 physical ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Quality of life SF‐36 mental ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Psychological intervention versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008012-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Psychological intervention versus psychological intervention/clinical management</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Depression symptoms ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Depression symptoms ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Depression symptoms ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Depression remission ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Depression remission ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Depression remission ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Cardiovascular mortality ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Quality of life SF‐36 physical ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Quality of life SF‐36 mental ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Quality of life SF‐36 physical ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Quality of life SF‐36 mental ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Quality of life SF‐36 physical ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Quality of life SF‐36 mental ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Psychological intervention versus psychological intervention/clinical management</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008012-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Pharmacological intervention versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Depression symptoms ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.83 [‐1.33, ‐0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Depression symptoms change score ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.36, ‐0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Depression remission ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.47, 2.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Depression response ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>891</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [1.65, 4.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 All‐cause mortality ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.10, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 All‐cause mortality ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.64, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Cardiovascular mortality ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Myocardial infarction ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.26, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Myocardial infarction ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Angina ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.44, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Heart failure ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.33, 2.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Arrhythmia ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.01, 17.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Stroke ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.20, 4.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 Coronary revascularisation procedure ‐ long term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.32, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.15 Healthcare costs ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.16 Hospitalisations ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.39, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.17 Emergency department visits ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.18 Quality of life Q‐LES‐Q ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.19 Quality of life WHOQOL‐BREF Physical ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.20 Quality of life WHOQOL‐BREF Psychological ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.21 Quality of life WHOQOL‐BREF Social relationships ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.22 Quality of life WHOQOL‐BREF Environmental ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.23 Quality of life WHOQOL‐BREF Physical ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.24 Quality of life WHOQOL‐BREF Psychological ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.25 Quality of life WHOQOL‐BREF Social Relationships ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.26 Quality of life WHOQOL‐BREF Environmental ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.27 Systolic BP ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐3.52, 3.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.28 Diastolic BP ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐1.55, 2.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.29 Heart rate ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>662</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐2.40, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.30 Platelet biomarker βTG ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐0.99, ‐0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.31 Platelet biomarker PF4 ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.48, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.32 Platelet biomarker P‐selectin ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐1.12, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.33 Platelet biomarker PECAM‐1 ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.34 Platelet biomarker TxB <sub>2</sub> ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.35 ECG PR interval ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.35 [‐8.40, ‐0.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.36 ECG QRS interval ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [‐0.41, 5.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.37 ECG QT interval ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.38 ECG QTc interval ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [‐1.96, 7.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.39 Non‐cardiac adverse events and side effects ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.07, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Pharmacological intervention versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008012-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Pharmacological intervention versus pharmacological intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Depression symptoms ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Depression symptoms change score ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Depression remission ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Depression response ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 All‐cause mortality ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Myocardial infarction ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Angina ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Heart failure ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Arrhythmia ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 Coronary revascularisation procedure ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 Emergency department visits ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.12 Systolic BP ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.13 Diastolic BP ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.14 Heart rate ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.15 ECG PR interval ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.16 ECG QRS interval ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.17 ECG QTc interval ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.18 Non‐cardiac adverse events and side effects ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Pharmacological intervention versus pharmacological intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008012.pub4/references#CD008012-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008012.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008012-note-0019">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008012-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008012-note-0018">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD008012-note-0015">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD008012-note-0013">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD008012-note-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD008012-note-0017">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008012-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008012\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008012\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008012\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008012\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008012\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008012.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008012.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008012.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008012.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008012.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729686934"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008012.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729686937"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008012.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ee2ee790e9377',t:'MTc0MDcyOTY4Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 